Document:

Exhibit 4.1

 

EXECUTION VERSION

 

Arbor Realty Trust, Inc.

 

as Issuer

 

U.S. Bank National Association

 

as Trustee

 

Third Supplemental Indenture

 

Dated as of November 13, 2017

 

to the Senior Debt Securities Indenture

 

Dated as of May 12, 2014

 

5.375% Convertible Senior Notes due 2020

 

 

TABLE OF CONTENTS

 

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE 1   DEFINITIONS AND OTHER PROVISIONS OF   GENERAL APPLICATION
    	
1
    
	
 
    	
 
    	
 
    
	
Section 1.01
    	
Scope   of Supplemental Indenture
    	
1
    
	
Section 1.02
    	
Definitions
    	
1
    
	
Section 1.03
    	
References   to Interest
    	
8
    
	
 
    	
 
    	
 
    
	
ARTICLE 2     THE SECURITIES
    	
8
    
	
 
    	
 
    
	
Section 2.01
    	
Title   and Terms; Payments
    	
8
    
	
Section 2.02
    	
Forms
    	
9
    
	
Section 2.03
    	
Transfer   and Exchange
    	
10
    
	
Section 2.04
    	
Payments   on the Securities
    	
12
    
	
 
    	
 
    	
 
    
	
ARTICLE 3     REDEMPTIONS AND PURCHASES
    	
13
    
	
 
    	
 
    
	
Section 3.01
    	
Amendments   to the Base Indenture
    	
13
    
	
Section 3.02
    	
Purchase   at Option of Holders upon a Fundamental Change
    	
13
    
	
Section 3.03
    	
Effect   of Fundamental Change Purchase Notice
    	
15
    
	
Section 3.04
    	
Withdrawal   of Fundamental Change Purchase Notice
    	
15
    
	
Section 3.05
    	
Deposit   of Fundamental Change Purchase Price
    	
16
    
	
Section 3.06
    	
Securities   Purchased in Whole or in Part
    	
16
    
	
Section 3.07
    	
Covenant   To Comply with Applicable Laws upon Purchase of Securities
    	
16
    
	
Section 3.08
    	
Repayment   to the Company
    	
16
    
	
 
    	
 
    	
 
    
	
ARTICLE 4   CONVERSION
    	
16
    
	
 
    	
 
    
	
Section 4.01
    	
Right   To Convert
    	
16
    
	
Section 4.02
    	
Conversion   Procedures
    	
18
    
	
Section 4.03
    	
Settlement   Upon Conversion
    	
19
    
	
Section 4.04
    	
Adjustment   of Conversion Rate
    	
22
    
	
Section 4.05
    	
Other   Adjustments
    	
29
    
	
Section 4.06
    	
Adjustment to   Conversion Rate Upon Conversion in Connection with a Make-Whole Fundamental   Change
    	
29
    
	
Section 4.07
    	
Effect   of Recapitalization, Reclassification, Consolidation, Merger or Sale
    	
30
    
	
Section 4.08
    	
Stock   Issued Upon Conversion
    	
32
    
	
Section 4.09
    	
Responsibility   of Trustee
    	
32
    
	
Section 4.10
    	
Notice   to Holders
    	
32
    
	
Section 4.11
    	
Exchange   in Lieu of Conversion
    	
33
    
	
 
    	
 
    	
 
    
	
ARTICLE 5   PARTICULAR COVENANTS OF THE COMPANY
    	
34
    
	
 
    	
 
    
	
Section 5.01
    	
Payment   of Principal, Interest and Fundamental Change Purchase Price
    	
34
    
	
Section 5.02
    	
Maintenance   of Office or Agency
    	
34
    
	
Section 5.03
    	
Appointments   to Fill Vacancies in Trustee’s Office
    	
34
    
	
Section 5.04
    	
Provisions   as to Paying Agent
    	
34
    
	
Section 5.05
    	
Reports
    	
35
    
	
Section 5.06
    	
Statements   as to Defaults
    	
35
    

 

 

	
Section 5.07
    	
Supplementary   Interest Notice
    	
35
    
	
Section 5.08
    	
Covenant   to Take Certain Actions
    	
36
    
	
Section 5.09
    	
Consolidation,   Merger and Sale of Assets
    	
36
    
	
 
    	
 
    	
 
    
	
ARTICLE 6   REMEDIES
    	
37
    
	
 
    	
 
    
	
Section 6.01
    	
Amendments   to the Base Indenture
    	
37
    
	
Section 6.02
    	
Events   of Default
    	
37
    
	
Section 6.03
    	
Acceleration;   Rescission and Annulment
    	
38
    
	
Section 6.04
    	
Supplementary   Interest
    	
38
    
	
Section 6.05
    	
Waiver   of Past Defaults
    	
38
    
	
Section 6.06
    	
Control   by Majority
    	
39
    
	
Section 6.07
    	
Limitation   on Suits
    	
39
    
	
Section 6.08
    	
Rights   of Holders to Receive Payment and to Convert
    	
39
    
	
Section 6.09
    	
Collection   of Indebtedness; Suit for Enforcement by Trustee
    	
39
    
	
Section 6.10
    	
Trustee   May Enforce Claims Without Possession of Securities
    	
40
    
	
Section 6.11
    	
Trustee   May File Proofs of Claim
    	
40
    
	
Section 6.12
    	
Restoration   of Rights and Remedies
    	
40
    
	
Section 6.13
    	
Rights   and Remedies Cumulative
    	
40
    
	
Section 6.14
    	
Delay   or Omission Not a Waiver
    	
40
    
	
Section 6.15
    	
Priorities
    	
41
    
	
Section 6.16
    	
Undertaking   for Costs
    	
41
    
	
Section 6.17
    	
Waiver   of Stay, Extension and Usury Laws
    	
41
    
	
Section 6.18
    	
Notices   from the Trustee
    	
41
    
	
 
    	
 
    	
 
    
	
ARTICLE 7   SATISFACTION AND DISCHARGE
    	
42
    
	
 
    	
 
    
	
Section 7.01
    	
Inapplicability   of Provisions of Base Indenture; Satisfaction and Discharge of the Indenture
    	
42
    
	
Section 7.02
    	
Deposited   Monies to Be Held in Trust by Trustee
    	
42
    
	
Section 7.03
    	
Paying   Agent to Repay Monies Held
    	
42
    
	
Section 7.04
    	
Return   of Unclaimed Monies
    	
42
    
	
Section 7.05
    	
Reinstatement
    	
43
    
	
 
    	
 
    	
 
    
	
ARTICLE 8     SUPPLEMENTAL INDENTURES
    	
43
    
	
 
    	
 
    
	
Section 8.01
    	
Supplemental   Indentures Without Consent of Holders
    	
43
    
	
Section 8.02
    	
Supplemental   Indentures With Consent of Holders
    	
44
    
	
Section 8.03
    	
Notice   of Amendment or Supplement
    	
44
    
	
 
    	
 
    	
 
    
	
ARTICLE 9   MISCELLANEOUS
    	
45
    
	
 
    	
 
    
	
Section 9.01
    	
Effect   on Successors and Assigns
    	
45
    
	
Section 9.02
    	
Governing   Law
    	
45
    
	
Section 9.03
    	
No   Security Interest Created
    	
45
    
	
Section 9.04
    	
Trust   Indenture Act
    	
45
    
	
Section 9.05
    	
Benefits   of Supplemental Indenture
    	
45
    
	
Section 9.06
    	
Calculations
    	
45
    
	
Section 9.07
    	
Execution   in Counterparts
    	
45
    
	
Section 9.08
    	
Notices
    	
45
    
	
Section 9.09
    	
Ratification   of Base Indenture
    	
46
    

 

 

	
Section 9.10
    	
The   Trustee
    	
46
    
	
Section 9.11
    	
No   Recourse Against Others
    	
46
    
	
 
    	
 
    	
 
    
	
SCHEDULE
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Schedule   A Additional Shares
    	
 
    
	
 
    	
 
    
	
EXHIBIT
    	
 
    
	
 
    	
 
    
	
Exhibit A   Form of Security
    	
 
    

 

 

THIRD SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 13, 2017, between Arbor Realty Trust, Inc., a Maryland corporation (the “Company”), and U.S. Bank National Association (the “Trustee”), as trustee under the Senior Debt Securities Indenture dated as of May 12, 2014, between the Company and the Trustee (as amended or supplemented from time to time in accordance with the terms thereof, the “Base Indenture”).

 

RECITALS OF THE COMPANY

 

WHEREAS, the Company executed and delivered the Base Indenture to the Trustee to provide, among other things, for the issuance, from time to time, of the Company’s senior debt securities, in an unlimited aggregate principal amount, in one or more series to be established by the Company under, and authenticated and delivered as provided in, the Base Indenture;

 

WHEREAS, Section 901(6) of the Base Indenture provides for the Company and the Trustee to enter into supplemental indentures to the Base Indenture to establish the form and terms of Securities of any series as contemplated by Section 201 of the Base Indenture;

 

WHEREAS, the Board of Directors has duly adopted resolutions authorizing the Company to execute and deliver this Supplemental Indenture;

 

WHEREAS, pursuant to the terms of the Base Indenture, the Company has authorized the creation and issuance under this Supplemental Indenture of its 5.375% Convertible Senior Notes due 2020 (the “Securities”), the form and substance of such Securities and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and this Supplemental Indenture; and

 

WHEREAS, the Company has requested that the Trustee execute and deliver this Supplemental Indenture, and that all requirements necessary to make (i) this Supplemental Indenture a valid instrument in accordance with its terms, and (ii) the Securities, when executed by the Company and authenticated and delivered by the Trustee, the valid obligations of the Company have been performed, and the execution and delivery of this Supplemental Indenture have been duly authorized in all respects.

 

NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE WITNESSETH, for and in consideration of the premises and the purchases of the Securities by the Holders thereof, it is mutually agreed, for the benefit of the Company and the equal and proportionate benefit of all Holders, as follows:

 

ARTICLE 1

 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

 

Section 1.01                             Scope of Supplemental Indenture.  The changes, modifications and supplements to the Base Indenture effected by this Supplemental Indenture shall be applicable only with respect to, and shall govern only the terms of (and only the rights of the Holders and the obligations of the Company with respect to), the Securities, which may be issued from time to time, and shall not apply to any other securities that may be issued under the Base Indenture (or govern the rights of the Holders or the obligations of the Company with respect to any such other securities) unless a supplemental indenture with respect to such other securities specifically incorporates such changes, modifications and supplements.  The provisions of this Supplemental Indenture shall, with respect to the Securities, supersede any corresponding provisions in the Base Indenture.  Subject to the preceding sentence, and except as otherwise provided herein, the provisions of the Base Indenture shall apply to the Securities and govern the rights of the Holders of the Securities and the obligations of the Company and the Trustee with respect thereto.

 

Section 1.02                             Definitions.  For all purposes of the Indenture, except as otherwise expressly provided or unless the context otherwise requires:

 

(i) the terms defined in this Article 1 shall have the meanings assigned to them in this Article 1 and include the plural as well as the singular; and

 

1

 

(ii) all words, terms and phrases defined in the Base Indenture (but not otherwise defined herein) shall have the same meanings as in the Base Indenture.

 

“Additional Shares” has the meaning specified in Section 4.06(a) hereof.

 

“Agent Members” has the meaning specified in Section 2.02(c) hereof.

 

“Applicable Procedures” means, with respect to any matter at any time, the policies and procedures of the Depositary, if any, that are applicable to such matter at such time.

 

“Base Indenture” has the meaning specified in the first paragraph of this Supplemental Indenture, as such instrument may be supplemented from time to time by one or more indentures supplemental thereto, including this Supplemental Indenture, entered into pursuant to the applicable provisions of the Base Indenture, including, for all purposes of the Base Indenture, this Supplemental Indenture and any such other supplemental indenture, the provisions of the Trust Indenture Act that are deemed to be a part of and govern the Base Indenture, this Supplemental Indenture and any other such supplemental indenture, respectively.

 

“Bid Solicitation Agent” means the Company or such other Person as may be appointed, from time to time, by the Company to solicit bids for the Trading Price of the Securities in accordance with Section 4.01(b)(2) hereof. Initially, the “Bid Solicitation Agent” means the Company.

 

“Business Day” means, notwithstanding anything to the contrary in Section 101 of the Base Indenture, any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or required by law or executive order to close or be closed.

 

“Capital Stock” means, for any Person, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) the equity of such Person, but excluding any debt securities convertible into such equity.

 

“Cash Settlement” has the meaning specified in Section 4.03(a)(4) hereof.

 

“Clause A Distribution” has the meaning specified in Section 4.04(c) hereof.

 

“Clause B Distribution” has the meaning specified in Section 4.04(c) hereof.

 

“Clause C Distribution” has the meaning specified in Section 4.04(c) hereof.

 

“Close of Business” means 5:00 P.M., New York City time.

 

“Combination Settlement” has the meaning specified in Section 4.03(a)(4) hereof.

 

“Common Equity” of any Person means the Capital Stock of such Person that is generally entitled (a) to vote in the election of directors of such Person or (b) if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person.

 

“Common Stock” means, subject to Section 4.07, the shares of common stock, $0.01 par value per share, of the Company authorized at the date of this instrument as originally executed or shares of any class or classes of common stock resulting from any reclassification or reclassifications thereof.

 

“Company” has the meaning specified in the first paragraph of this Supplemental Indenture, and subject to the provisions of Section 5.09, shall include its successors and assigns.

 

2

 

“Conversion Agent” means the office or agency designated by the Company where Securities may be presented for conversion.

 

“Conversion Date” has the meaning specified in Section 4.02(b) hereof.

 

“Conversion Notice” has the meaning specified in Section 4.02(b)(1) hereof.

 

“Conversion Price” means, in respect of each Security, as of any date, $1,000 divided by the Conversion Rate in effect on such date.

 

“Conversion Rate” means initially 107.7122 shares of Common Stock per $1,000 principal amount of Securities, subject to adjustment as set forth herein.

 

“Custodian” means the Trustee, as custodian with respect to the Securities (so long as the Securities constitute Global Securities), or any successor entity.

 

“Daily Conversion Value” means, for each of the 40 consecutive Trading Days during the Observation Period, 2.5% of the product of (i) the Conversion Rate in effect on such Trading Day and (ii) the Daily VWAP on such Trading Day.

 

“Daily Measurement Value” has the meaning specified in Section 4.03(a)(6)(A) hereof.

 

“Daily Settlement Amount” has the meaning specified in Section 4.03(a)(6) hereof.

 

“Daily VWAP” means, for each of the 40 consecutive Trading Days during the relevant Observation Period, the per-share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg page “ABR <equity> AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one share of the Common Stock on such Trading Day determined, using a volume-weighted average method, by a nationally recognized independent investment banking firm retained for this purpose by the Company).  The “Daily VWAP” will be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.

 

“Default” means any event that is, or with the passage of time or the giving of notice or both would be, an Event of Default.

 

“Effective Date” means (i) the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, reflecting the relevant share split or share combination, as applicable, or (ii) with respect to a Fundamental Change or Make-Whole Fundamental Change, the date such Fundamental Change or Make-Whole Fundamental Change becomes effective.

 

“Event of Default” has the meaning, notwithstanding anything to the contrary in Section 101 of the Base Indenture, specified in Section 6.02 hereof.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Exchange Election” has the meaning specified in Section 4.11 hereof.

 

“Ex-Dividend Date” means, the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question, from the Company or, if applicable, from the seller of the Common Stock on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market.

 

3

 

“Form of Assignment and Transfer” means the “Form of Assignment and Transfer” attached as Attachment 3 to the Form of Security attached hereto as Exhibit A.

 

“Form of Fundamental Change Repurchase Notice” means the “Form of Fundamental Change Repurchase Notice” attached as Attachment 2 to the Form of Security attached hereto as Exhibit A.

 

“Form of Notice of Conversion” means the “Form of Notice of Conversion” attached as Attachment 1 to the Form of Security attached hereto as Exhibit A.

 

“Fundamental Change” shall be deemed to have occurred at the time after the Securities are originally issued if any of the following occurs:

 

(1) a “person” or “group” (within the meaning of Section 13(d) of the Exchange Act), other than the Company, its wholly-owned subsidiaries and its and their employee benefit plans files a Schedule TO or any schedule, form or report under the Securities Exchange Act of 1934, as amended, that discloses that such person or group has become the direct or indirect “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act, of the Company’s Common Equity representing more than 50% of the voting power of the Company’s Common Equity;

 

(2) the consummation of (A) any recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination) as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets; (B) any share exchange, consolidation or merger of the Company pursuant to which the Common Stock shall be converted into cash, securities or other property or assets; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, to any Person other than one of the Company’s wholly-owned subsidiaries; provided, however, that a transaction described in clause (B) in which the holders of all classes of the Company’s Common Equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of common equity of the continuing or surviving corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions as such ownership immediately prior to such transaction shall not be a fundamental change pursuant to this clause (2);

 

(3) the Company’s stockholders approve any plan or proposal for the liquidation or dissolution of the Company; or

 

(4) the Common Stock (or other common stock underlying the Securities) ceases to be listed or quoted on any of The New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or any of their respective successors).

 

A transaction or transactions described in clause (1) or clause (2) above will not constitute a Fundamental Change, however, if at least 90% of the consideration received or to be received by holders of the Common Stock, excluding cash payments for fractional shares, in connection with such transaction or transactions consists of shares of common stock that are listed or quoted on any of The New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or any of their respective successors) or will be so listed or quoted when issued or exchanged in connection with such transaction or transactions, and as a result of such transaction or transactions the Securities become convertible into such consideration, excluding cash payments for fractional shares (subject to Section 4.03).

 

If any transaction in which the Common Stock is replaced by the securities of another entity occurs, following completion of any related Make-Whole Fundamental Change Period (or, in the case of a transaction that would have been a Fundamental Change or a Make-Whole Fundamental Change but for the immediately preceding paragraph, following the effective date of such transaction), references to the Company in this definition of “Fundamental Change” above shall instead be references to such other entity.

 

“Fundamental Change Company Notice” has the meaning specified in Section 3.02(b) hereof.

 

4

 

“Fundamental Change Expiration Time” has the meaning specified in Section 3.02(a)(1) hereof.

 

“Fundamental Change Repurchase Date” has the meaning specified in Section 3.02(a) hereof.

 

“Fundamental Change Repurchase Notice” has the meaning specified in Section 3.02(a)(1) hereof.

 

“Fundamental Change Repurchase Price” has the meaning specified in Section 3.02(a) hereof.

 

“Global Security” means a Security which is executed by the Company and authenticated and delivered to the Depositary or its nominee, all in accordance with the Indenture and pursuant to a Company Order, which shall be registered in the name of the Depositary or its nominee and which shall represent the amount of uncertificated Securities as specified therein.

 

“Holder” means, notwithstanding anything to the contrary in Section 101 of the Base Indenture, the Person in whose name a Security is registered in the Security Register.

 

“Indenture” means, notwithstanding anything to the contrary in Section 101 of the Base Indenture, the Base Indenture, as originally executed and as supplemented by this Supplemental Indenture, each as may be amended or supplemented from time to time.

 

“Initial Dividend Threshold” has the meaning specified in Section 4.04(d) hereof.

 

“Interest Payment Date” means, with respect to the payment of interest on the Securities and notwithstanding anything to the contrary in Section 101 of the Base Indenture, each May 15 and November 15 of each year, beginning on May 15, 2018.

 

“Issue Date” means, with respect to the Securities, November 13, 2017.

 

“Last Reported Sale Price” of the Common Stock for any date means the closing sale price per share (or, if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported in composite transactions for the principal U.S. national or regional securities exchange on which the Common Stock is traded. If the Common Stock is not listed for trading on a U.S. national or regional securities exchange on the relevant Trading Day, the “Last Reported Sale Price” will be the last quoted bid price for the Common Stock in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. or a similar organization.  If the Common Stock is not so quoted, the “Last Reported Sale Price” will be the average of the mid-point of the last bid and ask prices for the Common Stock on the relevant date from each of at least three nationally recognized independent investment banking firms selected by the Company for this purpose.

 

“Make-Whole Fundamental Change” means any event that is a Fundamental Change determined after giving effect to any exceptions to or exclusions from such definition but without regard to the proviso in clause (2) of the definition thereof.

 

“Make-Whole Fundamental Change Period” has the meaning specified in Section 4.06(a) hereof.

 

“Market Disruption Event,” for the purposes of determining amounts due upon conversion, means (1) a failure by the primary U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading to open for trading during its regular trading session or (2) the occurrence or existence, prior to 1:00 p.m., New York City time, on any Scheduled Trading Day for the Common Stock for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common Stock.

 

“Maturity Date” means, with respect to any Security and the payment of the principal amount thereof, November 15, 2020.

 

5

 

“Measurement Period” has the meaning specified in Section 4.01(b)(2) hereof.

 

“Merger Event” has the meaning specified in Section 4.07(a) hereof.

 

“Observation Period” with respect to any Security surrendered for conversion means:

 

(x)                                 if the relevant Conversion Date occurs prior to August 15, 2020, the 40 consecutive Trading Day period beginning on, and including, the second Trading Day immediately succeeding such Conversion Date; and

 

(y)                                 if the relevant Conversion Date occurs on or after August 15, 2020, the 40 consecutive Trading Days beginning on, and including, the 41st Scheduled Trading Day immediately preceding the Maturity Date.

 

“Open of Business” means 9:00 A.M., New York City time.

 

“Outstanding” means, with respect to the Securities, notwithstanding anything to the contrary in Section 101 of the Base Indenture, any Securities authenticated by the Trustee except (i) Securities cancelled by it, (ii) Securities delivered to it for cancellation and (iii)(A) Securities replaced pursuant to Section 306 of the Base Indenture, on and after the time such Security is replaced (unless the Trustee and the Company receive proof satisfactory to them that such Security is held by a bona fide purchaser), (B) Securities converted pursuant to Article 4 hereof, on and after their Conversion Date, (C) any and all Securities, as of the Maturity Date, if the Paying Agent holds, in accordance with this Indenture, money sufficient to pay all of the Securities then payable, and (D) any and all Securities owned by the Company or any other obligor upon the Securities or any Affiliate of the Company or of such other obligor, except that in determining whether the Trustee shall be protected in relying upon any request, demand, authorization, direction, notice consent or waiver or other action that is to be made by a requisite principal amount of Outstanding Securities, only such Securities which a Responsible Officer of the Trustee knows to be so owned shall be disregarded.

 

“Paying Agent” has the meaning set forth in the Base Indenture and shall be the Person authorized by the Company to pay the principal amount of, interest on, or Fundamental Change Repurchase Price of, any Securities on behalf of the Company.

 

“Physical Securities” means any non-Global Security issued pursuant to Section 2.03 hereof that is in definitive, fully-registered form, without interest coupons.

 

“Physical Settlement” has the meaning specified in Section 4.03(a)(4) hereof.

 

“Preliminary Prospectus Supplement” means the Preliminary Prospectus Supplement of the Company, dated November 7, 2017, to the Prospectus, relating to the offering and sale of the Securities.

 

“Prospectus” means the Prospectus of the Company dated July 26, 2016.

 

“Record Date” means, with respect to any dividend, distribution or other transaction or event in which the holders of the Common Stock (or other applicable security) have the right to receive any cash, securities or other property or in which the Common Stock (or such other security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of the Common Stock (or such other security) entitled to receive such cash, securities or other property (whether such date is fixed by the Board of Directors, statute, contract or otherwise).

 

“Reference Property” has the meaning specified in Section 4.07(a) hereof.

 

“Regular Record Date” means, with respect to any Interest Payment Date, the March 15 (whether or not a Business Day) or the September 15 (whether or not a Business Day), as the case may be, immediately preceding such Interest Payment Date (whether or not such date is a Business Day).

 

6

 

“Reporting Event of Default” has the meaning specified in Section 6.04(a) hereof.

 

“Scheduled Trading Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading Day” means a Business Day.

 

“Security” or “Securities” has the meaning specified in the fourth paragraph of the Recitals of this Supplemental Indenture, notwithstanding anything to the contrary in Section 101 of the Base Indenture.

 

“Settlement Amount” has the meaning specified in Section 4.03(a) hereof.

 

“Settlement Method” means, with respect to any conversion of Securities, Physical Settlement, Cash Settlement or Combination Settlement, as elected (or deemed to have been elected) by the Company.

 

“Settlement Notice” has the meaning specified in Section 4.03(a)(4) hereof.

 

“Significant Subsidiary” means, with respect to any Person, a Subsidiary of such Person that would constitute a “significant subsidiary” as such term is defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant to the Securities Act, as in effect on the original date of issuance of the Securities.

 

“Specified Dollar Amount” has the meaning specified in Section 4.03(a)(6)(A) hereof.

 

“Spin-Off” has the meaning specified in Section 4.04(c) hereof.

 

“Stock Price” has the meaning specified in Section 4.06(c) hereof.

 

“Supplemental Indenture” has the meaning specified in the first paragraph hereof, as such instrument may be supplemented from time to time by one or more indentures supplemental thereto, entered into pursuant to the applicable provisions of the Base Indenture and the Supplemental Indenture, including, for all purposes of this Supplemental Indenture and any such other supplemental indenture, the provisions of the Trust Indenture Act that are deemed to be a part of and govern the Base Indenture, this Supplemental Indenture and any other such supplemental indenture, respectively.

 

“Supplementary Interest” has the meaning specified in Section 6.04(a) hereof.

 

“Trading Day” means a day on which (i) trading in the Common Stock (or other security for which a closing sale price must be determined) generally occurs on The New York Stock Exchange or, if the Common Stock (or such other security) is not then listed on The New York Stock Exchange, on the principal other U.S. national or regional securities exchange on which the Common Stock (or such other security) is then listed or, if the Common Stock (or such other security) is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock (or such other security) is then traded and (ii) a Last Reported Sale Price for the Common Stock (or closing sale price for such other security) is available on such securities exchange or market. If the Common Stock (or such other security) is not so listed or traded, “Trading Day” means a “Business Day.”

 

For the purposes of determining amounts due upon conversion only, “Trading Day” means a day on which (i) there is no Market Disruption Event and (ii) trading in Common Stock generally occurs on The New York Stock Exchange or, if the Common Stock is not then listed on The New York Stock Exchange, on the principal other U.S. national or regional securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then listed or admitted for trading. If the Common Stock is not so listed or admitted for trading, “Trading Day” means a Business Day.

 

“Trading Price” of the Securities on any date of determination means the average of the secondary market bid quotations obtained by the Bid Solicitation Agent for $1,000,000 principal amount of Securities at

 

7

 

approximately 3:30 p.m., New York City time, on such determination date from three independent nationally recognized securities dealers selected for this purpose by the Company; provided that if three such bids cannot reasonably be obtained by the Bid Solicitation Agent but two such bids are obtained, then the average of the two bids shall be used, and if only one such bid can reasonably be obtained by the Bid Solicitation Agent, that one bid shall be used.  If the Bid Solicitation Agent cannot reasonably obtain at least one bid for $1,000,000 principal amount of Securities from a nationally recognized securities dealer, then the Trading Price per $1,000 principal amount of Securities will be deemed to be less than 98% of the product of (i) the Last Reported Sale Price of the Common Stock on such date of determination and (ii) the Conversion Rate in effect on such determination date.  If (x) the Company is not acting as Bid Solicitation Agent and the Company does not, when it is required to, instruct the Bid Solicitation Agent to obtain bids or if the Company gives such instruction to the Bid Solicitation Agent and the Bid Solicitation Agent fails to make such determination, or (y) the Company is acting as Bid Solicitation Agent and the Company fails to make such determination, then, in either case, the Trading Price per $1,000 principal amount of Securities will be deemed to be less than 98% of the product of (i) Last Reported Sale Price of the Common Stock on such determination date and (ii) the Conversion Rate in effect on such determination date for each Trading Day of such failure.

 

“Trigger Event” has the meaning specified in Section 4.04(c) hereof.

 

“Trustee” means the Person named as the “Trustee” in the first paragraph of this Supplemental Indenture until a successor Trustee shall have become such pursuant to the applicable provisions of the Base Indenture and this Supplemental Indenture, and thereafter “Trustee” shall mean or include each Person who is then a Trustee hereunder.

 

“Underwriters” means J.P. Morgan Securities LLC, JMP Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated as representatives of the several underwriters relating to the initial public offering of Securities.

 

“Unit of Reference Property” has the meaning specified in Section 4.07(a) hereof.

 

“U.S.” or “United States” means the United States of America.

 

“Valuation Period” has the meaning specified in Section 4.04(c) hereof.

 

Section 1.03                             References to Interest.  Any reference to interest on, or in respect of, any Security in this Supplemental Indenture shall be deemed to include Supplementary Interest if, in such context, Supplementary Interest is, was or would be payable pursuant to Section 6.04.  Any express mention of the payment of Supplementary Interest in any provision hereof shall not be construed as excluding Supplementary Interest in those provisions hereof where such express mention is not made.

 

ARTICLE 2

 

THE SECURITIES

 

Section 2.01                             Title and Terms; Payments.

 

(a)                                 Establishment; Designation.  Pursuant to Sections 201 and 301 of the Base Indenture, there is hereby established and authorized a new series of Securities under this Indenture, which series of Securities shall be designated the “5.375% Convertible Senior Notes due 2020.”

 

(b)                                 Initial Issuance.  Subject to Section 2.01(c) hereof, the aggregate principal amount of Securities that may initially be authenticated and delivered under this Indenture is limited to $125,000,000 (or up to $143,750,000 if the Underwriters’ over-allotment option is exercised in full).  In addition, the Company may execute, and the Trustee may authenticate and deliver, in each case, in accordance with Section 301 of the Base Indenture, an unlimited aggregate principal amount of additional Securities upon the transfer, exchange, purchase or

 

8

 

conversion of Securities pursuant to Sections 304, 305 and 306 of the Base Indenture and Sections 3.06 and 4.02 hereof.

 

(c)                                  Further Issues.  The Company may, without the consent of the Holders, issue additional Securities under this Indenture with the same terms and the same CUSIP number as the Securities initially issued under this Indenture (other than differences in the issue price and interest accrued prior to the issue date of such additional Securities) in an unlimited aggregate principal amount; provided, that if any such additional Securities are not fungible with the Securities initially issued hereunder for United States federal income tax purposes, such additional Securities will have a separate CUSIP number.  Any such additional Securities will, for all purposes of this Indenture, including waivers, amendments and offers to purchase, be treated as part of the same series as the Securities initially issued under this Indenture.

 

(d)                                 Purchases.  The Company shall cause all Securities surrendered for payment, repurchase (including as described under Article 3 hereof), registration of transfer or exchange or conversion, if surrendered to any person other than the Trustee (including any of the Company’s agents, Subsidiaries or affiliates), to be delivered to the Trustee for cancellation. All Securities delivered to the Trustee shall be cancelled promptly by the Trustee. No Securities shall be authenticated in exchange for any Securities cancelled as provided in this Section 2.01(d).

 

The Company and its Subsidiaries may, to the extent permitted by law, and directly or indirectly (regardless of whether such Securities are surrendered to it), repurchase Securities in the open market or otherwise, whether by the Company or its Subsidiaries or through a private or public tender or exchange offer or through counterparties pursuant to private agreements, including by cash-settled swaps or other derivatives. The Company shall cause any Securities so repurchased (other than Securities repurchased pursuant to cash-settled swaps or other derivatives) to be surrendered to the Trustee for cancellation, and they will no longer be considered Outstanding under this Indenture upon their repurchase.

 

(e)                                  Denominations.  Notwithstanding Section 302 of the Base Indenture, the Securities will be issued only in minimum denominations of $1,000 and multiples of $1,000 in excess thereof.

 

Section 2.02                             Forms.

 

(a)                                 In General.  Pursuant to Section 201 of the Base Indenture, the Securities will be substantially in the forms set forth in Exhibit A hereto, and may include such insertions, omissions, substitutions and other variations as are required or permitted by this Indenture, and may have such letters, numbers or other marks of identification and such legends or endorsements placed thereon as may be required to comply with the rules of any securities exchange or as may, consistently herewith, be determined by the officers executing such Securities, as evidenced by their execution of the Securities.

 

Each Security will bear a Trustee’s certificate of authentication substantially in the form included in Exhibit A hereto.  Each Security will also bear the Form of Notice of Conversion, the Form of Fundamental Change Repurchase Notice and the Form of Assignment and Transfer.

 

Any Security that is a Global Security will bear a legend substantially in the form of the legend set forth in Exhibit A hereto and shall also bear the “Schedule of Increases and Decreases of Global Security” set forth in Annex A to Exhibit A hereto.

 

The terms and provisions contained in the Securities will constitute, and are hereby expressly made, a part of this Indenture and, to the extent applicable, the Company and the Trustee, by their execution and delivery of this Supplemental Indenture, expressly agree to such terms and provisions and to be bound thereby.  However, to the extent that any provision of any Security conflicts with the express provisions of this Indenture, the provisions of this Indenture will govern and control.

 

(b)                                 Initial and Subsequent Form of Securities.  The Company hereby initially appoints The Depository Trust Company as the Depositary for the Securities, which initially shall be issued in the form of one or

 

9

 

more Global Securities without interest coupons (i) registered in the name of Cede & Co., as nominee of the Depositary, and (ii) delivered to the Trustee as custodian for the Depositary.

 

So long as the Securities are eligible for book-entry settlement with the Depositary, unless otherwise required by law, and except to the extent provided in Section 2.03(d)(1) through (3) hereof, all Securities will be represented by one or more Global Securities.

 

(c)                                  Global Securities.  Each Global Security will represent the aggregate principal amount of the then Outstanding Securities endorsed thereon and provide that it represents such aggregate principal amount of the then Outstanding Securities, which aggregate principal amount may, from time to time, be reduced or increased to reflect transfers, exchanges, conversions or purchases by the Company.

 

Only the Trustee, or the Custodian holding such Global Security for the Depositary, at the direction of the Trustee, may endorse a Global Security to reflect the amount of any increase or decrease in the aggregate principal amount of the then Outstanding Securities represented thereby, and whenever the Holder of a Global Security delivers instructions to the Trustee to increase or decrease the aggregate principal amount of the then Outstanding Securities represented by a Global Security in accordance with this Indenture and the Applicable Procedures, the Trustee, or the Custodian holding such Global Security for the Depositary, at the direction of the Trustee, will endorse such Global Security to reflect such increase or decrease in the aggregate principal amount of the then Outstanding Securities represented thereby.  None of the Trustee, the Company or any agent of the Trustee or the Company will have any responsibility or bear any liability for any aspect of the records relating to or payments made on account of the ownership of any beneficial interest in a Global Security or with respect to maintaining, supervising or reviewing any records relating to such beneficial interest.

 

Members of, or participants in, the Depositary (“Agent Members”) shall have no rights under this Indenture with respect to any Global Security held on their behalf by the Depositary, or the Trustee as its custodian, or under the Global Security, and Cede & Co., or such other Person designated by the Depositary as its nominee, may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner of the Global Security for all purposes whatsoever.  Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depositary or impair, as between the Depositary and its Agent Members, the operation of customary practices governing the exercise of the rights of any Holder.

 

Section 2.03                             Transfer and Exchange.

 

(a)                                 In General.  Notwithstanding anything to the contrary in Section 305 of the Base Indenture, the Company is not required to transfer or exchange any Securities or portions thereof that have been surrendered for purchase in accordance with Article 3 hereof (unless the related Fundamental Change Repurchase Notice is withdrawn in accordance with the provisions of Section 3.04) or for conversion in accordance with Article 4 hereof, and a written form of transfer substantially in the form of the Form of Assignment and Transfer will be deemed to be a written instrument of transfer satisfactory to the Company and the Security Registrar.

 

At such time as all interests in a Global Security have been purchased, converted, cancelled or exchanged for Securities in certificated form, such Global Security shall, upon receipt thereof, be canceled by the Trustee in accordance with standing procedures and instructions existing between the Depositary and the Custodian for the Global Security.  At any time prior to such cancellation, if any interest in a Global Security is purchased, converted, cancelled or exchanged for Securities in certificated form, the principal amount of such Global Security shall, in accordance with the standing procedures and instructions existing between the Depositary and the Custodian for the Global Security, be appropriately reduced, and an endorsement shall be made on such Global Security, by the Trustee or the Custodian for the Global Security, at the direction of the Trustee, to reflect such reduction.

 

No service charge will be imposed by the Company, the Trustee or the Security Registrar for any registration of transfer or exchange of Securities, but the Company may require a Holder to pay a sum sufficient to cover any transfer tax or other similar governmental charge required by law or permitted by this Indenture.

 

10

 

(b)                                 Global Securities.  Notwithstanding anything to the contrary in Section 305 of the Base Indenture, every transfer and exchange of a beneficial interest in a Global Security will be effected through the Depositary in accordance with the Applicable Procedures and the provisions of this Indenture, and each Global Security may be transferred only as a whole and only (A) by the Depositary to a nominee of the Depositary, (B) by a nominee of the Depositary to the Depositary or to another nominee of the Depositary, or (C) by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary.

 

(c)                                  Holders Deemed Owners.  Prior to due presentment of a Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name such Security is registered as the owner of such Security for the purpose of receiving payment of principal of and any interest (subject to Section 308 of the Base Indenture) on such Security at the Maturity Date, in connection with a Fundamental Change, upon any conversion and for all other purposes whatsoever, including delivery of shares of Common Stock on conversion, for distribution of notices to such Holders or solicitations of their consent, whether or not such Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary.

 

(d)                                 Notwithstanding anything to the contrary in Section 305 of the Base Indenture, each Global Security will be exchanged for Physical if:

 

(1)                                 the Depositary delivers notice to the Company at any time that the Depositary is unwilling or unable to continue to act as Depositary, and, in each case, the Company promptly delivers a copy of such notice to the Trustee and the Company fails to appoint a successor Depositary within 90 days after receiving notice from the Depositary;

 

(2)                                 the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor Depositary is not appointed within 90 days; or

 

(3)                                 if an Event of Default with respect to the Securities has occurred and is continuing, and an owner of a beneficial interest in a Global Security requests to exchange such beneficial interest for Physical Securities by delivering a written request to the Security Registrar,

 

In the case of an exchange for Physical Securities under clause (1) above:

 

(A)                               each Global Security will be deemed surrendered to the Trustee for cancellation;

 

(B)                               the Trustee will cause each Global Security to be cancelled in accordance with the Applicable Procedures; and

 

(C)                               the Company, in accordance with Section 303 of the Base Indenture, will promptly execute, and, upon receipt of a Company Request, the Trustee, in accordance with Section 303 of the Base Indenture, will promptly authenticate and deliver, for each beneficial interest in each Global Security so exchanged, an aggregate principal amount of Physical Securities equal to the aggregate principal amount of such beneficial interest, registered in such names and in such authorized denominations as the Depositary specifies, and bearing any legends that such Physical Securities are required to bear under this Indenture.

 

In the case of an exchange for Physical Securities under clause (2) above:

 

(A)                               the Security Registrar will deliver notice of such request to the Company and the Trustee, which notice will identify the owner of the beneficial interest to be exchanged, the aggregate principal amount of such beneficial interest and the CUSIP of the relevant Global Security, in each case if and as such information is provided to the Security Registrar by the Depositary;

 

(B)                               the Company, in accordance with Section 303 of the Base Indenture, will promptly execute, and, upon receipt of a Company Request, the Trustee, in accordance with Section 303 of the Base Indenture, will promptly authenticate and deliver to such owner, for the beneficial interest so exchanged by such

 

11

 

owner, Physical Securities registered in such owner’s name having an aggregate principal amount equal to the aggregate principal amount of such beneficial interest and bearing any legends that such Physical Securities are required to bear under this Indenture; and

 

(C)                               the Security Registrar, in accordance with the Applicable Procedures, will cause the principal amount of such Global Security to be decreased by the aggregate principal amount of the beneficial interest so exchanged.  If all of the beneficial interests in a Global Security are so exchanged, such Global Security will be deemed surrendered to the Trustee for cancellation, and the Trustee will cause such Global Security to be cancelled in accordance with the Applicable Procedures.

 

In the case of an exchange for Physical Securities under clause (3) above:

 

(A)                               the Company will deliver notice of such request to the Security Registrar and the Trustee, which notice will identify each owner of a beneficial interest to be exchanged, the aggregate principal amount of each such beneficial interest and the CUSIP of the relevant Global Security;

 

(B)                               the Company, in accordance with Section 303 of the Base Indenture, will promptly execute, and, upon receipt of a Company Request, the Trustee, in accordance with Section 303 of the Base Indenture, will promptly authenticate and deliver to each such beneficial owner, Physical Securities registered in such beneficial owner’s name having an aggregate principal amount equal to the aggregate principal amount of its exchanged beneficial interest and bearing any legends that such Physical Securities are required to bear under this Indenture and any applicable law; and

 

(C)                               the Security Registrar, in accordance with the Applicable Procedures, will cause the principal amount of each relevant Global Security to be decreased by the aggregate principal amount of the beneficial interests so exchanged.  If all of the beneficial interests in a Global Security are so exchanged, such Global Security will be deemed surrendered to the Trustee for cancellation, and the Trustee will cause such Global Security to be cancelled in accordance with the Applicable Procedures.

 

In each of the cases described in clauses (1), (2) and (3) above, the Company may rely on the Depositary to provide all names of beneficial owners and their respective principal amounts beneficially owned and may issue Physical Securities registered in the names and amounts so provided by the Depositary.

 

(e)                                  Physical Securities.  Except to the extent otherwise provided in Section 2.03(a) hereof, Physical Securities may be transferred or exchanged in accordance with Section 303 of the Base Indenture.

 

Section 2.04                             Payments on the Securities.

 

(a)                                 In General.  Each Security will accrue interest at a rate equal to 5.375% per annum from the most recent date to which interest has been paid or duly provided for, or, if no interest has been paid or duly provided for, the Issue Date.  Interest on a Security will cease to accrue upon the earliest of the Maturity Date, subject to the provisions of Article 3 hereof, any Fundamental Change Repurchase Date for such Security, and subject to the provisions of Article 4 hereof, any Conversion Date for such Security.  Interest on any Security will be payable semi-annually in arrears on each Interest Payment Date, beginning May 15, 2018, to the Holder of such Security as of the Close of Business on the Regular Record Date immediately preceding the applicable Interest Payment Date.  As provided in Section 310 of the Base Indenture, interest will be computed on the basis of a 360-day year comprised of twelve 30-day months, and, for partial months, on the basis of the number of days actually elapsed in a 30-day month.  Pursuant to Section 6.04 hereof, in certain circumstances, the Company may be obligated to pay Holders Supplementary Interest.

 

The Securities will mature on the Maturity Date, and on the Maturity Date, each Holder of a then Outstanding Security will be entitled on such date to receive $1,000 in cash for each $1,000 in principal amount of then Outstanding Securities held, together with accrued and unpaid interest to, but not including, the Maturity Date on such then Outstanding Securities (except that accrued and unpaid interest will be paid on the Maturity Date to Holders of record on the related Regular Record Date).

 

12

 

Notwithstanding anything to the contrary, if the Maturity Date or any Interest Payment Date or Fundamental Change Repurchase Date or any Conversion Date falls, or if any payment, delivery, notice or other action by the Company is otherwise due, on a day that is not a Business Day, then any action to be taken on such date need not be taken on such date, but may be taken on the immediately following Business Day with the same force and effect as if taken on such date, and no additional interest will accrue and no Default shall occur on account of such delay.

 

(b)                                 Method of Payment.  The Company will pay the principal of, the Fundamental Change Repurchase Price for, and any cash portion of the Settlement Amount with respect to, any Physical Security to the Holder of such Security in cash at the designated office of the Paying Agent in the borough of Manhattan in The City of New York, New York, prior to 10:00 A.M. on the relevant payment or settlement date, as the case may be.  The Company will pay any interest on any Physical Security to the Holder of such Security (i) to Holders having an aggregate principal amount of $5,000,000 or less, by check mailed to the Holders of such Securities mailed to such Holder’s registered address, and (ii) to Holders having an aggregate principal amount of more than $5,000,000, either (A) by check mailed to such Holder’s registered address or, (B) upon application by such a Holder to the Security Registrar not later than the relevant Regular Record Date, by wire transfer in immediately available funds to such Holder’s account within the United States, which application shall remain in effect until such Holder notifies, in writing, the Securities Registrar to the contrary.

 

The Company will pay the principal of, interest on, the Fundamental Change Repurchase Price for, and any cash portion of the Settlement Amount with respect to, any Global Security to the Depositary by wire transfer of immediately available funds on the relevant payment date in accordance with Applicable Procedures.

 

(c)                                  Defaulted Payments.  Notwithstanding Section 307 of the Base Indenture, payments of the Fundamental Change Repurchase Price, principal and interest that are not made when due will accrue interest per annum at the then-applicable interest rate for the Securities plus one percent from the required payment date.

 

ARTICLE 3

 

REDEMPTIONS AND PURCHASES

 

Section 3.01                             Amendments to the Base Indenture.

 

(a)                                 No Redemption and No Sinking Fund.  Article XI and Article XII of the Base Indenture shall not apply with respect to the Securities.

 

Section 3.02                             Purchase at Option of Holders upon a Fundamental Change.  (a)  If a Fundamental Change occurs, then each Holder shall have the right, at such Holder’s option, to require the Company to repurchase for cash all of such Holder’s Securities, or any portion thereof that is equal to $1,000 or a multiple of $1,000, on a date (the “Fundamental Change Repurchase Date”) specified by the Company that is not less than 20 or more than 35 calendar days following the date of the Fundamental Change Company Notice, at a purchase price equal to 100% of the principal amount of the Securities to be repurchased, plus accrued and unpaid interest thereon, if any, to, but excluding, the Fundamental Change Repurchase Date (the “Fundamental Change Repurchase Price”); provided, however, that if the Fundamental Change Repurchase Date falls after a Regular Record Date and on or prior to the Interest Payment Date corresponding to such Regular Record Date, the Company shall instead pay the full amount of accrued and unpaid interest on such Security on the Interest Payment Date to the Holder of record of such Security as of such Regular Record Date and the Fundamental Change Repurchase Price shall be equal to 100% of the principal amount of the Securities to be purchased.

 

Purchases of Securities under this Section 3.02 shall be made, at the option of the Holder thereof, upon:

 

(1)                                 if the Securities to be purchased are Physical Securities, delivery to the Paying Agent by the Holder of a duly completed notice (the “Fundamental Change Repurchase Notice”) in the form set forth in Attachment 2 to the Form of Security attached hereto as Exhibit A and of the Securities, duly endorsed for transfer,

 

13

 

on or before the Close of Business on the Business Day immediately preceding the Fundamental Change Repurchase Date (the “Fundamental Change Expiration Time”); and

 

(2)                                 if the Securities to be purchased are Global Securities, delivery of the Securities, by book-entry transfer, in compliance with the Applicable Procedures of the Depositary and the satisfaction of any other requirements of the Depositary in connection with tendering beneficial interests in a Global Security for purchase, by the Fundamental Change Expiration Time.

 

The Fundamental Change Repurchase Notice in respect of any Securities to be purchased shall state:

 

(1)                                 if certificated, the certificate numbers of such Securities;

 

(2)                                 the portion of the principal amount of such Securities, which must be $1,000 or an integral multiple thereof; and

 

(3)                                 that such Securities are to be repurchased by the Company pursuant to the applicable provisions of the Securities and this Indenture.

 

Notwithstanding anything herein to the contrary, any Holder delivering to the Paying Agent the Fundamental Change Repurchase Notice contemplated by this Section 3.02 shall have the right to withdraw, in whole or in part, such Fundamental Change Repurchase Notice at any time prior to the Fundamental Change Expiration Time by delivery of a written notice of withdrawal to the Paying Agent in accordance with Section 3.04.

 

The Paying Agent shall promptly notify the Company of the receipt by it of any Fundamental Change Repurchase Notice or written notice of withdrawal thereof.

 

(b)                                 On or before the 20th calendar day after the occurrence of a Fundamental Change, the Company shall provide to all Holders of the Securities, the Trustee and the Paying Agent (in the case of any Paying Agent other than the Trustee) a notice (the “Fundamental Change Company Notice”) of the occurrence of such Fundamental Change and of the repurchase right at the option of the Holders arising as a result thereof.  Such notice shall be sent by first class mail or, in the case of any Global Securities, in accordance with the procedures of the Depositary for providing notices.  Simultaneously with providing such Fundamental Change Company Notice, the Company shall publish this information in a newspaper of general circulation in The City of New York or publish the information on the Company’s website or through such other public medium as the Company may use at that time.

 

Each Fundamental Change Company Notice shall specify:

 

(1)                                 the events causing the Fundamental Change;

 

(2)                                 the date of the Fundamental Change;

 

(3)                                 the last date on which a Holder of Securities may exercise the repurchase right pursuant to this Article 3;

 

(4)                                 the Fundamental Change Repurchase Price;

 

(5)                                 the Fundamental Change Repurchase Date;

 

(6)                                 the name and address of the Paying Agent and the Conversion Agent, if applicable;

 

(7)                                 if applicable, the Conversion Rate and any adjustments to the Conversion Rate;

 

14

 

(8)                                 that the Securities with respect to which a Fundamental Change Repurchase Notice has been delivered by a Holder may be converted only if the Holder withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Indenture; and

 

(9)                                 the procedures that Holders must follow to require the Company to purchase their Securities.

 

No failure of the Company to give the foregoing notices and no defect therein shall limit the repurchase rights of the Holders of Securities or affect the validity of the proceedings for the purchase of the Securities pursuant to this Section 3.02.

 

(c)                                  Notwithstanding the foregoing, there shall be no purchase of any Securities pursuant to this Section 3.02 if the principal amount of the Securities has been accelerated, and such acceleration has not been rescinded, on or prior to the Fundamental Change Repurchase Date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Securities).  The Paying Agent will promptly return to the respective Holders thereof any Physical Securities held by it during the acceleration of the Securities (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Securities) and shall deem to be cancelled any instructions for book-entry transfer of the Securities in compliance with the procedures of the Depositary, in which case, upon such return or cancellation, as the case may be, the Fundamental Change Repurchase Notice with respect thereto shall be deemed to have been withdrawn.

 

Section 3.03                             Effect of Fundamental Change Repurchase Notice.  Upon receipt by the Paying Agent of a Fundamental Change Repurchase Notice specified in Section 3.02, the Holder of the Security in respect of which such Fundamental Change Repurchase Notice was given shall (unless such Fundamental Change Repurchase Notice is withdrawn in accordance with Section 3.04) thereafter be entitled to receive solely the Fundamental Change Repurchase Price in cash with respect to such Security (and any previously accrued and unpaid interest on such Security).  Such Fundamental Change Repurchase Price shall be paid to such Holder, subject to receipt of funds by the Paying Agent, on the later of (x) the applicable Fundamental Change Repurchase Date (provided the conditions in Section 3.02 have been satisfied) and (y) the time of delivery or book-entry transfer of such Security to the Paying Agent by the Holder thereof in the manner required by Section 3.02, subject in each case to extensions to comply with applicable law.

 

Section 3.04                             Withdrawal of Fundamental Change Repurchase Notice.  A Fundamental Change Repurchase Notice may be withdrawn (in whole or in part) by means of a written notice of withdrawal delivered to the Paying Agent in accordance with the Fundamental Change Company Notice at any time prior to the Fundamental Change Expiration Time, specifying:

 

(1)                                 the principal amount of the Securities with respect to which such notice of withdrawal is being submitted;

 

(2)                                 if Physical Securities have been issued, the certificate numbers of the withdrawn Securities; and

 

(3)                                 the principal amount, if any, which remains subject to the Fundamental Change Repurchase Notice;

 

provided, however, that if the Securities are Global Securities, the notice must comply with Applicable Procedures of the Depositary.

 

The Paying Agent will promptly return to the respective Holders thereof any Physical Securities with respect to which a Fundamental Change Repurchase Notice has been withdrawn in compliance with the provisions of this Section 3.04.

 

15

 

Section 3.05                             Deposit of Fundamental Change Repurchase Price.  Prior to 10:00 a.m., New York City time, on the Fundamental Change Repurchase Date, the Company shall deposit with the Paying Agent (or, if the Company or a Subsidiary or an Affiliate of either of them is acting as the Paying Agent, shall segregate and hold in trust as provided herein) an amount of money (in immediately available funds if deposited on such Business Day) sufficient to pay the Fundamental Change Repurchase Price of all the Securities or portions thereof that are to be purchased as of the Fundamental Change Repurchase Date.  If the Paying Agent holds cash sufficient to pay the Fundamental Change Repurchase Price of the Securities for which a Fundamental Change Repurchase Notice has been tendered and not withdrawn in accordance with this Indenture on the Fundamental Change Repurchase Date, then as of such Fundamental Change Repurchase Date, (a) such Securities will cease to be Outstanding and interest will cease to accrue thereon (whether or not book-entry transfer of such Securities is made or such Securities have been delivered to the Paying Agent) and (b) all other rights of the Holders in respect thereof will terminate (other than the right to receive the Fundamental Change Repurchase Price and, if the Fundamental Change Repurchase Date falls after a Regular Record Date but on or prior to the Business Day immediately following the corresponding Interest Payment Date, the right of the Holder of record on such Regular Record Date to receive the related interest payment).

 

Section 3.06                             Securities Purchased in Whole or in Part.  Any Security that is to be purchased, whether in whole or in part, shall be surrendered at the office of the Paying Agent (with, if the Company or the Trustee so requires in the case of Physical Securities, due endorsement by, or a written instrument of transfer in form satisfactory to the Company and the Trustee duly executed by, the Holder thereof or such Holder’s attorney duly authorized in writing) and the Company shall execute and the Trustee shall authenticate and deliver to the Holder of such Security, without service charge, a new Security or Securities, of any authorized denomination as requested by such Holder in aggregate principal amount equal to, and in exchange for, the portion of the principal amount of the Security so surrendered that is not purchased.  Any Holder whose Securities are purchased pursuant to this Article 3 shall receive payment of the Fundamental Change Repurchase Price on the later of (i) the Fundamental Change Repurchase Date or (ii) the time of book-entry transfer or the delivery of the Securities so purchased.

 

Section 3.07                             Covenant To Comply with Applicable Laws upon Purchase of Securities.  In connection with any offer to purchase Securities under Section 3.02, the Company shall, in each case if required by law, (i) comply with Rule 13e-4, Rule 14e-1 and any other tender offer rules under the Exchange Act that may then be applicable, (ii) file a Schedule TO or any other required schedule under the Exchange Act and (iii) otherwise comply with all federal and state securities laws in connection with such purchase offer.

 

Section 3.08                             Repayment to the Company.  To the extent that the aggregate amount of cash deposited by the Company pursuant to Section 3.05 exceeds the aggregate Fundamental Change Repurchase Price of the Securities or portions thereof that the Company is obligated to purchase as of the Fundamental Change Repurchase Date, then, following the Fundamental Change Repurchase Date, the Paying Agent shall promptly return any such excess to the Company.

 

ARTICLE 4

 

CONVERSION

 

Section 4.01                             Right To Convert.  (a)  Subject to and upon compliance with the provisions of this Indenture, each Holder shall have the right, at such Holder’s option, to convert its Securities, or any portion of its Securities such that the principal amount that remains Outstanding of each Security that is not converted in full equals $1,000 or an integral multiple of $1,000 in excess thereof, into the Settlement Amount determined in accordance with Section 4.03(a) hereof, (x) prior to the Close of Business on the Business Day immediately preceding August 15, 2020, only upon satisfaction of one or more of the conditions described in Section 4.01(b) hereof, and (y) on or after August 15, 2020, at any time prior to the Close of Business on the Business Day immediately preceding the Maturity Date.

 

(b)                                 (1)                                 Prior to the Close of Business on the Business Day immediately preceding August 15, 2020, a Holder may surrender Securities for conversion at any time during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 (and only during such calendar quarter) if the Last Reported Sale

 

16

 

Price of the Common Stock for at least 20 Trading Days (whether or not consecutive) during the period of 30 consecutive Trading Days ending on the last Trading Day of the immediately preceding calendar quarter is greater than or equal to 110% of the Conversion Price in effect on each applicable Trading Day.

 

(2)                                 Prior to the Close of Business on the Business Day immediately preceding August 15, 2020, a Holder may surrender all or any portion of its Securities for conversion at any time during the five Business Day period after any five consecutive Trading Day period (the “Measurement Period”) in which the Trading Price per $1,000 principal amount of Securities, as determined following a request by a Holder in accordance with the procedures set forth in this Section 4.01(b)(2), for each Trading Day of such Measurement Period was less than 98% of the product of (i) the Last Reported Sale Price of the Common Stock on such Trading Day and (ii) the Conversion Rate in effect on such Trading Day.  The Trading Price shall be determined by the Bid Solicitation Agent pursuant to this Section 4.01(b)(2) and the definition of “Trading Price” set forth in Section 1.02 hereof.  The Company shall provide written notice to the Bid Solicitation Agent (if other than the Company) of the three independent nationally recognized securities dealers selected by the Company in accordance with the definition of Trading Price, along with the appropriate contact information for each.  The Bid Solicitation Agent (if other than the Company) shall have no obligation to determine the Trading Price per $1,000 principal amount of Securities unless the Company has requested such determination; and the Company shall have no obligation to make such request (or, if the Company is the Bid Solicitation Agent, the Company shall have no obligation to determine the Trading Price of the Securities) unless a Holder of a Security provides the Company with reasonable evidence that the Trading Price per $1,000 principal amount of Securities would be less than 98% of the product of (i) the Last Reported Sale Price of the Common Stock on such Trading Day and (ii) the Conversion Rate in effect on such Trading Day.  At such time, the Company shall instruct the Bid Solicitation Agent (if other than the Company) to determine (or, if the Company is the Bid Solicitation Agent, the Company shall determine) the Trading Price per $1,000 principal amount of the Securities beginning on the next Trading Day and on each successive Trading Day until the Trading Price per $1,000 principal amount of Securities for a Trading Day is greater than or equal to 98% of the product of (i) the Last Reported Sale Price of the Common Stock on such Trading Day and (ii) the Conversion Rate in effect on such Trading Day.  Whenever the condition to conversion set forth in this Section 4.01(b)(2) has been met, but was not met on the immediately preceding Trading Day, the Company will so notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee).  If, at any time after the condition to conversion set forth in this Section 4.01(b)(2) has been met, the condition to conversion set forth in this Section 4.01(b)(2) ceases to be met, the Company will so notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) promptly after such condition ceases to be met. The Company will initially act as Bid Solicitation Agent.

 

(3)                                 If, prior to the Close of Business on the Business Day immediately preceding August 15, 2020, the Company elects to (x) issue to all or substantially all holders of the Common Stock any rights, options or warrants entitling them for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of the Common Stock at a price per share that is less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance (taking into account any consideration received by the Company as described in Section 4.04(b)); or (y) distribute to all or substantially all holders of the Common Stock the Company’s assets, securities or rights to purchase the Company’s securities, which distribution has a per-share value, as reasonably determined by the Board of Directors, exceeding 10% of the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the date of announcement for such distribution, then, in either case, the Company must deliver notice of such issuance or distribution, and of the Ex-Dividend Date for such issuance or distribution, to the Holders at least 50 Scheduled Trading Days prior to the Ex-Dividend Date for such issuance or distribution. Once the Company has given such notice, Holders may surrender all or any portion of their Securities for conversion at any time until the earlier of (a) the Close of Business on the Business Day immediately preceding the Ex-Dividend Date for such issuance or distribution and (b) the Company’s announcement that such issuance or distribution will not take place, even if the Securities are not otherwise convertible at such time; provided, however, that Holders shall not have the right to convert their Securities pursuant to this Section 4.01(b)(3) if the Company provides that Holders shall participate, at the same time and upon the same terms, as holders of the Common Stock in any of the transactions described above without having to convert their Securities as if they held a number of shares of the Common Stock equal to the Conversion Rate in effect immediately prior to the Open of Business on the Ex-Dividend Date for such issuance or

 

17

 

distribution multiplied by the principal amount (expressed in thousands) of Securities held by such Holder on the Ex-Dividend Date for such issuance or distribution.

 

(4)                                 If (i) a Fundamental Change or a Make-Whole Fundamental Change occurs prior to the Close of Business on the Business Day immediately preceding August 15, 2020, regardless of whether a Holder has the right to require the Company to repurchase the Securities as described under Article 3 or (ii) the Company is a party to a consolidation, merger, binding share exchange, or transfer or lease of all or substantially all of its assets (other than a merger effected solely to change the Company’s jurisdiction or incorporation that does not otherwise constitute a Fundamental Change or a Make-Whole Fundamental Change), in each case, pursuant to which the Common Stock would be converted into cash, securities or other assets, all or any portion of a Holder’s Securities may be surrendered for conversion at any time from or after the effective date of the transaction until 35 Trading Days after such effective date or, if such transaction is also a Fundamental Change, until the related Fundamental Change Repurchase Date.  The Company will notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) no later than the effective date of such transaction.

 

(c)                                  Notwithstanding any other provision of the Securities or this Indenture, no Holder of Securities will be entitled to receive Common Stock following conversion of such Securities to the extent that receipt of such Common Stock would cause such Holder to exceed the ownership limitations contained in the Company’s charter.

 

(d)                                 If any delivery of shares of Common Stock owed to a Holder upon conversion of Securities is not made, in whole or in part, as a result of the limitations described in Section 4.01(c), the Company’s obligation to make such delivery shall not be extinguished and the Company shall deliver such shares as promptly as practicable after any such converting Holder gives notice to the Company that such delivery would not result in it exceeding the ownership limitations in the Company’s charter.

 

Section 4.02                             Conversion Procedures.

 

(a)                                 Each Security shall be convertible at the office of the Conversion Agent and, if applicable, in accordance with the Applicable Procedures of the Depositary.

 

(b)                                 To exercise the conversion privilege with respect to a beneficial interest in a Global Security, the Holder must comply with the Applicable Procedures of the Depositary in effect at that time, and pay the funds, if any, required by Section 4.02(f), and the Conversion Agent must be informed of the conversion in accordance with the Applicable Procedures of the Depositary.

 

To exercise the conversion privilege with respect to any Physical Securities, the Holder of such Physical Securities shall:

 

(1)                                 complete and manually sign a conversion notice in the form set forth in the Form of Notice of Conversion (the “Conversion Notice”) or a facsimile of the Conversion Notice;

 

(2)                                 deliver the Conversion Notice, which is irrevocable, and the Security to the Conversion Agent;

 

(3)                                 if required, furnish appropriate endorsements and transfer documents; and

 

(4)                                 if required, make any payment required under Section 4.02(f).

 

If, upon conversion of a Security, any shares of Common Stock are to be issued to a Person other than the Holder of such Security, the related Conversion Notice shall include such other Person’s name and address.

 

If a Security is subject to a Fundamental Change Repurchase Notice, such Security may not be converted unless such Fundamental Change Repurchase Notice is withdrawn in accordance with Section 3.04 hereof prior to the relevant Fundamental Change Expiration Time. If a Holder submits its Securities for repurchase pursuant to a

 

18

 

Fundamental Change Repurchase Notice, such Holder’s right to withdraw the Fundamental Change Repurchase Notice and convert the Securities that are subject to repurchase shall terminate at the Close of Business on the Business Day immediately preceding the relevant Fundamental Change Repurchase Date.

 

For any Security, the first Business Day on which the Holder of such Security satisfies all of the applicable requirements set forth above with respect to such Security and on which conversion of such Security is not otherwise prohibited under this Indenture shall be the “Conversion Date” with respect to such Security.

 

Each conversion shall be deemed to have been effected as to any such Securities (or portion thereof) surrendered for conversion at the Close of Business on the applicable Conversion Date; provided, however, that the Person in whose name the certificate for any shares of Common Stock delivered upon conversion is registered shall be treated as a stockholder of record as of the Close of Business on (i) such Conversion Date (in the case of Physical Settlement) or (ii) the last Trading Day of the applicable Observation Period (in the case of Combination Settlement) except to the extent required by Section 4.04 hereof.  At the Close of Business on the Conversion Date for a Security, the converting Holder shall no longer be the Holder of such Security.

 

(c)                                  Endorsement.  Any Securities surrendered for conversion shall, unless shares of Common Stock issuable on conversion are to be issued in the same name as the registration of such Securities, be duly endorsed by, or be accompanied by instruments of transfer in form satisfactory to the Company duly executed by, the Holder or its duly authorized attorney.

 

(d)                                 Physical Securities.  If any Physical Securities in a denomination greater than $1,000 shall be surrendered for partial conversion, the Company shall execute and the Trustee shall authenticate and deliver to the Holder of the Securities so surrendered, without charge, new Securities in authorized denominations in an aggregate principal amount equal to the unconverted portion of the surrendered Securities.

 

(e)                                  Global Securities.  Upon the conversion of a beneficial interest in Global Securities, the Conversion Agent shall make a notation in its records as to the reduction in the principal amount represented thereby.  The Company shall notify the Trustee in writing of any conversions of Securities effected through any Conversion Agent other than the Trustee.

 

(f)                                   Interest Due Upon Conversion.  If a Holder converts a Security after the Close of Business on a Regular Record Date but prior to the Open of Business on the Interest Payment Date corresponding to such Regular Record Date, such Holder must accompany such Security with an amount of cash equal to the amount of interest payable on such Security on the corresponding Interest Payment Date (regardless of whether the converting Holder was the Holder of record on the corresponding Regular Record Date); provided, however, that a Holder need not make such payment (1) if the Conversion Date follows the Regular Record Date immediately preceding the Maturity Date; (2) if the Company has specified a Fundamental Change Repurchase Date that is after a Regular Record Date and on or prior to the Business Day immediately following the corresponding Interest Payment Date; or (3) to the extent of any overdue interest, if any overdue interest exists at the time of conversion with respect to such Security.

 

(g)                                  Taxes Due upon Conversion.  If a Holder converts a Security, the Company will pay any documentary, stamp or similar issue or transfer tax due on the issue of any shares of the Common Stock upon the conversion, unless the tax is due because the Holder requests that any shares be issued in a name other than the Holder’s name, in which case the Holder will pay that tax.

 

Section 4.03                             Settlement Upon Conversion.

 

(a)                                 Settlement Amount.  Subject to this Section 4.03 and Section 4.06(b), if a Holder converts a Security, the Company shall pay or deliver to such Holder, as the case may be, in respect of each $1,000 principal amount of Securities being converted, solely cash, solely shares of Common Stock (together with cash in lieu of fractional shares as provided herein) or a combination of cash and Common Stock (the “Settlement Amount”), at the Company’s election, as set forth in this Section 4.03.

 

19

 

(1)                                 The Company shall pay or deliver, as the case may be, the Settlement Amount on the second Business Day immediately following (i) the last Trading Day of the Observation Period in the case of Cash Settlement or Combination Settlement or (ii) the Conversion Date in the case of Physical Settlement.

 

(2)                                 All conversions for which the relevant Conversion Date occurs on or after August 15, 2020 will be settled using the same Settlement Method.

 

(3)                                 Except for any conversions for which the relevant Conversion Date occurs on or after August 15, 2020, the Company will use the same Settlement Method for all conversions with the same Conversion Date, but the Company will not have any obligation to use the same Settlement Method with respect to conversions with different Conversion Dates.

 

(4)                                 With respect to each Conversion Date occurring prior to August 15, 2020, the Company shall deliver a notice (each, a “Settlement Notice”) of the relevant Settlement Method not later than the Close of Business on the Trading Day immediately following the related Conversion Date (or in the case of any conversions for which the relevant Conversion Date occurs on or after August 15, 2020, no later than August 15, 2020).  Each such Settlement Notice shall specify whether the Company shall satisfy its conversion obligation by (i) delivering solely shares of Common Stock (together with cash in lieu of fractional shares as provided herein) (“Physical Settlement”), (ii) paying solely cash (“Cash Settlement”) or (iii) paying and delivering, as the case may be, a combination of cash and shares of Common Stock (“Combination Settlement”).  In the case of an election that provides for Combination Settlement, the relevant Settlement Notice shall indicate the Specified Dollar Amount.  If the Company does not deliver a Settlement Notice within the time periods specified above, or if the Company provides a Settlement Notice within the time periods specified above and elects Combination Settlement but the Settlement Notice does not specify a Specified Dollar Amount, the Company will be deemed to have elected Combination Settlement with a Specified Dollar Amount of $1,000.

 

(5)                                 The Settlement Amount in respect of any conversion shall be computed as follows:

 

(A)                               if the Company elects Physical Settlement, the Company will deliver to the converting Holder in respect of each $1,000 principal amount of Securities being converted a number of shares of Common Stock equal to the Conversion Rate;

 

(B)                               if the Company elects Cash Settlement, the Company shall pay to the converting Holder in respect of each $1,000 principal amount of Securities being converted cash in an amount equal to the sum of the Daily Conversion Values for each of the 40 consecutive Trading Days during the related Observation Period; and

 

(C)                               if the Company elects (or is deemed to have elected) Combination Settlement, the Company shall pay or deliver, as the case may be, to the converting Holder in respect of each $1,000 principal amount of Securities being converted, a Settlement Amount equal to the sum of the Daily Settlement Amounts for each of the 40 consecutive Trading Days during the related Observation Period.

 

(6)                                 The “Daily Settlement Amount” for each of the 40 consecutive Trading Days of the applicable Observation Period, will consist of:

 

(A)                               cash equal to the lesser of (i) the maximum cash amount per $1,000 principal amount of Securities to be received upon conversion as specified in the Settlement Notice (the “Specified Dollar Amount”), if any, divided by 40 (such quotient being referred to as the “Daily Measurement Value”) and (ii) the Daily Conversion Value; and

 

(B)                               if the Daily Conversion Value for such Trading Day exceeds the Daily Measurement Value for such Trading Day, a number of shares of Common Stock equal to (i) the difference between the Daily Conversion Value and the Daily Measurement Value, divided by (ii) the Daily VWAP for such Trading Day.

 

20

 

(7)                                 In the case of Cash Settlement or Combination Settlement, the Settlement Amount or Daily Conversion Values shall be determined by the Company promptly following the last day of the Observation Period.  Promptly after such determination, the Company shall notify the Trustee and the Conversion Agent of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash deliverable in lieu of fractional shares of Common Stock.  The Trustee and the Conversion Agent shall be entitled to rely exclusively on the notice given by the Company and shall have no responsibility for any such determination.

 

(b)                                 Fractional Shares.  Notwithstanding the foregoing, the Company will not issue fractional shares of Common Stock with respect to any converted Security in respect of which shares of Common Stock are deliverable.  Instead, if any such shares of Common Stock includes a fraction of a share of Common Stock, the Company will, in lieu of delivering such fraction of a share of Common Stock, pay an amount of cash equal to the product of (i) such fraction of a share and (ii) the Daily VWAP on the relevant Conversion Date (in the case of Physical Settlement) or on the last Trading Day of the applicable Observation Period (in the case of Combination Settlement), subject in each case to the following paragraph.

 

If a Holder surrenders more than one Security for conversion on a single Conversion Date, the Company will calculate the amount of cash and the number of shares of Common Stock due with respect to such Securities as if such Holder had surrendered for conversion one Security having an aggregate principal amount equal to the sum of the principal amounts of each of the Securities surrendered for conversion by such Holder on such Conversion Date.

 

(c)                                  Settlement of Accrued Interest and Deemed Payment of Principal.  Subject to Section 4.02(f), if a Holder converts a Security, the Company will not adjust the Conversion Rate to account for any accrued and unpaid interest on such Security and the Company’s delivery of the amount of cash and the number of shares of Common Stock, if any, into which a Security is convertible will be deemed to satisfy and discharge in full the Company’s obligation to pay the principal of, and accrued and unpaid interest, if any, on, such Security to, but excluding, the Conversion Date; provided, however, that if a Holder converts a Security after the Close of Business on a Regular Record Date and prior to the Open of Business on the corresponding Interest Payment Date, the Company will still be obligated to pay the interest due on such Interest Payment Date to the Holder of such Security on such Regular Record Date.  As a result of the foregoing, and Section 4.02(f), the Company will pay accrued and unpaid interest on the Maturity Date on all Securities converted after the Regular Record Date immediately preceding the Maturity Date to the holders of record of such Securities on such Regular Record Date, and converting Holders will not be required to pay the Company equivalent amounts.

 

As a result, except as otherwise provided in the proviso to the first sentence of the immediately preceding paragraph, any accrued and unpaid interest with respect to a converted Security will be deemed to be paid in full rather than cancelled, extinguished or forfeited.  In addition, except as otherwise provided in the proviso to the first sentence of the immediately preceding paragraph, if the Settlement Amount for any Security includes both cash and shares of the Common Stock, accrued and unpaid interest will be deemed to be paid first out of the amount of cash delivered upon such conversion.  Except as otherwise provided herein, in no event will a Holder be entitled to receive any dividend or other distribution with respect to any Common Stock issued on conversion of such Holder’s Securities if the applicable Conversion Date is after the Regular Record Date for such dividend or distribution.  Prior to any conversion in accordance with this Section 4.03, a Holder shall not be the owner of any Common Stock issuable upon conversion of such Holder’s Securities.

 

(d)                                 Notices.  Whenever a Conversion Date occurs with respect to a Security, the Conversion Agent will, as promptly as possible, and in no event later than the Business Day immediately following such Conversion Date, deliver to the Company and the Trustee, if it is not then the Conversion Agent, notice that a Conversion Date has occurred, which notice will state such Conversion Date, the principal amount of Securities converted on such Conversion Date and the names of the Holders that converted Securities on such Conversion Date.

 

If any delivery of shares of the Company’s Common Stock owed to a Holder upon conversion of Securities is not made, in whole or in part, as a result of the limitations described in this Section 4.03(d), the Company’s obligation to make such delivery shall not be extinguished and the Company shall deliver such shares as promptly as

 

21

 

practicable after any such converting Holder gives notice to the Company that such delivery would not result in it exceeding the ownership limitations in the Company’s charter.

 

Section 4.04                             Adjustment of Conversion Rate.  The Conversion Rate will be adjusted as described in this Section 4.04, except that the Company shall not make any adjustments to the Conversion Rate if Holders participate (other than in the case of (x) a share split or share combination or (y) a tender or exchange offer), at the same time and upon the same terms as holders of the Common Stock and solely as a result of holding the Securities, in any of the transactions described below without having to convert their Securities, as if they held a number of shares of Common Stock equal to the Conversion Rate, multiplied by the principal amount (expressed in thousands) of Securities held by such Holder.

 

(a)                                 If the Company exclusively issues shares of Common Stock as a dividend or distribution on shares of the Common Stock, or if the Company effects a share split or share combination, the Conversion Rate will be adjusted based on the following formula:

 

	
CR1
    	
=
    	
CR0 x
    	
 
    	
OS1
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
OS0
    	
 
    

 

where,

 

	
CR0
    	
=
    	
the Conversion Rate in effect immediately prior to   the Open of Business on the Ex-Dividend Date of such dividend or   distribution, or immediately prior to the Open of Business on the Effective   Date of such share split or share combination, as applicable;
    
	
 
    	
 
    	
 
    
	
CR1
    	
=
    	
the Conversion Rate in effect immediately after the   Open of Business on such Ex-Dividend Date or such Effective Date;
    
	
 
    	
 
    	
 
    
	
OS0
    	
=
    	
the number of shares of Common Stock outstanding   immediately prior to the Open of Business on such Ex-Dividend Date or such   Effective Date; and
    
	
 
    	
 
    	
 
    
	
OS1
    	
=
    	
the number of shares of Common Stock outstanding   immediately after giving effect to such dividend, distribution, share split   or share combination.
    

 

Any adjustment made under this Section 4.04(a) shall become effective immediately after the Open of Business on the Ex-Dividend Date for such dividend or distribution, or immediately after the Open of Business on the Effective Date for such share split or share combination, as applicable.  If any dividend or distribution of the type described in this Section 4.04(a) is declared but not so paid or made, the Conversion Rate shall be immediately readjusted, effective as of the date the Board of Directors determines not to pay such dividend or distribution to the Conversion Rate that would then be in effect if such dividend or distribution had not been declared.

 

(b)                                 If the Company issues to all or substantially all holders of the Common Stock any rights, options or warrants entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of the Common Stock, at a price per share that is less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, the Conversion Rate will be increased based on the following formula:

 

	
CR1
    	
=
    	
CR0 x
    	
 
    	
OS0 + X
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
OS0 + Y
    	
 
    

 

where,

 

	
CR0
    	
=
    	
the Conversion Rate in effect immediately prior to   the Open of Business on the Ex-Dividend Date for such issuance;
    

 

22

 

	
CR1
    	
=
    	
the Conversion Rate in effect immediately after the   Open of Business on such Ex-Dividend Date;
    
	
 
    	
 
    	
 
    
	
OS0
    	
=
    	
the number of shares of Common Stock outstanding   immediately prior to the Open of Business on such Ex-Dividend Date;
    
	
 
    	
 
    	
 
    
	
X
    	
=
    	
the total number of shares of Common Stock issuable   pursuant to such rights, options or warrants; and
    
	
 
    	
 
    	
 
    
	
Y
    	
=
    	
the number of shares of Common Stock equal to the   aggregate price payable to exercise such rights, options or warrants, divided by the average of the Last   Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day   period ending on, and including, the Trading Day immediately preceding the   date of announcement of the issuance of such rights, options or warrants.
    

 

Any increase made under this Section 4.04(b) will be made successively whenever any such rights, options or warrants are issued and shall become effective immediately after the Open of Business on the Ex-Dividend Date for such issuance.  To the extent that shares of Common Stock are not delivered after the expiration of such rights, options or warrants, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect had the increase with respect to the issuance of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually delivered.  If such rights, options or warrants are not so issued, or if no such rights, options or warrants are exercised prior to their expiration, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such Ex-Dividend Date for such issuance had not occurred.

 

For the purpose of this Section 4.04(b) and Section 4.01(b)(3) hereof, in determining whether any rights, options or warrants entitle the holders of the Common Stock to subscribe for or purchase shares of the Common Stock at less than such average of the Last Reported Sale Prices for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, and in determining the aggregate offering price of such shares of the Common Stock, there shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by the Board of Directors.

 

(c)                                  If the Company distributes shares of its Capital Stock, evidences of its indebtedness, other assets or property of the Company or rights, options or warrants to acquire its Capital Stock or other securities, to all or substantially all holders of the Common Stock, excluding:

 

(1)                                 dividends, distributions or issuances as to which an adjustment was effected pursuant to Section 4.04(a) hereof or Section 4.04(b) hereof;

 

(2)                                 dividends or distributions paid exclusively in cash as to which the provisions set forth in Section 4.04(d) hereof shall apply; and

 

(3)                                 Spin-Offs as to which the provisions set forth below in this Section 4.04(c) shall apply;

 

then the Conversion Rate shall be increased based on the following formula:

 

	
CR1
    	
=
    	
CR0 x
    	
 
    	
SP0
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
SP0 - FMV
    	
 
    

 

where,

 

	
CR0
    	
=
    	
the Conversion Rate in effect immediately prior to   the Open of Business on the Ex-Dividend Date for such distribution;
    

 

23

 

	
CR1
    	
=
    	
the Conversion Rate in effect immediately after the   Open of Business on such Ex-Dividend Date;
    
	
 
    	
 
    	
 
    
	
SP0
    	
=
    	
the average of the Last Reported Sale Prices of the Common   Stock over the 10 consecutive Trading Day period ending on, and including,   the Trading Day immediately preceding the Ex-Dividend Date for such   distribution; and
    
	
 
    	
 
    	
 
    
	
FMV
    	
=
    	
the fair market value (as determined by the Board of   Directors) of the shares of the Company’s Capital Stock, evidences the   Company’s indebtedness, assets, property, rights, options or warrants   distributed with respect to each outstanding share of the Common Stock on the   Ex-Dividend Date for such distribution.
    

 

Any increase made under the portion of this Section 4.04(c) above will become effective immediately after the Open of Business on the Ex-Dividend Date for such distribution.  If such distribution is not so paid or made, the Conversion Rate shall be decreased to be the Conversion Rate that would then be in effect if such distribution had not been declared. Notwithstanding the foregoing, if “FMV” (as defined above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, each Holder of Securities shall receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of the Common Stock, the amount and kind of the Company’s Capital Stock, evidences of the Company’s indebtedness, other assets or property of the Company or rights, options or warrants to acquire the Company’s Capital Stock or other securities that such Holder would have received if such Holder owned a number of shares of Common Stock equal to the Conversion Rate in effect on the Ex-Dividend Date for the distribution.

 

With respect to an adjustment pursuant to this Section 4.04(c) where there has been a payment of a dividend or other distribution on the Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to a Subsidiary or other business unit, that are, or, when issued, will be, listed or admitted for trading on a U.S. national securities exchange (a “Spin-Off”), the Conversion Rate will be increased based on the following formula:

 

	
CR1
    	
=
    	
CR0 x
    	
 
    	
FMV0 + MP0
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
MP0
    	
 
    

 

where,

 

	
CR0
    	
=
    	
the Conversion Rate in effect immediately prior to   the end of the Valuation Period;
    
	
 
    	
 
    	
 
    
	
CR1
    	
=
    	
the Conversion Rate in effect immediately after the   end of the Valuation Period;
    
	
 
    	
 
    	
 
    
	
FMV0
    	
=
    	
the average of the Last Reported Sale Prices of the   Capital Stock or similar equity interest distributed to holders of Common   Stock applicable to one share of Common Stock (determined by reference to the   definition of Last Reported Sale Price as if references therein to Common   Stock were to such Capital Stock or similar equity interest) over the first   10 consecutive Trading Day period after, and including, the Ex-Dividend Date   of the Spin-Off (the “Valuation Period”);   and
    
	
 
    	
 
    	
 
    
	
MP0
    	
=
    	
the average of the Last Reported Sale Prices of   Common Stock over the Valuation Period.
    

 

The increase to the Conversion Rate under the preceding paragraph of this Section 4.04(c) will occur on the last Trading Day of the Valuation Period; provided that (x) in respect of any conversion of Securities for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the Valuation Period, the reference to “10” in the preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have elapsed between the Ex-Dividend Date for such Spin-Off and such Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Securities for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the

 

24

 

Valuation Period, the reference to “10” in the preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have elapsed between the Ex-Dividend Date for such Spin-Off and such Trading Day in determining the Conversion Rate as of such Trading Day.  In addition, if the Ex-Dividend Date for such Spin-Off is after the 10th Trading Day immediately preceding, and including, the end of any Observation Period in respect of a conversion of Securities, references to “10” or “10th” within this Section 4.04(c) shall be deemed to be replaced, solely in respect of that conversion, with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date for such Spin-Off to, and including, the last Trading Day of such Observation Period.

 

Subject to Section 4.04(g), for the purposes of this Section 4.04(c), rights, options or warrants distributed by the Company to all holders of the Common Stock entitling them to subscribe for or purchase shares of the Company’s Capital Stock, including Common Stock (either initially or under certain circumstances), which rights, options or warrants, until the occurrence of a specified event or events (a “Trigger Event”): (1) are deemed to be transferred with such shares of Common Stock; (2) are not exercisable; and (3) are also issued in respect of future issuances of Common Stock, shall be deemed not to have been distributed for purposes of this Section 4.04(c), (and no adjustment to the Conversion Rate under this Section 4.04(c) will be required) until the occurrence of the earliest Trigger Event, whereupon such rights, options or warrants shall be deemed to have been distributed and an appropriate adjustment (if any is required) to the Conversion Rate shall be made under this Section 4.04(c).  If any such right, option or warrant, including any such existing rights, options or warrants distributed prior to the Issue Date are subject to events, upon the occurrence of which such rights, options or warrants become exercisable to purchase different securities, evidences of indebtedness or other assets, then the date of the occurrence of any and each such event shall be deemed to be the date of distribution and Ex-Dividend Date of such deemed distribution with respect to new rights, options or warrants with such rights (in which case the original rights, options or warrants shall be deemed to terminate and expire on such date without exercise by any of the holders).  In addition, in the event of any distribution or deemed distribution of rights, options or warrants, or any Trigger Event or other event (of the type described in the preceding sentence) with respect thereto that was counted for purposes of calculating a distribution amount for which an adjustment to the Conversion Rate under this Section 4.04(c) was made, (1) in the case of any such rights, options or warrants which shall all have been redeemed or purchased without exercise by any holders thereof, upon such final redemption or purchase (x) the Conversion Rate shall be readjusted as if such rights, options or warrants had not been issued and (y) the Conversion Rate shall then again be readjusted to give effect to such distribution, deemed distribution or Trigger Event, as the case may be, as though it were a cash distribution, equal to the per share redemption or purchase price received by holders of Common Stock with respect to such rights, options or warrants (assuming each such holder had retained such rights, options or warrants), made to all holders of Common Stock as of the date of such redemption or purchase, and (2) in the case of such rights, options or warrants which shall have expired or been terminated without exercise by any holders thereof, the Conversion Rate shall be readjusted as if such rights, options and warrants had not been issued.

 

For purposes of Section 4.04(a) hereof, Section 4.04(b) hereof and this Section 4.04(c), if any dividend or distribution to which this Section 4.04(c) applies includes one or both of:

 

(A)                               a dividend or distribution of shares of Common Stock to which Section 4.04(a) hereof also applies (the “Clause A Distribution”); or

 

(B)                               a dividend or distribution of rights, options or warrants to which Section 4.04(b) hereof also applies (the “Clause B Distribution”),

 

then (i) such dividend or distribution, other than the Clause A Distribution and the Clause B Distribution, shall be deemed to be a dividend or distribution to which this Section 4.04(c) applies (the “Clause C Distribution”) and any Conversion Rate adjustment required to be made under this Section 4.04(c) with respect to such Clause C Distribution shall be made, (ii) the Clause B Distribution, if any, shall be deemed to immediately follow the Clause C Distribution and any Conversion Rate adjustment required by Section 4.04(a) hereof with respect thereto shall then be made, except that, if determined by the Company, (A) the “Ex-Dividend Date” of the Clause B Distribution, if any, shall be deemed to be the Ex-Dividend Date of the Clause C Distribution and (B) any shares of Common Stock included in the Clause B Distribution shall not be deemed to be “outstanding immediately prior to the Open of Business on such Ex-Dividend Date” within the meaning of Section 4.04(b) hereof, and (iii) the Clause A Distribution, if any, shall be deemed to immediately follow the Clause C Distribution or the Clause B Distribution,

 

25

 

as the case may be, except that, if determined by the Company, (A) the “Ex-Dividend Date” of the Clause A Distribution, if any, shall be deemed to be the Ex-Dividend Date of the Clause C Distribution, and (B) any shares of Common Stock included in the Clause A Distribution shall not be deemed to be “outstanding immediately prior to the Open of Business on such Ex-Dividend Date or such Effective Date” within the meaning of Section 4.04(a) hereof.

 

(d)                                 If any cash dividend or distribution is made to all or substantially all holders of the Common Stock, other than a regular, quarterly cash dividend that does not exceed $0.19 per share (the “Initial Dividend Threshold”), the Conversion Rate shall be adjusted based on the following formula:

 

	
CR1
    	
=
    	
CR0 x
    	
 
    	
SP0
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
SP0 — C
    	
 
    

 

where,

 

	
CR0
    	
=
    	
the Conversion Rate in effect immediately prior to   the Open of Business on the Ex-Dividend Date for such dividend or   distribution;
    
	
 
    	
 
    	
 
    
	
CR1
    	
=
    	
the Conversion Rate in effect immediately after the Open   of Business on the Ex-Dividend Date for such dividend or distribution;
    
	
 
    	
 
    	
 
    
	
SP0
    	
=
    	
the Last Reported Sale Price of the Common Stock on   the Trading Day immediately preceding the Ex-Dividend Date for such dividend   or distribution; and
    
	
 
    	
 
    	
 
    
	
C
    	
=
    	
the amount in cash per share the Company distributes   to all or substantially all holders of the Common Stock; provided that   in the case of a regular quarterly cash dividend, such amount shall only   include the amount of such dividend or distribution in excess of the Initial   Dividend Threshold.
    

 

The Initial Dividend Threshold is subject to adjustment in a manner inversely proportional to adjustments to the Conversion Rate; provided that no adjustment will be made to the Initial Dividend Threshold for any adjustment to the Conversion Rate under this Section 4.04(d).

 

Any increase made under this Section 4.04(d) shall become effective immediately after the Open of Business on the Ex-Dividend Date for such dividend or distribution.  If such dividend or distribution is not so paid, the Conversion Rate shall be decreased, effective as of the date the Board of Directors determines not to make or pay such dividend or distribution, to be the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. Notwithstanding the foregoing, if “C” (as defined above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, each Holder shall receive, for each $1,000 principal amount of Securities it holds, at the same time and upon the same terms as holders of shares of the Common Stock, the amount of cash that such Holder would have received if such Holder owned a number of shares of Common Stock equal to the Conversion Rate on the Ex-Dividend Date for such cash dividend or distribution.

 

(e)                                  If the Company or any of its Subsidiaries make a payment in respect of a tender or exchange offer for the Common Stock, to the extent that the cash and value of any other consideration included in the payment per share of the Common Stock exceeds the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the last date on which tenders or exchanges may be made pursuant to such tender or exchange offer, the Conversion Rate shall be increased based on the following formula:

 

	
CR1
    	
=
    	
CR0 x
    	
 
    	
AC + (SP1 x OS1)
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
OS0 x SP1
    	
 
    

 

26

 

where,

 

	
CR0
    	
=
    	
the Conversion Rate in effect immediately prior to   the Close of Business on the 10th Trading Day immediately following, and   including, the Trading Day next succeeding the date such tender or exchange   offer expires;
    
	
CR1
    	
=
    	
the Conversion Rate in effect immediately after the   Close of Business the 10th Trading Day immediately following, and including,   the Trading Day next succeeding the date such tender or exchange offer   expires;
    
	
 
    	
 
    	
 
    
	
AC
    	
=
    	
the aggregate value of all cash and any other   consideration (as determined by the Board of Directors) paid or payable for   shares of Common Stock purchased in such tender offer or exchange offer;
    
	
 
    	
 
    	
 
    
	
OS0
    	
=
    	
the number of shares of Common Stock outstanding   immediately prior to the date such tender or exchange offer expires (prior to   giving effect to the purchase of all shares accepted for purchase or exchange   in such tender or exchange offer);
    
	
 
    	
 
    	
 
    
	
OS1
    	
 
    	
the number of shares of Common Stock outstanding   immediately after the date such tender or exchange offer expires (after giving   effect to the purchase of all shares accepted for purchase or exchange in   such tender or exchange offer); and
    
	
 
    	
 
    	
 
    
	
SP1
    	
 
    	
the average of the Last Reported Sale Prices of the   Common Stock over the 10 consecutive Trading Day period commencing on, and including,   the Trading Day next succeeding the date such tender or exchange offer   expires.
    

 

The increase to the Conversion Rate under the preceding paragraph of this Section 4.04(e) will occur at the Close of Business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires; provided that (x) in respect of any conversion of Securities for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to “10” or “10th” in this Section 4.04(e) shall be deemed replaced with such lesser number of Trading Days as have elapsed between the expiration date of such tender or exchange offer and such Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Securities for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to “10” or “10th” in this Section 4.04(e) shall be deemed replaced with such lesser number of Trading Days as have elapsed between the expiration date of such tender or exchange offer and such Trading Day in determining the Conversion Rate as of such Trading Day.  In addition, if the Trading Day next succeeding the date such tender or exchange offer expires is after the 10th Trading Day immediately preceding, and including, the end of any Observation Period in respect of a conversion of Securities, references to “10 Trading Days” or “10th” within this Section 4.04(e) shall be deemed to be replaced, solely in respect of that conversion, with such lesser number of Trading Days as have elapsed from, and including, the Trading Day next succeeding the date such tender or exchange offer expires to, and including, the last Trading Day of such Observation Period.

 

(f)                                   Special Settlement Provisions.   Notwithstanding anything to the contrary herein, if a Conversion Rate adjustment becomes effective on any Ex-Dividend Date as described above, and a Holder that has converted its Securities on or after such Ex-Dividend Date and on or prior to the related Regular Record Date would be treated as the record holder of shares of Common Stock as of the related Conversion Date in accordance with the provisions of the last paragraph of Section 4.02(b) based on an adjusted Conversion Rate for such Ex-Dividend Date, then, notwithstanding the foregoing Conversion Rate adjustment provisions, the Conversion Rate adjustment relating to such Ex-Dividend Date will not be made for such converting Holder. Instead, such Holder will be treated as if such Holder were the record owner of the shares of Common Stock on an unadjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment.

 

27

 

(g)                                  Poison Pill.  To the extent that the Company has a rights plan in effect upon conversion of a Security into Common Stock, the Holder converting such Security will receive, in addition to any shares of Common Stock otherwise received in connection with such conversion, the rights under the rights plan. However, if, prior to any conversion, the rights have separated from the shares of Common Stock in accordance with the provisions of the applicable rights plan, the Conversion Rate will be adjusted at the time of separation as if the Company distributed to all or substantially all holders of the Common Stock, shares of Capital Stock, evidences of indebtedness, assets, property, rights, options or warrants as described in Section 4.04(c) hereof, subject to readjustment in the event of the expiration, termination or redemption of such rights.

 

(h)                                 Deferral of Adjustments.  If an adjustment to the Conversion Rate otherwise required by this Section 4.04 would result in a change of less than 1% to the Conversion Rate, then, notwithstanding anything to the contrary herein, the Company may, at its election, defer and carry forward such adjustment, except that all such deferred adjustments must be given effect immediately upon the earliest to occur of the following: (i) when all such deferred adjustments would result in an aggregate change of at least 1% to the Conversion Rate; (ii) the Conversion Date of, or any Trading Day of an Observation Period for, any Security; (iii) the date a Fundamental Change or Make-Whole Fundamental Change occurs; and (iv) August 15, 2020.

 

(i)                                     Limitation on Adjustments.  Except as stated in this Section 4.04, the Company will not adjust the Conversion Rate for the issuance of shares of Common Stock or any securities convertible into or exchangeable for shares of Common Stock or the right to purchase shares of the Common Stock or such convertible or exchangeable securities.

 

In addition, notwithstanding anything to the contrary herein, the Conversion Rate will not be adjusted:

 

(1)                                 upon the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock under any plan;

 

(2)                                 upon the issuance of any shares of Common Stock or options or rights to purchase those shares pursuant to any present or future employee, director or consultant benefit plan or program of or assumed by the Company or any of its Subsidiaries;

 

(3)                                 upon the issuance of any shares of Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security not described in the preceding clause (2)  and outstanding as of the date the Securities were first issued;

 

(4)                                 upon the issuance of any shares of Common Stock at a price below the Conversion Price or otherwise, other than any such issuance described in Section 4.04(a), (b) or (c) above;

 

(5)                                 for a third-party tender offer by any party other than a tender offer by one or more of the Company’s subsidiaries as described in Section 4.04(e);

 

(6)                                 upon the repurchase of any shares of the Common Stock pursuant to an open market share repurchase program or other buy-back transaction, including structured or derivative transactions, that is not a tender offer or exchange offer of the kind described in Section 4.04(e);

 

(7)                                 solely for a change in the par value of the Common Stock; or

 

(8)                                 for accrued and unpaid interest on the Securities, if any.

 

(j)                                    For purposes of this Section 4.04, the number of shares of Common Stock at any time outstanding shall not include shares held in the treasury of the Company so long as the Company does not pay any dividend or make any distribution on shares of Common Stock held in the treasury of the Company, but shall include shares issuable in respect of scrip certificates issued in lieu of fractions of shares of Common Stock.

 

28

 

(k)                                 Withholding on Adjustments.  If, in connection with any adjustment to the Conversion Rate as set forth in this Section 4.04, a Holder shall be deemed for U.S. federal tax purposes to have received a distribution and the Company reasonably believes it is required to collect withholding tax with respect to any such deemed distribution, the Company may withhold from cash payments of interest in accordance with the provisions of Section 2.04 hereof or from cash and Common Stock, if any, otherwise deliverable to a Holder upon a conversion of Securities in accordance with the provisions of Section 4.03 hereof or repurchase of a Security in accordance with the provisions of Article 3 hereof.

 

Section 4.05                             Other Adjustments.

 

(a)                                 Adjustments of Prices.  Whenever any provision of this Indenture requires the Company to calculate the Last Reported Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts over a span of multiple days (including an Observation Period and the Stock Price for purposes of Section 4.06), the Board of Directors will make appropriate adjustments to each to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment to the Conversion Rate where the Ex-Dividend Date, Effective Date or the expiration date of the event occurs, at any time during the period when such Last Reported Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts are to be calculated.

 

(b)                                 Voluntary Adjustments.  To the extent permitted by the rules of The New York Stock Exchange, the Company is permitted to increase the Conversion Rate of the Securities by any amount for a period of at least 20 Business Days if the Board of Directors determines that such increase would be in the Company’s best interest.  The Company may also (but is not required to) increase the Conversion Rate to avoid or diminish income tax to holders of Common Stock or rights to purchase shares of Common Stock in connection with a dividend or distribution of shares (or rights to acquire shares) or similar event.

 

Section 4.06                             Adjustment to Conversion Rate Upon Conversion in Connection with a Make-Whole Fundamental Change.

 

(a)                                 Increase in the Conversion Rate.  If the Effective Date of a Make-Whole Fundamental Change occurs prior to the Maturity Date and a Holder elects to convert its Securities in connection with such Make-Whole Fundamental Change, the Company shall, under certain circumstances, increase the Conversion Rate for the Securities so surrendered for conversion by a number of additional shares of Common Stock (the “Additional Shares”), as described in this Section 4.06.  A conversion of Securities shall be deemed for these purposes to be “in connection with” such Make-Whole Fundamental Change if the relevant Conversion Notice is received by the Conversion Agent during the period from, and including, the Effective Date of the Make-Whole Fundamental Change up to, and including, the Close of Business on the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, in the case of a Make-Whole Fundamental Change that would have been a Fundamental Change but for the proviso in clause (2) of the definition thereof, the 35th Trading Day immediately following the Effective Date of such Make-Whole Fundamental Change) (such period, the “Make-Whole Fundamental Change Period”).

 

(b)                                 Cash Mergers.  Upon surrender of Securities for conversion in connection with a Make-Whole Fundamental Change, the Company shall, at its option, satisfy its conversion obligation by Physical Settlement, Cash Settlement or Combination Settlement, pursuant to Section 4.03. However, if the consideration paid for the Common Stock in any Make-Whole Fundamental Change described in clause (2) of the definition of Fundamental Change is composed entirely of cash, then, for any conversion of Securities following the Effective Date of such Make-Whole Fundamental Change, the payment and delivery obligations upon the conversion of a Security shall be calculated based solely on the Stock Price for such Make-Whole Fundamental Change and shall be deemed to be an amount of cash, per $1,000 principal amount of Securities converted, equal to the product of (i) the Conversion Rate in effect on the applicable Conversion Date (as increased by any number of Additional Shares required by this Section 4.06) multiplied by (ii) such Stock Price.  In such event, the Company will determine the settlement amount and pay such amount of cash to a converting Holder on the second Business Day following the applicable Conversion Date.

 

29

 

(c)                                  Determining the Number of Additional Shares.  The number of Additional Shares, if any, by which the Conversion Rate will be increased for a Holder that converts its Securities in connection with a Make-Whole Fundamental Change shall be determined by reference to the table attached as Schedule A hereto, based on the Effective Date the Make-Whole Fundamental Change and the price (the “Stock Price”) paid (or deemed to be paid) per share of the Common Stock in the Make-Whole Fundamental Change.  If the holders of the Common Stock receive in exchange for their Common Stock only cash in a Make-Whole Fundamental Change described in clause (2) of the definition of Fundamental Change, the Stock Price shall be the cash amount paid per share.  Otherwise, the Stock Price shall be the average of the Last Reported Sale Prices of the Common Stock over the five consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Effective Date of the Make-Whole Fundamental Change.

 

(d)                                 Interpolation and Limits.  The exact Stock Prices and Effective Dates may not be set forth in the table in Schedule A, in which case:

 

(1)                                 If the Stock Price is between two Stock Prices in the table or the Effective Date is between two Effective Dates in the table, the number of Additional Shares by which the Conversion Rate shall be increased will be determined by a straight-line interpolation between the number of Additional Shares set forth for the higher and lower Stock Prices and the earlier and later Effective Dates, as applicable, based on a 365-day year.

 

(2)                                 If the Stock Price is greater than $11.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table in Schedule A pursuant to Section 4.06(d)(4) hereof), the Conversion Rate shall not be increased.

 

(3)                                 If the Stock Price is less than $8.44 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table in Schedule A pursuant to Section 4.06(d)(4) hereof), the Conversion Rate shall not be increased.

 

Notwithstanding the foregoing, in no event will the Conversion Rate per $1,000 principal amount of Securities exceed 118.4834 shares of Common Stock, subject to adjustment in the same manner as the Conversion Rate as set forth in Section 4.04 hereof.

 

(4)                                 The Stock Prices set forth in the column headings of the table in Schedule A hereto shall be adjusted as of any date on which the Conversion Rate of the Securities is otherwise adjusted.  The adjusted Stock Prices shall equal the Stock Prices applicable immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the Conversion Rate immediately prior to such adjustment giving rise to the Stock Price adjustment and the denominator of which is the Conversion Rate as so adjusted.  The number of Additional Shares set forth in such table shall be adjusted in the same manner and at the same time as the Conversion Rate is adjusted as set forth in Section 4.04.

 

(e)                                   Notices.  The Company shall notify the Holders of the Effective Date of any Make-Whole Fundamental Change and issue a press release announcing such Effective Date no later than five Business Days after such Effective Date.

 

Section 4.07                             Effect of Recapitalization, Reclassification, Consolidation, Merger or Sale.

 

(a)                                 Merger Events.  In the case of:

 

(1)                                 any recapitalization, reclassification or change of the Common Stock (other than a change to the par value, or from par value to no par value, or changes resulting from a subdivision or combination);

 

(2)                                 any consolidation, merger or combination involving the Company;

 

(3)                                 any sale, lease or other transfer to a third party of the consolidated assets of the Company and its Subsidiaries substantially as an entirety; or

 

30

 

(4)                                 any statutory share exchange;

 

in each case, as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets (including cash or any combination thereof) (any such event, a “Merger Event,” any such stock, other securities, other property or assets, “Reference Property,” and the amount of kind of Reference Property that a holder of one share of Common Stock is entitled to receive in the applicable Merger Event a “Unit of Reference Property”) then, at and after the effective time of such Merger Event, the right to convert each $1,000 principal amount of Securities based on a number of shares of the Common Stock equal to the applicable Conversion Rate will, without the consent of the Holders, be changed into a right to convert each $1,000 principal amount of Securities based on a number of Units of Reference Property equal to the applicable Conversion Rate and, prior to or at the effective time of such Merger Event, the Company or the successor or purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture permitted under Section 8.01(g) (which shall comply with the Trust Indenture Act as in force at the date of execution of such supplemental indenture) providing for such change in the right to convert each $1,000 principal amount of Securities; provided, however, that at and after the effective time of the Merger Event (i) the Company shall continue to have the right to determine the form of consideration to be paid or delivered, as the case may be, upon conversion of the Securities in accordance with Section 4.02 and (ii) (A) any amount payable in cash upon conversion of the Securities in accordance with Sections 4.03 and 4.06 hereof shall continue to be payable in cash, (B) the number of shares of Common Stock that the Company would have been required to deliver upon conversion of the Securities in accordance with Sections 4.03 and 4.06 hereof shall instead be deliverable in Units of Reference Property and (C) the Daily VWAP and the Last Reported Sale Price will, to the extent reasonably possible, be calculated based on the value of a Unit of Reference Property and the definitions of Trading Day and Market Disruption Event shall be determined by reference to the components of a Unit of Reference Property.

 

If the Merger Event causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of stockholder election) as contemplated by the preceding paragraph, a Unit of Reference Property will be deemed to be (i) the per-share of Common Stock weighted average of the types and amounts of consideration received by the holders of the Common Stock in the Merger Event that affirmatively make such an election or (ii) if no holders of the Common Stock affirmatively make such an election, the types and amounts of consideration actually received by the holders of the Common Stock and, in each case, the Company shall notify Holders of the weighted average as soon as practicable after such determination is made.

 

If the holders of the Common Stock to receive only cash in such Merger Event, then for all conversions that occur after the effective date of such Merger Event, (i) the consideration due upon conversion of each $1,000 principal amount of Securities shall be solely cash in an amount equal to the Conversion Rate in effect on the Conversion Date (as may be increased pursuant to Section 4.06), multiplied by the price paid per share of the Common Stock in such Merger Event and (ii) the Company shall satisfy its conversion obligation by paying cash to converting Holders on the second Business Day immediately following such Conversion Date.

 

The Company shall not become a party to any Merger Event unless its terms are consistent with this Section 4.07.  Such supplemental indenture described in the third immediately preceding paragraph shall provide for anti-dilution and other adjustments that are as nearly equivalent as possible to the adjustments described in this Article 4. If the Reference Property in respect of any Merger Event includes shares of stock, securities or other property or assets of a Person other than the successor or purchasing Person, as the case may be, in such Merger Event, then such supplemental indenture shall also be executed by such other Person, and such supplemental indenture shall contain such additional provisions to protect the interests of the Holders, including the right of Holders to require the Company to repurchase their Securities upon a Fundamental Change pursuant to Article 3, as the Board of Directors reasonably considers necessary by reason of the foregoing.

 

In connection with any adjustment to the Conversion Rate described herein, the Company shall also adjust the Initial Dividend Threshold based on the number of shares of common stock comprising the Reference Property and (if applicable) the value of any non-stock consideration comprising the Reference Property. If the Reference Property is composed solely of non-stock consideration, the Initial Dividend Threshold shall be zero.

 

31

 

(b)                                 Notice of Supplemental Indentures.  When the Company executes a supplemental indenture pursuant to subsection (a) of this Section 4.07, the Company shall promptly file with the Trustee an Officers’ Certificate briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset that will comprise a unit of Reference Property after any such Merger Event, any adjustment to be made with respect thereto and that all conditions precedent have been complied with, and shall promptly deliver notice thereof to all Holders. The Company shall cause notice of the execution of such supplemental indenture to be delivered to each Holder within 20 days after execution thereof.  Failure to deliver such notice shall not affect the legality or validity of such supplemental indenture.  The above provisions of this Section 4.07 shall similarly apply to successive Merger Events.

 

Section 4.08                             Stock Issued Upon Conversion.

 

(a)                                 Reservation of Shares.  To the extent necessary to satisfy its obligations under this Indenture, prior to issuing any shares of Common Stock, the Company will reserve out of its authorized but unissued shares of Common Stock a sufficient number of shares of Common Stock to permit the conversion of the Securities.

 

(b)                                 Certain other Covenants.  The Company covenants that all shares of Common Stock that may be issued upon conversion of Securities shall be newly issued shares or treasury shares, shall be duly authorized, validly issued, fully paid and non-assessable and shall be free from preemptive rights and free from any tax, lien or charge (other than those created by the Holder or due to a change in registered owner).

 

The Company shall list or cause to have quoted any shares of Common Stock to be issued upon conversion of Securities on each national securities exchange or over-the-counter or other domestic market on which the Common Stock is then listed or quoted.

 

Section 4.09                             Responsibility of Trustee.  The Trustee and any Conversion Agent shall not at any time be under any duty or responsibility to any Holder of Securities to determine or calculate the Conversion Rate, to determine whether any facts exist which may require any adjustment of the Conversion Rate, or to confirm the accuracy of any such adjustment when made or the appropriateness of the method employed, or herein or in any supplemental indenture provided to be employed, in making the same.  The Trustee and any other Conversion Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any shares of Common Stock or of any other securities or property that may at any time be issued or delivered upon the conversion of any Securities; and the Trustee and the Conversion Agent make no representations with respect thereto.  Neither the Trustee nor any Conversion Agent shall be responsible for any failure of the Company to issue, transfer or deliver any shares of Common Stock or stock certificates or other securities or property or cash upon the surrender of any Securities for the purpose of conversion or to comply with any of the duties, responsibilities or covenants of the Company contained in this Article 4.  The rights, privileges, protections, immunities and benefits given to the Trustee, including without limitation its right to be compensated, reimbursed, and indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, including its capacity as Conversion Agent.

 

Section 4.10                             Notice to Holders.

 

(a)                                 Notice to Holders Prior to Certain Actions.  The Company shall deliver notices of the events specified below at the times specified below and containing the information specified below unless, in each case, (i) pursuant to this Indenture, the Company is already required to deliver notice of such event containing at least the information specified below at an earlier time or, (ii) the Company, at the time it is required to deliver a notice, does not have knowledge of all of the information required to be included in such notice, in which case, the Company shall (A) deliver notice at such time containing only the information that it has knowledge of at such time (if it has knowledge of any such information at such time), and (B) promptly upon obtaining knowledge of any such information not already included in a notice delivered by the Company, deliver notice to each Holder containing such information.  In each case, the failure by the Company to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

(1)                                 Issuances, Distributions, and Dividends and Distributions.  If the Company (A) announces any issuance of any rights, options or warrants that would require an adjustment in the Conversion

 

32

 

Rate pursuant to Section 4.04(b) hereof; (B) authorizes any distribution that would require an adjustment in the Conversion Rate pursuant to Section 4.04(c) hereof (including any separation of rights from the Common Stock described in Section 4.04(g) hereof); or (C) announces any dividend or distribution that would require an adjustment in the Conversion Rate pursuant to Section 4.04(d) hereof, then the Company shall deliver to the Holders, as promptly as possible, but in any event at least 15 calendar days prior to the applicable Ex-Dividend Date, notice describing such issuance, distribution, dividend or distribution, as the case may be, and stating the expected Ex-Dividend Date and Record Date for such issuance, distribution, dividend or distribution, as the case may be.  In addition, the Company shall deliver to the Holders notice if the consideration included in such issuance, distribution, dividend or distribution, or the Ex-Dividend Date or Record Date of such issuance, distribution, dividend or distribution, as the case may be, changes.

 

(2)                                 Voluntary Increases.  If the Company increases the Conversion Rate pursuant to Section 4.05(b), the Company shall deliver notice to the Holders at least 15 calendar days prior to the date on which such increase will become effective, which notice shall state the date on which such increased will become effective and the amount by which the Conversion Rate will be increased.

 

(3)                                 Dissolutions, Liquidations and Winding-Ups.  If there is a voluntary or involuntary dissolution, liquidation or winding-up of the Company, the Company shall deliver notice to the Holders at promptly as possible, but in any event at least 15 calendar days prior to the earlier of (i) the date on which such dissolution, liquidation or winding-up, as the case may be, is expected to become effective or occur, and (ii) the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their Common Stock for securities or other property deliverable upon such dissolution, liquidation or winding-up, as the case may be, which notice shall state the expected effective date and Record Date for such event, as applicable, and the amount and kind of property that a holder of one share of the Common Stock is expected to be entitled, or may elect, to receive in such event.  The Company shall deliver an additional notice to holders, as promptly as practicable, whenever the expected effective date or Record Date, as applicable, or the amount and kind of property that a holder of one share of the Common Stock is expect to be entitled to receive in such event, changes.

 

(b)                                 Notices After Certain Actions and Events.  Whenever an adjustment to the Conversion Rate becomes effective pursuant to Sections 4.04, 4.05 or 4.06 hereof, the Company will (i) file with the Trustee an Officers’ Certificate stating that such adjustment has become effective, the Conversion Rate, and the manner in which the adjustment was computed and (ii) deliver notice to the Holders stating that such adjustment has become effective and the Conversion Rate or conversion privilege as adjusted.  Failure to give any such notice, or any defect therein, shall not affect the validity of any such adjustment.

 

Section 4.11                             Exchange in Lieu of Conversion. When a Holder surrenders its Securities for conversion, the Company may, at its election (an “Exchange Election”), direct the Conversion Agent to surrender, on or prior to the Business Day following the Conversion Date, such Securities to a financial institution designated by the Company for exchange in lieu of conversion. In order to accept any Securities surrendered for conversion, the designated institution must agree to timely deliver, in exchange for such Securities, the Settlement Amount that would otherwise be due upon conversion pursuant to Section 4.03. If the Company makes an Exchange Election, the Company shall, by the Close of Business on the Business Day following the relevant Conversion Date, notify the Holder surrendering its Securities for conversion that the Company has made the Exchange Election and the Company will notify the designated financial institution of the relevant deadline for delivery of the Settlement Amount.

 

Any Securities exchanged by the designated institution will remain outstanding, subject to the Applicable Procedures of the Depositary. If the designated institution agrees to accept any Securities for exchange but does not timely deliver the related Settlement Amount, or if such designated financial institution does not accept the Securities for exchange, the Company shall deliver the relevant Settlement Amount as if it had not made an Exchange Election.

 

33

 

ARTICLE 5

 

PARTICULAR COVENANTS OF THE COMPANY

 

Section 5.01                             Payment of Principal, Interest and Fundamental Change Repurchase Price.  This Section 5.01 shall replace Section 1001 of the Base Indenture in its entirety.

 

The Company covenants and agrees that it will cause to be paid the principal of (including the Fundamental Change Repurchase Price), and accrued and unpaid interest, if any, on each of the Securities at the places, at the respective times and in the manner provided herein and in the Securities.

 

Section 5.02                             Maintenance of Office or Agency.  This Section 5.02 replaces Section 1002 of the Base Indenture in its entirety and references in the Base Indenture to Section 1002 of the Base Indenture shall be deemed replaced with references to this Section 5.02.

 

The Company will maintain in the Borough of Manhattan, The City of New York, an office of the Paying Agent, an office of the Security Registrar and an office or agency where Securities may be surrendered for conversion (“Conversion Agent”) and where notices and demands to or upon the Company in respect of the Securities and this Indenture may be served.  The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency.  If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office or the office or agency of the Trustee in the Borough of Manhattan, The City of New York.

 

The Company may also from time to time designate co-registrars one or more other offices or agencies where the Securities may be presented or surrendered for any or all such purposes and may from time to time rescind such designations; provided that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the Borough of Manhattan, The City of New York, for such purposes.  The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency.  The terms “Paying Agent” and “Conversion Agent” include any such additional or other offices or agencies, as applicable.

 

The Company hereby initially designates the Trustee as the Paying Agent, Security Registrar, Custodian, Conversion Agent and the Corporate Trust Office, which shall be in the continental United States, shall be considered as one such office or agency of the Company for each of the aforesaid purposes.

 

With respect to any Global Security, the Corporate Trust Office of the Trustee or any Paying Agent shall be the Place of Payment where such Global Security may be presented or surrendered for payment or conversion or for registration of transfer or exchange, or where successor Securities may be delivered in exchange therefor; provided, however, that any such payment, conversion, presentation, surrender or delivery effected pursuant to the Applicable Procedures of the Depositary for such Global Security shall be deemed to have been effected at the Place of Payment for such Global Security in accordance with the provisions of this Indenture.

 

Section 5.03                             Appointments to Fill Vacancies in Trustee’s Office.  The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 609 of the Base Indenture, a Trustee, so that there shall at all times be a Trustee hereunder.

 

Section 5.04                             Provisions as to Paying Agent.  This Section 5.04 shall replace Section 1003 of the Base Indenture in its entirety and references in the Base Indenture to Section 1003 of the Base Indenture shall be deemed replace with references to this Section 5.04.

 

(a)                                 If the Company shall appoint a Paying Agent other than the Trustee, the Company will cause such Paying Agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section 5.04:

 

34

 

(1)                                 that it will hold all sums held by it as such agent for the payment of the principal of, accrued and unpaid interest, if any, on, and the Fundamental Change Repurchase Price for, the Securities in trust for the benefit of the holders of the Securities;

 

(2)                                 that it will give the Trustee prompt notice of any failure by the Company to make any payment of the principal of, accrued and unpaid interest, if any, on, or the Fundamental Change Repurchase Price for, the Securities when the same shall be due and payable; and

 

(3)                                 that at any time during the continuance of an Event of Default, upon request of the Trustee, it will forthwith pay to the Trustee all sums so held in trust.

 

The Company shall, on or before each due date of the principal of, accrued and unpaid interest, if any, on, and Fundamental Change Repurchase Price for, the Securities, deposit with the Paying Agent a sum sufficient to pay such principal, accrued and unpaid interest, or Fundamental Change Repurchase Price, as the case may be, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee of any failure to take such action; provided that, if such deposit is made on the due date, such deposit must be received by the Paying Agent by 10:00 a.m., New York City time, on such date.

 

(b)                                 If the Company shall act as its own Paying Agent, it will, on or before each due date of the principal of, accrued and unpaid interest, if any, on, or Fundamental Change Repurchase Price for, the Securities, set aside, segregate and hold in trust for the benefit of the holders of the Securities a sum sufficient to pay such principal, accrued and unpaid interest, if any, on or Fundamental Change Repurchase Price, as the case may be, so becoming due and will promptly notify the Trustee in writing of any failure to take such action and of any failure by the Company to make any payment of the principal of, accrued and unpaid interest on, or Fundamental Change Repurchase Price for, the Securities when the same shall become due and payable.

 

(c)                                  Anything in this Section 5.04 to the contrary notwithstanding, the Company may, at any time, for the purpose of obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay or cause to be paid to the Trustee all sums held in trust by the Company or any Paying Agent hereunder as required by this Section 5.04, such sums to be held by the Trustee upon the trusts herein contained and upon such payment by the Company or any Paying Agent to the Trustee, the Company or such Paying Agent shall be released from all further liability with respect to such sums.

 

Section 5.05                             Reports.  This Section 5.05 will replace Section 704 of the Base Indenture in its entirety.

 

The Company shall file with the Trustee, within 15 days after it is required to file the same with the SEC (giving effect to any grace period provided by Rule 12b-25 under the Exchange Act), copies of any documents or reports that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act.  Documents that the Company files with the SEC via the EDGAR system will be deemed to be filed with the Trustee as of the time such documents are filed via EDGAR, it being understood that the Trustee shall have no responsibility to determine if such filings have been made.

 

Section 5.06                             Statements as to Defaults.  The Company shall deliver to the Trustee, as soon as possible, and in any event within 30 days after the occurrence of any Default or Event of Default, an Officers’ Certificate setting forth the details of such Default or Event of Default, its status and the action that the Company proposes to take with respect thereto.  Such Officers’ Certificate shall also comply with any additional requirements set forth in Section 103 of the Base Indenture.

 

Section 5.07                             Supplementary Interest Notice.  If Supplementary Interest is payable by the Company pursuant to Section 6.04 hereof, the Company shall deliver to the Trustee an Officers’ Certificate to that effect stating (a) the amount of such Supplementary Interest that is payable and (b) the date on which such interest is payable.  Unless and until a Responsible Officer of the Trustee receives at the Corporate Trust Office such a certificate, the Trustee may assume without inquiry that no such Supplementary Interest is payable.  If the Company has paid Supplementary Interest directly to the Persons entitled to them, the Company shall deliver to the Trustee an Officers’ Certificate setting forth the particulars of such payment.

 

35

 

Section 5.08                             Covenant to Take Certain Actions.  Before taking any action which would cause an adjustment to the Conversion Rate such that the Conversion Price per share of Common Stock issuable upon conversion of the Securities would be less than the par value of the Common Stock, the Company shall take all corporate actions that may, in the opinion of its counsel, be necessary so it may validly and legally issue shares of Common Stock at such adjusted Conversion Rate.

 

Section 5.09                             Consolidation, Merger and Sale of Assets.  This Section 5.09 will replace Article VIII of the Base Indenture in its entirety.

 

The Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another person, unless (i) the resulting, surviving or transferee Person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Company’s obligations under the Securities  and this Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under this Indenture.  Upon any such consolidation, merger or sale, conveyance, transfer or lease, the resulting, surviving or transferee Person (if not the Company) shall succeed to, and may exercise every right and power of, the Company under this Indenture, and the Company shall be discharged from its obligations under the Securities and this Indenture except in the case of any such lease.

 

In case of any such consolidation, merger, sale, conveyance, transfer or lease and upon the assumption by the transferee Person (if not the Company), by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the due and punctual payment of the principal of and accrued and unpaid interest on all of the Securities, the due and punctual delivery or payment, as the case may be, of any consideration due upon conversion of the Securities and the due and punctual performance of all of the covenants and conditions of this Indenture to be performed by the Company, such transferee Person shall succeed to and, except in the case of a lease of all or substantially all of the consolidated properties and assets of the Company and its Subsidiaries, taken as a whole, shall be substituted for the Company, with the same effect as if it had been named herein as the party of the first part. Such transferee Person thereupon may cause to be signed, and may issue either in its own name or in the name of the Company any or all of the Securities issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such transferee Person instead of the Company and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver, or cause to be authenticated and delivered, any Securities that previously shall have been signed and delivered by the Officers of the Company to the Trustee for authentication, and any Securities that such transferee Person thereafter shall cause to be signed and delivered to the Trustee for that purpose. All the Securities so issued shall in all respects have the same legal rank and benefit under this Indenture as the Securities theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Securities had been issued at the date of the execution hereof. In the event of any such consolidation, merger, sale, conveyance or transfer (but not in the case of a lease), upon compliance with this Section 5.09 the Person named as the “Company” in the first paragraph of this Indenture (or any successor that shall thereafter have become such in the manner prescribed in this Section 5.09) may be dissolved, wound up and liquidated at any time thereafter and, except in the case of a lease, such Person shall be released from its liabilities as obligor and maker of the Securities and from its obligations under this Indenture and the Securities.

 

If the transferee Person is not the Company, no such consolidation, merger, sale, conveyance, transfer or lease shall be effective unless the Trustee shall have received an Officers’ Certificate and an Opinion of Counsel certifying that any such consolidation, merger, sale, conveyance, transfer or lease and any such assumption and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture complies with this Indenture.

 

36

 

ARTICLE 6

 

REMEDIES

 

Section 6.01                             Amendments to the Base Indenture.

 

(a)                                 The Holders shall not have the benefit of Article V of the Base Indenture and, with respect to the Securities, this Article 6 supersedes Article V of the Base Indenture in its entirety.

 

(b)                                 The references to Section 501(5) and Section 501(6) in Section 606 of the Base Indenture is, with respect to the Securities, hereby deemed replaced by a reference to Section 6.02(h) and Section 6.02(i) hereof, respectively.

 

(c)                                  The references to Section 502 and Section 507(2) in Section 104 of the Base Indenture are, with respect to the Securities, hereby deemed replaced by references to Section 6.03 and Section 6.07(b) hereof, respectively.

 

Section 6.02                             Events of Default.  Each of the following events (and only the following events) shall be an “Event of Default” wherever used with respect to the Securities:

 

(a)                                 default in any payment of interest on any Security when due and payable and the default continues for a period of 30 days;

 

(b)                                 default in the payment of principal of any Security when due and payable at its stated maturity, upon any required repurchase, upon declaration of acceleration or otherwise;

 

(c)                                  failure by the Company to comply with its obligation to convert the Securities in accordance with this Indenture upon exercise of a Holder’s conversion right and such failure continues for three Business Days;

 

(d)                                 failure by the Company to give a Fundamental Change Company Notice pursuant to Section 3.02(b) or notice of a transaction pursuant to Section 4.01(b)(4), in each case when due;

 

(e)                                  failure by the Company to comply with its obligations under Section 5.09;

 

(f)                                   failure by the Company for 60 days after written notice from the Trustee or the Holders of at least 25% in principal amount of the Securities then Outstanding has been received to comply with any of the Company’s other agreements contained in the Securities or this Indenture;

 

(g)                                  default by the Company or any of its Significant Subsidiaries with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $25.0 million (or its foreign currency equivalent) in the aggregate of the Company and/or any such Significant Subsidiary, whether such indebtedness exists on the date of this Supplemental Indenture or shall hereafter be created (i) resulting in such indebtedness becoming or being declared due and payable or (ii) constituting a failure to pay the principal or interest of any such debt when due and payable at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise;

 

(h)                                 the Company or any Significant Subsidiary shall commence a voluntary case or other proceeding seeking the liquidation, reorganization or other relief with respect to the Company, any Significant Subsidiary or its or their debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company, any Significant Subsidiary or any substantial part of the Company’s or any Significant Subsidiary’s property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due;

 

(i)                                     an involuntary case or other proceeding shall be commenced against the Company or any Significant Subsidiary seeking liquidation, reorganization or other relief with respect to the Company or any Significant Subsidiary or its or their debts under any bankruptcy, insolvency or other similar law now or hereafter in

 

37

 

effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company, any Significant Subsidiary or any substantial part of its or their property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of thirty consecutive days; and

 

(j)                                    a final judgment or judgments for the payment of $25.0 million (or its foreign currency equivalent) or more (excluding any amounts covered by insurance) in the aggregate rendered against the Company or any of its Significant Subsidiaries, which judgment is not discharged, bonded, paid, waived or stayed within 60 days after (i) the date on which the right to appeal thereof has expired if no such appeal has commenced, or (ii) the date on which all rights to appeal have been extinguished.

 

Section 6.03                             Acceleration; Rescission and Annulment. If one or more Events of Default shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body), then, and in each and every such case (other than an Event of Default specified in Section 6.02(h) or Section 6.02(i)), unless the principal of all of the Securities shall have already become due and payable, either the Trustee or the holders of at least 25% in aggregate principal amount of the Securities, by notice in writing to the Company (and to the Trustee if given by the Holders), may declare the unpaid principal of and accrued interest, if any, due and payable immediately.  If an Event of Default specified in Section 6.02(h) or Section 6.02(i) occurs and is continuing, then all unpaid principal amounts and accrued interest, if any, shall immediately become due and payable, without any action by the Trustee or any Holder of Securities.

 

Section 6.04                             Supplementary Interest.

 

(a)                                 Notwithstanding any provisions of this Indenture to the contrary, if the Company so elects, the sole remedy for an Event of Default relating to (i) the Company’s failure to file with the Trustee pursuant to Section 314(a)(1) of the Trust Indenture Act any documents or reports that it is required to file with the Commission pursuant to Section 13 or 15(d) of the Exchange Act, or (ii) the Company’s failure to comply with Section 5.05 hereof (a “Reporting Event of Default”), will, for the first 180 days after the occurrence of such an Event of Default, consist exclusively of the right to receive additional interest on the Securities (the “Supplementary Interest”) at a rate equal to (i) 0.25% per annum of the Outstanding principal amount of the Securities for the first 90 days during which such Event of Default has occurred and is continuing beginning on, and including, the date on which such an Event of Default first occurs and (ii) 0.50% per annum of the Outstanding principal amount of the Securities for each day during the next 90-day period during which such Event of Default is continuing beginning on, and including, the 91st day after such an Event of Default first occurs.  If the Company so elects, such Supplementary Interest will be payable in the same manner and on the same dates as the stated interest payable on the Securities. On the 181st day after such Event of Default (if the Reporting Event of Default is not cured or waived prior to such 181st day), the Securities will be subject to acceleration pursuant to Section 6.03. The provisions of this Section 6.04 will not affect the rights of Holders of Securities in the event of the occurrence of any Event of Default that is not a Reporting Event of Default. In the event the Company does not elect to pay the Supplementary Interest following an Event of Default in accordance with this Section 6.04  or the Company elected to make such payment but do not pay the Supplementary Interest when due, the Securities will be immediately subject to acceleration as provided in Section 6.03.

 

(b)                                 In order to elect to pay the Supplementary Interest as the sole remedy during the first 180 days after the occurrence of an Reporting Event of Default, the Company must notify all Holders of Securities, the Trustee and the Paying Agent of such election prior to the beginning of such 180-day period. Upon the Company’s failure to timely give such notice, the Securities will be immediately subject to acceleration as provided in Section 6.03.

 

Section 6.05                             Waiver of Past Defaults.  The Trustee may withhold notice to the Holders of Securities of any Default or Event of Default, except a Default or Event of Default relating to the payment of principal or interest or the failure to deliver the consideration due upon conversion, if it determines that withholding such notice is in the Holders’ interest. The Holders of a majority in principal amount of the Securities may waive any Default or Event of Default and rescind any acceleration with respect to the Securities and its consequences, except a

 

38

 

continuing Default or Event of Default in the payment of principal or interest on the Securities or the failure to deliver the consideration due upon conversion if (i) rescission would not conflict with any judgment or decree of a court of competent jurisdiction and (ii) all existing Events of Default, other than the nonpayment of principal of and interest on the Securities that have become due solely by such declaration of acceleration, have been cured or waived.  Any such waiver shall cure such Default or Event of Default.

 

Section 6.06                             Control by Majority.  At any time, the Holders of a majority of the aggregate principal amount of the then Outstanding Securities may direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or for exercising any trust or power conferred on the Trustee, with respect to the Securities, provided that:

 

(a)                                 the Trustee may refuse to follow any direction that conflicts with law or this Indenture;

 

(b)                                 the Trustee may take any other action deemed proper by it which is not inconsistent with such direction; and

 

(c)                                  subject to the Trustee’s duties under the Trust Indenture Act, the Trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the Holders not involved in the proceeding.

 

Prior to taking any action hereunder, the Trustee will be entitled to indemnification reasonably satisfactory to it against all losses and expenses caused by taking or not taking such action.

 

Section 6.07                             Limitation on Suits.   A Holder of the Securities will only have the right to institute a proceeding under this Indenture or to appoint a receiver or trustee, or to seek other remedies if:

 

(a)                                 the Holder has delivered to the Trustee written notice that an Event of Default has occurred and is continuing with respect to the Securities;

 

(b)                                 the Holders of at least 25% of the aggregate principal amount of the Securities have requested the Trustee to pursue the remedy;

 

(c)                                  such Holders have offered the Trustee security or indemnity reasonably satisfactory to it against any loss, liability or expense;

 

(d)                                 the Trustee has not complied with such request within 60 days after the receipt of the request and the offer of such security or indemnity; and

 

(e)                                  the Holders of a majority in principal amount of the Outstanding Securities have not given the Trustee a direction that, in the opinion of the Trustee, is inconsistent with such request within such 60-day period.

 

A Holder may not use this Indenture to prejudice the rights of any other Holder or to obtain a preference or priority over any other Holder, it being understood that the Trustee does not have any affirmative duty to ascertain whether any usage of this Indenture by a Holder is unduly prejudicial to such other Holders.

 

Section 6.08                             Rights of Holders to Receive Payment and to Convert.  Notwithstanding anything to the contrary elsewhere in this Indenture, the right of any Holder to receive payment of the principal (including the Fundamental Change Repurchase Price, if applicable) of, interest on, and the consideration due upon conversion of, its Securities, on or after the respective due date, or to bring suit for the enforcement of any such payment or conversion rights, will not be impaired or affected without the consent of such Holder and will not be subject to the requirements of Section 6.07 hereof.

 

Section 6.09                             Collection of Indebtedness; Suit for Enforcement by Trustee.  If an Event of Default specified in Section 6.02(a), 6.02(b) or 6.02(c) hereof occurs and is continuing, the Trustee is authorized to recover judgment in its own name and as trustee of an express trust against the Company for the whole amount of principal

 

39

 

of, interest on, Fundamental Change Repurchase Price for, and the amount of cash or the combination of cash and shares of Common Stock, if any, as the case may be, due upon the conversion of, the Securities, as the case may be, and such further amount as is sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, as well as any other amounts that may be due under Section 606 of the Base Indenture.

 

Section 6.10                             Trustee May Enforce Claims Without Possession of Securities.  All rights of action and claims under this Indenture or the Securities may be prosecuted and enforced by the Trustee without the possession of any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders in respect of which such judgment has been recovered.

 

Section 6.11                             Trustee May File Proofs of Claim.  The Trustee is authorized to file such proofs of claim and other papers or documents as may be necessary or advisable to have the claims of the Trustee and the Holders allowed in any judicial proceedings relative to the Company, its creditors or its property and, unless prohibited by law or applicable regulations, will be entitled to collect, receive and distribute any money or other property payable or deliverable on any such claims, and any custodian in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee, and, in the event that the Trustee consents to the making of such payments directly to the Holders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 606 of the Base Indenture.  To the extent that the payment of any such compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 606 of the Base Indenture out of the estate in any such proceeding, will be denied for any reason, payment of the same will be secured by a lien on, and is paid out of, any and all distributions, dividends, money, securities and other properties that the Holders may be entitled to receive in such proceeding, whether in liquidation or under any plan of reorganization or arrangement or otherwise.  Nothing herein contained will be deemed to authorize the Trustee to authorize or consent to, or to accept or to adopt on behalf of any Holder, any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.

 

Section 6.12                             Restoration of Rights and Remedies.  If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.

 

Section 6.13                             Rights and Remedies Cumulative.  Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in Section 305 of the Base Indenture, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy.

 

Section 6.14                             Delay or Omission Not a Waiver.  No delay or omission of the Trustee or of any Holder to exercise any right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein.  Every right and remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time and as often as may be deemed expedient by the Trustee (subject to the limitations contained in this Indenture) or by the Holders, as the case may be.

 

40

 

Section 6.15                             Priorities.  If the Trustee collects any money pursuant to this Article 6, it will pay out the money in the following order:

 

FIRST: to the Trustee, its agents and attorneys for amounts due under Section 606 of the Base Indenture, including payment of all compensation, expenses and liabilities incurred, and all advances made, by the Trustee and the costs and expenses of collection;

 

SECOND: to the Holders, for any amounts due and unpaid on the principal of, accrued and unpaid interest on, Fundamental Change Repurchase Price for, and any cash due upon conversion of, any Security, without preference or priority of any kind, according to such amounts due and payable on all of the Securities; and

 

THIRD: the balance, if any, to the Company or to such other party as a court of competent jurisdiction directs.

 

The Trustee may fix a record date and payment date for any payment to the Holders pursuant to this Section 6.15.  If the Trustee so fixes a record date and a payment date, at least 15 days prior to such record date, the Company will deliver to each Holder and the Trustee a written notice, which notice will state such record date, such payment date and the amount of such payment.

 

Section 6.16                             Undertaking for Costs.  All parties to this Indenture agree, and each Holder, by such Holder’s acceptance of a Security, shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; provided, however, that the provisions of this Section 6.16 shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in aggregate principal amount of the Securities then Outstanding, or to any suit instituted by any Holder for the enforcement of the payment of the principal of, accrued and unpaid interest, if any, on, or Fundamental Change Repurchase Price for, any Security on or after the due date expressed or provided for in this Indenture or to any suit for the enforcement of the right to convert any Security in accordance with the provisions of Article 4 hereof.

 

Section 6.17                             Waiver of Stay, Extension and Usury Laws.  The Company covenants that, to the extent that it may lawfully do so, it will not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, that may affect the covenants or the performance of this Indenture; and the Company, to the extent that it may lawfully do so, hereby expressly waives all benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will instead suffer and permit the execution of every such power as though no such law has been enacted.

 

Section 6.18                             Notices from the Trustee.  Notwithstanding anything to the contrary in the Base Indenture, whenever a Default occurs and is continuing and is known to the Trustee, the Trustee must deliver notice of such Default to the Holders within 90 days after the date on which such Default first occurred.  Except in the case of a Default in the payment of the principal of, interest on, or Fundamental Change Repurchase Price for, any Security or of a Default in the payment or delivery, as the case may be, of the consideration due upon conversion of a Security, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee or a trust committee of directors and/or Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interests of the Holders.

 

41

 

ARTICLE 7

 

SATISFACTION AND DISCHARGE

 

Section 7.01                             Inapplicability of Provisions of Base Indenture; Satisfaction and Discharge of the Indenture.  Article IV and Article XIII of the Base Indenture shall not apply with respect to the Securities.  The provisions set forth in this Article 7 shall, with respect to the Securities, supersede in their entirety Article XI and Article XIII of the Base Indenture.

 

When (a) the Company shall deliver to the Security Registrar for cancellation all Securities theretofore authenticated (other than any Securities that have been destroyed, lost or stolen and in lieu of or in substitution for which other Securities shall have been authenticated and delivered) and not theretofore canceled, or (b) all the Securities not theretofore canceled or delivered to the Trustee for cancellation shall have become due and payable (whether on the Maturity Date, on any Fundamental Change Repurchase Date, upon conversion or otherwise) and the Company shall deposit with the Trustee, in trust, or deliver to the Holders, as applicable, an amount of cash or the combination of cash and shares of Common Stock (or, if applicable, Reference Property), if any, as the case may be (solely to settle amounts due with respect to outstanding conversions), sufficient to pay all amounts due on all of such Securities (other than any Securities that shall have been mutilated, destroyed, lost or stolen and in lieu of or in substitution for which other Securities shall have been authenticated and delivered) not theretofore canceled or delivered to the Trustee for cancellation, including principal and interest due, accompanied, except in the event the Securities are due and payable solely in cash at the Maturity Date or upon an earlier Fundamental Change Repurchase Date, by a verification report as to the sufficiency of the deposited amount from a firm of nationally recognized independent certified accountants or other financial professionals, and if the Company shall also pay or cause to be paid all other sums payable hereunder by the Company, then this Indenture shall cease to be of further effect (except as to (i) rights hereunder of Holders to receive all amounts owing upon the Securities and the other rights, duties and obligations of Holders, as beneficiaries hereof with respect to the amounts, if any, so deposited with the Trustee and (ii) the rights, obligations and immunities of the Trustee hereunder), and the Trustee, on written demand of the Company accompanied by an Officers’ Certificate and an Opinion of Counsel and at the cost and expense of the Company, shall execute proper instruments acknowledging satisfaction and discharge of this Indenture; the Company, however, hereby agrees to reimburse the Trustee for any costs or expenses thereafter reasonably and properly incurred by the Trustee, including the fees and expenses of its counsel, and to compensate the Trustee for any services thereafter reasonably and properly rendered by the Trustee in connection with this Indenture or the Securities.

 

Section 7.02                             Deposited Monies to Be Held in Trust by Trustee.  Subject to Section 7.04 hereof, all monies and shares of Common Stock, if any, deposited with the Trustee pursuant to Section 7.01 hereof shall be held in trust for the sole benefit of the Holders of the Securities, and such monies and shares of Common Stock shall be applied by the Trustee to the payment, either directly or through any Paying Agent (including the Company if acting as its own Paying Agent), to the Holders of the particular Securities for the payment or settlement of which such monies or shares of Common Stock have been deposited with the Trustee, of all sums or amounts due and to become due thereon for principal and interest, if any.

 

Section 7.03                             Paying Agent to Repay Monies Held.  Upon the satisfaction and discharge of this Indenture, all monies and shares of Common Stock, if any, then held by any Paying Agent (if other than the Trustee) shall, upon written request of the Company, be repaid to it or paid to the Trustee, and thereupon such Paying Agent shall be released from all further liability with respect to such monies and shares of Common Stock.

 

Section 7.04                             Return of Unclaimed Monies.  Subject to the requirements of applicable law, any monies and shares of Common Stock deposited with or paid to the Trustee for payment of the principal of or interest, if any, on the Securities and not applied but remaining unclaimed by the Holders of the Securities for two years after the date upon which the principal of or interest, if any, on such Securities, as the case may be, shall have become due and payable, shall be repaid to the Company by the Trustee on demand, and all liability of the Trustee shall thereupon cease with respect to such monies and shares of Common Stock; and the Holder shall thereafter look only to the Company for any payment or delivery that such Holder may be entitled to collect unless an applicable abandoned property law designates another person.

 

42

 

Section 7.05                             Reinstatement.  If the Trustee or the Paying Agent is unable to apply any money or shares of Common Stock in accordance with Section 7.02 by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the Company’s obligations under this Indenture and the Securities shall be revived and reinstated as though no deposit had occurred pursuant to Section 7.01 until such time as the Trustee or the Paying Agent is permitted to apply all such money and shares of Common Stock in accordance with Section 7.02; provided, however, that if the Company makes any payment of interest on, principal of or payment or delivery in respect of any Security following the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or shares of Common Stock, if any, held by the Trustee or Paying Agent.

 

ARTICLE 8

 

SUPPLEMENTAL INDENTURES

 

Section 8.01                             Supplemental Indentures Without Consent of Holders.  Section 901 of the Base Indenture shall not apply with respect to the Securities, and this Section 8.01 shall replace Section 901 of the Base Indenture in its entirety.

 

Without the consent of any Holder, the Company (when authorized by a Board Resolution) and the Trustee, at any time and from time to time, may enter into one or more indentures supplemental hereto, in form satisfactory to the Trustee, to:

 

(a)                                 cure any ambiguity, omission, defect or inconsistency under this Indenture or the Securities;

 

(b)                                 provide for the assumption by a successor corporation of the Company’s obligations under this Indenture as set forth in Section 5.09;

 

(c)                                  add guarantees with respect to the Securities;

 

(d)                                 secure the Securities;

 

(e)                                  add to the covenants or Events of Default for the benefit of the Holders or surrender any right or power conferred upon the Company;

 

(f)                                   make any change that does not adversely affect the rights of any Holder;

 

(g)                                  in connection with a transaction pursuant to Section 4.07, provide that the Securities are convertible into Reference Property, subject to the provisions of Section 4.03;

 

(h)                                 provide for the issuance of additional Securities pursuant to Section 2.01(c);

 

(i)                                     comply with any requirement of the Commission in connection with the qualification of this Indenture under the Trust Indenture Act;

 

(j)                                    conform the provisions of this Indenture or the Securities to the “Description of notes” section of the Preliminary Prospectus Supplement, as supplemented by the related Pricing Term Sheet dated as of November 7, 2017;

 

(k)                                 comply with the rules of any applicable Depositary so long as such amendment does not adversely affect the rights of any Holder in any material respect;

 

(l)                                     irrevocably elect or eliminate one of the Settlement Methods and/or irrevocably elect a Specified Dollar Amount;

 

43

 

(m)                             increase the Conversion Rate as provided in this Indenture; or

 

(n)                                 to evidence and provide the acceptance of the appointment of a successor Trustee under the Indenture.

 

Section 8.02                             Supplemental Indentures With Consent of Holders.  Section 902 of the Base Indenture shall not apply with respect to the Securities, and this Section 8.02 shall replace Section 902 of the Base Indenture in its entirety.

 

With the consent of the Holders of not less than a majority in principal amount of the Outstanding Securities affected by such supplemental indenture, including without limitation, consents obtained in connection with a purchase of, or tender or exchange offer for, Securities and by Act of said Holders delivered to the Company and the Trustee, the Company, when authorized by a Board Resolution, and the Trustee may enter into an indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of modifying in any manner the rights of the Holders under this Indenture; provided, however, that no such supplemental indenture shall, without the consent of the Holder of each Outstanding Security affected thereby:

 

(a)                                 reduce the amount of Securities whose Holders must consent to an amendment;

 

(b)                                 reduce the rate of or extend the stated time for payment of interest, including any additional interest, on any Security;

 

(c)                                  reduce the principal of, or any premium on, or extend the stated maturity of any Security;

 

(d)                                 make any change that adversely affects the conversion rights of any Securities;

 

(e)                                  reduce the Fundamental Change Repurchase Price of any Security or amend or modify in any manner adverse to the Holders the Company’s obligation to make such payments, whether through an amendment or waiver of provisions of the covenants, definitions or otherwise;

 

(f)                                   make any Security payable in money, or at a place of payment, other than that stated in the Security;

 

(g)                                  change the ranking of the Securities; or

 

(h)                                 impair the right of any Holder to receive payment of principal and interest on such Holder’s Securities on or after the due dates therefor or to institute suit for the enforcement of any payment on or with respect to such Holder’s Securities.

 

It shall not be necessary for any Act or consent of Holders under this Section 8.02 to approve the particular form of any proposed supplemental indenture, but it shall be sufficient if such Act or consent shall approve the substance thereof.  The Company may, but shall not be obligated to, fix a record date for the purpose of determining the Persons entitled to consent to any indenture supplemental hereto.  If a record date is fixed, the Holders on such record date, or their duly designated proxies, and only such Persons, shall be entitled to consent to such supplemental indenture, whether or not such Holders remain Holders after such record date; provided that, unless such consent shall have become effective by virtue of the requisite percentage having been obtained prior to the date which is 90 days after such record date, any such consent previously given shall automatically and without further action by any Holder be cancelled and of no further effect.

 

Section 8.03                             Notice of Amendment or Supplement.  After an amendment or supplement under this Article 8 becomes effective, the Company shall mail to the Holders a notice briefly describing such amendment or supplement.  However, the failure to give such notice to all the Holders, or any defect in the notice, shall not impair or affect the validity of the amendment or supplement.

 

44

 

ARTICLE 9

 

MISCELLANEOUS

 

Section 9.01                             Effect on Successors and Assigns.  Notwithstanding Section 109 of the Base Indenture, all agreements of the Company, the Trustee, the Security Registrar, the Paying Agent and the Conversion Agent in this Indenture and the Securities will bind their respective successors.

 

Section 9.02                             Governing Law.  THIS INDENTURE, THE SECURITIES, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS INDENTURE OR THE SECURITIES SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

 

Section 9.03                             No Security Interest Created.  Nothing in this Indenture or in the Securities, expressed or implied, shall be construed to constitute a security interest under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any jurisdiction.

 

Section 9.04                             Trust Indenture Act.  If any provision hereof limits, qualifies or conflicts with a provision of the Trust Indenture Act that is required under such Act to be a part of and govern this Indenture, the latter provision shall control.  If any provision of this Indenture modifies or excludes any provision of the Trust Indenture Act that may be so modified or excluded, the latter provision shall be deemed to apply to this Indenture as so modified or to be excluded, as the case may be.

 

Section 9.05                             Benefits of Supplemental Indenture.  Notwithstanding anything to the contrary in Section 111 of the Base Indenture, nothing in this Supplemental Indenture or in the Securities, expressed or implied, will give to any Person, other than the parties hereto, any Paying Agent, any Conversion Agent, any Authenticating Agent, any Security Registrar or their successors hereunder or the Holders of the Securities, any benefit or any legal or equitable right, remedy or claim under this Supplemental Indenture.

 

Section 9.06                             Calculations.  Except as otherwise provided in this Indenture, the Company shall be responsible for making all calculations called for under the Securities.  These calculations include, but are not limited to, determinations of the Stock Price, Last Reported Sale Prices of the Common Stock, the Daily VWAPs, the Daily Conversion Values, the Daily Settlement Amounts, accrued interest payable on the Securities and the Conversion Rate.  The Company shall make all these calculations in good faith and, absent manifest error, the Company’s calculations shall be final and binding on Holders of Securities.  The Company shall provide a schedule of its calculations to each of the Trustee and the Conversion Agent, and each of the Trustee and Conversion Agent is entitled to rely conclusively upon the accuracy of the Company’s calculations without independent verification.  The Trustee will forward the Company’s calculations to any Holder upon the request of that Holder at the sole cost and expense of the Company.

 

Whenever the Company is required to calculate the Conversion Rate, the Company will do so to the nearest 1/10,000th of a share of Common Stock.

 

Section 9.07                             Execution in Counterparts.  This Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument.

 

Section 9.08                             Notices.  The Company or the Trustee, by notice given to the other in the manner provided in Section 105 of the Base Indenture, may designate additional or different addresses for subsequent notices or communications.

 

Notwithstanding anything to the contrary in the Base Indenture, whenever the Company is required to deliver notice to the Holders, the Company will, by the date it is required to deliver such notice to the Holders, deliver a copy of such notice to the Trustee, the Paying Agent, the Security Registrar and the Conversion Agent.  Each notice to the Trustee, the Paying Agent, the Security Registrar and the Conversion Agent shall be sufficiently

 

45

 

given if in writing and mailed, first-class postage prepaid to the address most recently sent by the Trustee, the Paying Agent, the Security Registrar or the Conversion Agent, as the case may be, to the Company.

 

Section 9.09                             Ratification of Base Indenture.  The Base Indenture, as supplemented by this Supplemental Indenture, is in all respects ratified and confirmed, and this Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the extent herein provided.  For the avoidance of doubt, each of the Company and each Holder of Securities, by its acceptance of such Securities, acknowledges and agrees that all of the rights, privileges, protections, immunities and benefits afforded to the Trustee under the Base Indenture are deemed to be incorporated herein, and shall be enforceable by the Trustee hereunder, in each of its capacities hereunder as if set forth herein in full.

 

Section 9.10      The Trustee.  The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the Base Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of the Securities and of this Supplemental Indenture as fully and with like effect as set forth in full herein.

 

Section 9.11                             No Recourse Against Others.  No director, officer, employee, incorporator or stockholder of the Company shall have any liability for any obligations of the Company under the Securities, this Indenture or any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder, by accepting a Security, waives and releases all such liability.  The waiver and release are part of the consideration for issuance of the Securities.

 

[Remainder of the page intentionally left blank]

 

46

 

IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be duly executed as of the day and year first above written.

 

 

	
 
    	
ARBOR REALTY TRUST, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Paul Elenio
    
	
 
    	
 
    	
Name:
    	
Paul Elenio
    
	
 
    	
 
    	
Title:
    	
Chief Financial Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
U.S. BANK NATIONAL   ASSOCIATION,
    
	
 
    	
as Trustee
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Richard Prokosch
    
	
 
    	
 
    	
Name:
    	
Richard Prokosch
    
	
 
    	
 
    	
Title:
    	
Vice President
    

 

[Signature Page to Supplemental Indenture]

 

 

SCHEDULE A

 

The following table sets forth the number of Additional Shares by which the Conversion Rate shall be increased pursuant to Section 4.06 based on the Stock Price and Effective Date set forth below.

 

	
 
    	
 
    	
Stock Price
    	
 
    
	
Effective   Date
    	
 
    	
$
    	
8.44
    	
 
    	
$
    	
8.75
    	
 
    	
$
    	
9.00
    	
 
    	
$
    	
9.28
    	
 
    	
$
    	
9.50
    	
 
    	
$
    	
9.75
    	
 
    	
$
    	
10.00
    	
 
    	
$
    	
10.25
    	
 
    	
$
    	
10.50
    	
 
    	
$
    	
11.00
    	
 
    
	
November 13,   2017
    	
 
    	
10.7712
    	
 
    	
9.7272
    	
 
    	
7.5315
    	
 
    	
5.4088
    	
 
    	
3.9775
    	
 
    	
2.5893
    	
 
    	
1.4425
    	
 
    	
0.5779
    	
 
    	
0.1228
    	
 
    	
0.0000
    	
 
    
	
November 15,   2018
    	
 
    	
10.7712
    	
 
    	
9.2360
    	
 
    	
7.0272
    	
 
    	
4.9123
    	
 
    	
3.5034
    	
 
    	
2.1575
    	
 
    	
1.0662
    	
 
    	
0.2088
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    
	
November 15,   2019
    	
 
    	
10.7712
    	
 
    	
8.3139
    	
 
    	
6.0297
    	
 
    	
3.8892
    	
 
    	
2.5055
    	
 
    	
1.2330
    	
 
    	
0.2536
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    
	
November 15,   2020
    	
 
    	
10.7712
    	
 
    	
6.5501
    	
 
    	
3.3859
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    	
0.0000
    	
 
    
																																

 

 

EXHIBIT A

 

[FORM OF FACE OF SECURITY]

 

[For Global Securities, include the following legend]:

 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF.  THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

 

	
No.:
    	
[          ]
    
	
CUSIP:
    	
038923 AB4
    
	
ISIN:
    	
US038923AB43
    

 

Principal Amount $[                ]
 [as revised by the Schedule of Increases
 and Decreases in the Global Security attached hereto](1)

 

Arbor Realty Trust, Inc.
 5.375% Convertible Senior Notes due 2020

 

Arbor Realty Trust, Inc., a Maryland corporation, promises to pay to [            ] [include “Cede & Co.” for Global Security] or registered assigns, the principal amount of $[            ] on November 15, 2020 (the “Maturity Date”).

 

Interest Payment Dates: May 15 and November 15, beginning on May 15, 2018.

 

Regular Record Dates: May 1 and November 1.

 

Additional provisions of this Security are set forth on the other side of this Security.

 

(1)           Include for Global Securities only.

 

 

IN WITNESS WHEREOF, ARBOR REALTY TRUST, INC. has caused this instrument to be duly signed.

 

 

	
 
    	
ARBOR REALTY   TRUST, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    
	
 
    	
 
    
	
 
    	
Dated:
    

 

[Signature Page to Security]

 

 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

 

U.S. Bank National Association, as Trustee, certifies that this is one of the Securities referred to in the within-mentioned Indenture.

 

 

	
U.S.   Bank National Association, as Trustee
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Authorized   Signatory
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
Dated:
    	
 
    	
 
    

 

[Signature Page for Trustee Certification of Security]

 

 

[FORM OF REVERSE OF SECURITY]

 

ARBOR REALTY TRUST, INC.
 5.375% Convertible Senior Notes due 2020

 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued under a Senior Debt Securities Indenture dated as of May 12, 2014 (herein called the “Base Indenture”), and as further supplemented by the Third Supplemental Indenture, dated as of November 13, 2017  (herein called the “Supplemental Indenture” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”) by and between the Company and U.S. Bank National Association, herein called the “Trustee”, and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.  This Security is not subject to redemption at the option of the Company prior to the Maturity Date and does not benefit from a sinking fund.

 

As provided in and subject to the provisions of the Indenture, upon the occurrence of a Fundamental Change, the Holder of this Security will have the right, at such Holder’s option, to require the Company to purchase this Security, or any portion of this Security that is equal to $1,000 or a multiple of $1,000, on the Fundamental Change Repurchase Date at a price equal to the Fundamental Change Repurchase Price for such Fundamental Change Repurchase Date.

 

As provided in and subject to the provisions of the Indenture, the Holder hereof has the right, at its option (i) during certain periods and upon the occurrence of certain conditions specified in the Indenture, prior to the Close of Business on the Business Day immediately preceding August 15, 2020, and (ii) on or after August 15, 2020, at any time prior to the Close of Business on the Business Day immediately preceding the Stated Maturity, to convert this Security or a portion of this Security that is a multiple of $1,000, into an amount of cash, shares of Common Stock or a combination of cash and shares of Common Stock, as the case may be, determined in accordance with Article 4 of the Supplemental Indenture.

 

As provided in and subject to the provisions of the Indenture, the Company will make all payments in respect of the Fundamental Change Repurchase Price for, and the principal amount of, this Security to the Holder that surrenders this Security to the Paying Agent to collect such payments in respect of this Security.  The Company will pay cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts.

 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities to be effected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding.  The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities at the time Outstanding, on behalf of the Holders of all Securities, to waive compliance by the Company with certain provisions of the Indenture and certain past Defaults under the Indenture and their consequences.  Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture, or for the appointment of a receiver or trustee, or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Security, the Holders of not less than 25% in principal amount of the Securities at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity satisfactory to it, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity.  The foregoing shall not apply to any suit instituted by the Holder of this

 

 

Security for the enforcement of any payment of principal hereof or interest hereon or amounts due upon conversion on or after the respective due dates expressed herein.

 

No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay or deliver, as the case may be, the principal of (including the Fundamental Change Repurchase Price), interest on and the amount of cash, shares of Common Stock or combination of cash and shares of Common Stock, as the case may be, due upon conversion of, this Security at the time, place and rate, and in the coin and currency, herein prescribed.

 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or its attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

 

The Securities are issuable only in registered form without coupons in minimum denominations of $1,000 and multiples of $1,000.  As provided in the Indenture and subject to certain limitations therein set forth, the Securities are exchangeable for a like aggregate principal amount of Securities and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same.

 

Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or Trustee may treat the Person in whose name the Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

 

No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other similar governmental charge payable in connection therewith.

 

All defined terms used in this Security that are defined in the Indenture shall have the meanings assigned to them in the Indenture.  If any provision of this Security limits, qualifies or conflicts with a provision of the Indenture, such provision of the Indenture shall control.

 

 

ABBREVIATIONS

 

The following abbreviations, when used in the inscription of the face of this Security, shall be construed as though they were written out in full

 

	
TEN COM - as tenants in   common
    	
 
    	
UNIF GIFT MIN ACT
    	
 
    	
Custodian
    	
 
    	
 
    
	
 
    	
 
    	
(Cust)
    	
 
    	
 
    	
 
    	
 
    
	
TEN ENT -as tenants by the entireties
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
(Minor)
    	
 
    	
 
    	
 
    	
 
    
	
JT TEN - as joint tenants with right of Survivorship   and not as tenants in common
    	
 
    	
Uniform Gifts to Minors Act
    	
 
    	
 
    	
 
    	
(State)
    

 

Additional abbreviations may also be used though not in the above list.

 

 

ANNEX A

 

[Include for Global Security]

 

SCHEDULE OF INCREASES AND DECREASES OF GLOBAL SECURITY

 

Initial principal amount of Global Security:

 

	
Date
    	
 
    	
Amount of
   Increase in
   Principal
   Amount of
   Global Security
    	
 
    	
Amount of
   Decrease in
   Principal
   Amount of
   Global Security
    	
 
    	
Principal
   Amount of
   Global Security
   after Increase
   or Decrease
    	
 
    	
Notation by
   Security
   Registrar or
   Custodian
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

 

ATTACHMENT 1

 

[FORM OF NOTICE OF CONVERSION]

 

To:          Arbor Realty Trust, Inc.

 

The undersigned Holder of this Security hereby irrevocably exercises the option to convert this Security, or a portion hereof (which is a multiple of $1,000) below designated, into an amount of cash, shares of Common Stock or combination of cash and shares of Common Stock, as the case may be, in accordance with the terms of the Indenture referred to in this Security, and directs that any cash payable and any shares of Common Stock issuable and deliverable upon conversion, together with any Securities representing any unconverted principal amount hereof, be paid and/or issued and/or delivered, as the case may be, to the registered Holder hereof unless a different name is indicated below.

 

Subject to certain exceptions set forth in the Indenture, if this notice is being delivered on a date after the Close of Business on a Regular Record Date and prior to the Open of Business on the Interest Payment Date corresponding to such Regular Record Date, this notice must be accompanied by payment of an amount equal to the interest payable on such Interest Payment Date on the principal amount of this Security to be converted.  If any shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect to such issuance and transfer as set forth in the Indenture.

 

Principal amount to be converted (in an integral multiple of $1,000, if less than all):

 

 

	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature(s)
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature(s) must   be guaranteed by an institution which is a member of one of the following   recognized signature Guarantee Programs:
    
	
 
    	
(i) The Securities   Transfer Agent Medallion Program (STAMP); (ii) The New York Stock   Exchange Medallion Program (MNSP); (iii) The Stock Exchange Medallion   Program (SEMP); or (iv) another guarantee program acceptable to the   Trustee.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature Guarantee
    

 

 

Fill in for registration of any shares of Common Stock and Securities if to be issued otherwise than to the registered Holder.

 

	
 
    	
 
    
	
(Name)
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
(Address)
    	
 
    
	
 
    	
 
    
	
Please   print Name and Address
    	
 
    
	
(including   zip code number)
    	
 
    
	
Social   Security or other Taxpayer
    	
 
    
	
 
    	
 
    
	
Identifying   Number
    	
 
    	
 
    
			

 

 

ATTACHMENT 2

 

[FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE]

 

To:                             Arbor Realty Trust, Inc.

 

The undersigned registered owner of this Security hereby acknowledges receipt of a notice from Arbor Realty Trust, Inc. (the “Company”) as to the occurrence of a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs the Company to pay to the registered holder hereof in accordance with the applicable provisions of the Indenture referred to in this Security (i) the entire principal amount of this Security, or the portion thereof (that is equal to $1,000 or a multiple of $1,000) below designated, and (ii) if such Fundamental Change Repurchase Date does not occur during the period after a Regular Record Date and on or prior to the Interest Payment Date corresponding to such Regular Record Date, accrued and unpaid interest, if any, thereon to, but excluding, such Fundamental Change Repurchase Date.

 

In the case of certificated Securities, the certificate numbers of the Securities to be purchased are as set forth below:

 

	
Dated:
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature(s)
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Social Security or   Other Taxpayer Identification Number
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
principal amount to be   repaid (if less than all):
    
	
 
    	
$          ,000
    
	
 
    	
NOTICE: The signature   on the Fundamental Change Repurchase Notice must correspond with the name as   written upon the face of the Security in every particular without alteration   or enlargement or any change whatever.
    

 

 

ATTACHMENT 3

 

[FORM OF ASSIGNMENT AND TRANSFER]

 

For value received                 hereby sell(s), assign(s) and transfer(s) unto                 (Please insert social security or Taxpayer Identification Number of assignee) the within Security, and hereby irrevocably constitutes and appoints                      to                      transfer the said Security on the books of the Company, with full power of substitution in the premises.

 

	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature(s)
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature(s) must   be guaranteed by an institution which is a member of one of the following   recognized signature Guarantee Programs:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
(i) The Securities   Transfer Agent Medallion Program (STAMP); (ii) The New York Stock   Exchange Medallion Program (MNSP); (iii) The Stock Exchange Medallion   Program (SEMP); or (iv) another guarantee programBlueprint

Exhibit 10.1

 

 

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

 

LICENSE AGREEMENT

 

 

 

by and
between

 

 

 

SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO.
LTD.

 

and

 

PALATIN TECHNOLOGIES, INC.

 

 

 

 

 

September 6, 2017

 

 

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND
REPLACED WITH “[...***...]”. A COMPLETE VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS
AMENDED.

 

TABLE OF CONTENTS

 

	

1

	

DEFINITIONS AND INTERPRETATION.

	

2

	

1.1.

	

Defined Terms

	

2

	

1.2.

	

Interpretation

	

2

	

2

	

LICENSE GRANTS AND TECHNOLOGY TRANSFER.

	

2

	

2.1.

	

License from Palatin to Fosun Within the Territory

	

2

	

2.2.

	

Non-Exclusive License from Palatin to Fosun Outside the
Territory

	

2

	

2.3.

	

Fosun Sublicensees

	

3

	

2.4.

	

No Implied Rights

	

3

	

2.5.

	

Initial Data Transfer

	

3

	

2.6.

	

Continuing Disclosure and Knowledge Transfer

	

3

	

3

	

PAYMENTS BY Fosun TO PALATIN.

	

3

	

3.1.

	

Upfront Payment

	

3

	

3.2.

	

Development Milestone Payment

	

3

	

3.3.

	

Sales Milestone Payments

	

4

	

3.4.

	

Royalty Payments

	

4

	

3.5.

	

Reports and Payments

	

6

	

4

	

PRODUCT DEVELOPMENT AND COMMERCIALIZATION.

	

8

	

4.1.

	

General

	

8

	

4.2.

	

Diligence

	

9

	

4.3.

	

Regulatory Approvals

	

10

	

4.4.

	

Adverse Event Reporting

	

10

	

4.5.

	

Commercialization Activities

	

11

	

4.6.

	

Manufacturing

	

12

	

4.6.1.

	

Clinical Trial Materials.

	

12

	

5

	

INTELLECTUAL PROPERTY.

	

13

	

5.1.

	

Ownership of Intellectual Property

	

13

	

5.2.

	

Patent Rights

	

14

	

5.3.

	

Enforcement and Defense of Know-How

	

19

	

5.4.

	

Recording

	

19

 

 

i

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

   

	

6

	

CONFIDENTIALITY.

	

19

	

6.1.

	

Confidentiality

	

19

	

6.2.

	

Authorized Disclosure

	

20

	

6.3.

	

SEC Filings and Other Disclosures

	

21

	

6.4.

	

Public Announcements

	

21

	

7

	

REPRESENTATIONS AND WARRANTIES; COVENANTS; SECURITY
INTEREST.

	

21

	

7.1.

	

Mutual Representations and Warranties

	

21

	

7.2.

	

Mutual Covenants

	

22

	

7.3.

	

Representations and Warranties of Palatin

	

23

	

7.4.

	

Disclaimer

	

23

	

8

	

GOVERNMENT APPROVALS; REMEDY; TERM AND TERMINATION.

	

25

	

8.1.

	

Other Government Approvals

	

25

	

8.2.

	

Term

	

25

	

8.3.

	

Termination by Palatin

	

25

	

8.4.

	

Termination by Fosun

	

25

	

8.5.

	

Effects of Termination

	

25

	

9

	

LIMITATION ON LIABILITY, INDEMNIFICATION AND
INSURANCE.

	

27

	

9.1.

	

No Consequential Damages

	

27

	

9.2.

	

Indemnification by Fosun

	

27

	

9.3.

	

Indemnification by Palatin

	

28

	

9.4.

	

Procedure

	

28

	

9.5.

	

Insurance

	

30

	

10

	

MISCELLANEOUS.

	

30

	

10.1.

	

Assignment

	

30

	

10.2.

	

Further Actions

	

30

	

10.3.

	

Force Majeure

	

30

	

10.4.

	

Notices

	

31

	

10.5.

	

Amendment

	

32

	

10.6.

	

Waiver

	

32

	

10.7.

	

Severability

	

32

	

10.8.

	

Descriptive Headings

	

32

	

10.9.

	

Dispute Resolution

	

32

	

10.10.

	

Governing Law

	

33

	

10.11.

	

Entire Agreement

	

33

	

10.12.

	

Representation by Legal Counsel

	

33

	

10.13.

	

Independent Contractors

	

33

	

10.14.

	

Counterparts

	

33

	

10.15.

	

No Third Party Rights or Obligations

	

33

 

 

 

ii

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

EXHIBITS

 

Exhibit
A                       
Defined Terms

 

Exhibit
B                       
Palatin Patent Rights Existing as of the Effective
Date

 

Exhibit
C                       
Compounds Existing as of the Effective Date

 

Exhibit
D                       
Section 7.3.5. Representation

 

 

 

 

i

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

LICENSE AGREEMENT

 

This
License Agreement (the “Agreement”) is entered into as
of September 6, 2017 (the “Effective Date”), by and
between Shanghai Fosun Pharmaceutical Industrial Development Co.
Ltd., a limited liability company organized and existing under the
laws of the People’s Republic of China and having a
registered principal place of business at No. 1289 Yishan Road
(Building A, Fosun Technology Park), Shanghai City, 200233, the
People’s Republic of China (“Fosun”) and Palatin
Technologies, Inc., a corporation organized and existing under the
laws of Delaware and having a principal place of business at 4-B
Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512
(“Palatin”). Fosun and Palatin may each be referred to
herein individually as a “Party” and collectively as
the “Parties.”

 

WHEREAS, Palatin
owns or otherwise controls certain patents, patent applications,
technology, know-how, scientific and technical information and
other proprietary rights and information relating to the
identification, research and development of Compounds,
Pharmaceutical Products, Product Delivery Devices and
Products (each, as
defined below);

 

WHEREAS, Fosun has
experience and expertise in the development and commercialization
of pharmaceutical products, and desires to acquire an exclusive
license in the Territory (as defined below) under Palatin’s
patents, patent applications, technology, know-how, scientific and
technical information and other proprietary rights and information
relating to Compounds; and

 

WHEREAS, subject to
the terms of this Agreement, Palatin wishes to grant to Fosun, and
Fosun wishes to receive from Palatin, an exclusive license in the
Territory to commercialize Compounds and Products (as defined
below).

 

NOW
THEREFORE, in consideration of the mutual promises and covenants
set forth below and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the
Parties hereby agree as follows:

 

 

 

1

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

1. 

DEFINITIONS AND
INTERPRETATION.

 

1.1.           Defined
Terms. Capitalized terms not otherwise defined herein shall
have the meanings set forth in Exhibit A.

 

1.2.           Interpretation.
Except where the context expressly requires otherwise, (a) the
use of any gender herein shall be deemed to encompass references to
either or both genders, and the use of the singular shall be deemed
to include the plural (and vice versa), (b) the words
“include”, “includes” and
“including” shall be deemed to be followed by the
phrase “without limitation”, (c) the word
“will” shall be construed to have the same meaning and
effect as the word “shall”, (d) any definition of
or reference to any agreement, instrument or other document herein
shall be construed as referring to such agreement, instrument or
other document as from time to time amended, supplemented or
otherwise modified (subject to any restrictions on such amendments,
supplements or modifications set forth herein), (e) any reference
herein to any Person shall be construed to include the
Person’s successors and assigns, (f) the words
“herein”, “hereof” and
“hereunder”, and words of similar import, shall be
construed to refer to this Agreement in its entirety and not to any
particular provision hereof, (g) all references herein to Sections,
Exhibits or Schedules shall be construed to refer to Sections,
Exhibits or Schedules of this Agreement, and references to this
Agreement include all Exhibits and Schedules hereto, (h) the word
“notice” means notice in writing (whether or not
specifically stated) and shall include notices, consents, approvals
and other written communications contemplated under this Agreement,
(i) provisions that require that a Party or the Parties
“agree,” “consent” or “approve”
or the like shall require that such agreement, consent or approval
be specific and in writing, whether by written agreement, letter,
approved minutes or otherwise (but excluding e-mail and instant
messaging), (j) references to any specific law, rule or regulation,
or article, section or other division thereof, shall be deemed to
include the then-current amendments thereto or any replacement or
successor law, rule or regulation thereof, and (k) the term
“or” shall be interpreted in the inclusive sense
commonly associated with the term
“and/or.”

 

2. 

LICENSE GRANTS AND TECHNOLOGY
TRANSFER.

 

2.1.           License
from Palatin to Fosun Within the Territory. As of the
Effective Date, Palatin hereby grants to Fosun (a) an exclusive
license (exclusive even as to Palatin) under the Palatin
Technology, to Commercialize and have Commercialized (but not to
use, have used, Develop, have Developed, Manufacture and have
Manufactured) Compounds, Products, Pharmaceutical Products and
Product Delivery Devices, and otherwise practice and exploit the
Palatin Technology, and (b) a non-exclusive license under the
Palatin Technology, to use, have used, Develop, have Developed,
Manufacture and have Manufactured Compounds, Products,
Pharmaceutical Products and Product Delivery Devices, in each case
(a) and (b), in the Field and in the Territory.

 

2.2.           Non-Exclusive
License from Palatin to Fosun Outside the Territory. As of
the Effective Date, Palatin hereby grants to Fosun (a) a
non-exclusive license under the Palatin Technology, to Manufacture
and have Manufactured (but not to Commercialize or have
Commercialized) Compounds, Products, Pharmaceutical Products and
Product Delivery Devices, in the Field in all countries of North
America, and (b) a non-exclusive license under the Palatin
Technology, to Develop, have Developed, Manufacture and have
Manufactured (but not to Commercialize or have Commercialized)
Compounds, Products, Pharmaceutical Products and Product Delivery
Devices, and otherwise practice and exploit the Palatin Technology,
in the Field in all countries of the world outside the Territory,
other than the countries of North America (which are governed
solely by Section 2.2(a)), in each case, solely for purposes of
Developing and Manufacturing Compounds, Products, Pharmaceutical
Products and Product Delivery Devices for Commercialization in the
Territory.

 

 

2

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

2.3.           Fosun
Sublicensees. Fosun shall have the right to grant
sublicenses, directly or indirectly, to its Affiliates and Third
Parties of any and all rights granted to Fosun under this Agreement
by Palatin, including any and all rights licensed to Fosun pursuant
to Section 2.1 or Section 2.2. Each sublicense agreement shall be
in writing and provide that the applicable Sublicensee is bound by
all applicable terms and conditions of this Agreement, including
with respect to record keeping obligations and audit rights. Fosun
shall remain responsible for the payment to Palatin of all
Milestone Payments and royalties payable with respect to Net Sales
of Products made by such Sublicensees. Fosun shall be responsible
for the acts and omissions of its Sublicensees. Fosun shall deliver
to Palatin a true, accurate and complete copy of each sublicense
agreement entered into by Fosun, and any modification or
termination thereof, within [...***...] after the
applicable execution, modification or termination of the sublicense
agreement.

 

2.4.           No
Implied Rights. Except as expressly provided in this
Agreement, neither Party shall be deemed to have granted the other
Party (by implication, estoppel or otherwise) any right, title,
license or other interest in or with respect to any intellectual
property, Know-How or information Controlled by such
Party.

 

2.5.           Initial
Data Transfer. Within a reasonable time not to exceed
[...***...] following the Initial Payment Date (as
hereafter defined), Palatin shall disclose to Fosun all Palatin
Know-How necessary or useful in connection with securing Regulatory
Approval and Commercializing Products in the Territory, together
with such additional Palatin Know-How as Fosun may reasonably
request, in each case to the extent developed by and Controlled by
Palatin on or prior to the Effective Date, in either the format in
which such Palatin Know-How then exists or in such other format as
Fosun may reasonably request (including by download of digital
files to a secure website or e-room designated by
Fosun).

 

2.6.           Continuing
Disclosure and Knowledge Transfer. On a Calendar Quarter
basis, or more frequently at the reasonable request of Fosun during
the Term, Palatin shall disclose to Fosun any Palatin Know-How
developed or acquired by Palatin since Palatin’s most recent
disclosure, but only to the extent the same is Controlled by
Palatin. Such disclosure shall be in either the format in which
such Palatin Know-How then exists or in such other format as Fosun
may reasonably request (including by download of digital files to a
secure website or e-room designated by Fosun). Further, Palatin
shall make appropriate personnel available to Fosun at reasonable
times and upon reasonable prior notice for the purpose of assisting
Fosun to understand and use the Palatin Technology in connection
with Fosun’s Development, Manufacture, Commercialization and
use of Compounds and Products.

 

2.7.           Palatin
Retained Rights. Notwithstanding the rights granted to Fosun
in Section 2.1 and Section 2.2, and without limiting the generality
of Section 2.4, the Parties acknowledge that Palatin retains the
right to practice the Palatin Technology in the Territory to
fulfill its obligations under this Agreement.

 

3. 

PAYMENTS BY FOSUN TO
PALATIN.

 

3.1.           Upfront
Payment. Fosun shall pay to Palatin a one-time payment of
five million dollars ($5,000,000 USD), which shall be paid within
[...***...] following the Effective Date (with the date of
receipt by Palatin being the “Initial Payment
Date”).

 

3.2.           Development
Milestone Payment. Fosun shall pay Palatin the amount set
forth below within [...***...] following the first
occurrence of the event described below for the first
Product to achieve such
event (the “Development Milestone
Payment”).

 

	

Development Event

	

Development Milestone Payment

	

Regulatory
Approval in China by CFDA with respect to the Initial Indication,
provided that a clinical and commercial supply agreement has been
entered into between Palatin and AMAG and a supply agreement has
been entered into between Palatin and Fosun, or, as the case may
be, a supply agreement has been entered into among Palatin, AMAG
and Fosun as described in Section 4.6.4.

	

$7,500,000
USD

 

 

The
Development Milestone Payment set forth above shall be payable one
time only (regardless of the number of Products with respect to
which, or the number of times with respect to any Product, the
specified Development Event occurs).

 

 

3

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

3.3.            Sales
Milestone Payments. Fosun shall pay Palatin the following
one-time payments (each, a “Sales Milestone Payment”)
when aggregate Net Sales of all Products in a Calendar Year in the
Territory (the “Total Annual Net Sales”) first reach
the respective thresholds indicated below:

 

	

Total Annual Net Sales

	

Sales Milestone Payment

	

Total
Annual Net Sales reaching [...***...]

	

[...***...]

	

Total
Annual Net Sales reaching [...***...]

	

[...***...]

	

Total
Annual Net Sales reaching [...***...]

	

[...***...]

	

Total
Annual Net Sales reaching [...***...]

	

[...***...]

	

Total
Annual Net Sales reaching [...***...]

	

[...***...]

 

Fosun
shall make any Sales Milestone Payment payable with respect to a
Calendar Year within [...***...] after the end of the
applicable Calendar Year. For the avoidance of doubt, each of the
Sales Milestone Payments set forth above shall be payable one time
only, regardless of the number of times the corresponding Total
Annual Net Sales levels are achieved. The maximum aggregate amount
payable by Fosun in respect of the Development Milestone Payment
and Sales Milestone Payments (but excluding the upfront payment)
shall be one hundred million dollars ($100,000,000
USD).

 

3.4.           Royalty
Payments.

 

3.4.1.       
Royalties. Subject to the
provisions of Section 3.4.3, Fosun shall pay Palatin royalties in
the amount of the Marginal Royalty Rates (set forth below) of the
aggregate Net Sales resulting from the sale of Products, on a
Product-by-Product basis, in the Territory during each Calendar
Year of the applicable Royalty Term for each Product (each, the
“Per Product Annual Net Sales”):

 

	

Per Product Annual Net Sales

	

Marginal Royalty Rate

(% of Per Product Annual Net Sales)

	

Per
Product Annual Net Sales above $0, up to and including
[...***...]

	

[...***...]

	

Per
Product Annual Net Sales above [...***...]

	

[...***...]

	

Per
Product Annual Net Sales [...***...]

	

[...***...]

 

Each
Marginal Royalty Rate set forth in the table above shall apply only
to that portion of the Net Sales of a given Product in the
Territory during a given Calendar Year that falls within the
indicated range.

 

For
illustration purposes only, if Net Sales resulting from the sale of
a Product in the Territory during a Calendar Year
[...***...]

 

3.4.2.       
Fully Paid-Up, Royalty Free
License. Following expiration of the Royalty Term for any
Product in a given Jurisdiction in the Territory, no further
royalties shall be payable in respect of sales of such Product in
such Jurisdiction and,
thereafter the license granted to Fosun under Sections 2.1 and 2.2
with respect to such Product in such Jurisdiction shall
automatically become fully paid-up, perpetual, irrevocable and
royalty-free.

 

 

4

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

3.4.3.               Royalty
Adjustments. The following adjustments shall be made, on a
Product-by-Product and Jurisdiction-by-Jurisdiction basis, to the
royalties payable pursuant to Section 3.4.1, in each case, subject
to the limitations set forth in Section 3.4.4:

 

(a)           Third
Party Patents. If it is necessary for Fosun to license one
or more Patent Rights from one or more Third Parties in order to
Develop, Manufacture, Commercialize or use any Product, whether
directly or through any Fosun Affiliate or Sublicensee, then Fosun
may, in its sole discretion, negotiate and obtain a license under
such Patent Right(s) (each such Third Party license referred to
herein as an “Additional Third Party License”). Any
royalty otherwise payable to Palatin under this Agreement with
respect to Net Sales of any Product by Fosun, its Affiliates or
Sublicensees shall be reduced by [...***...] of the amounts
payable to Third Parties pursuant to any Additional Third Party
Licenses, such reduction to continue until all such amounts have
been expended, provided
that in no event shall the total royalty payable to Palatin
for any Product be less than [...***...] of the royalty
amounts otherwise payable for such Product.

 

(b)           No
Adjustment for Palatin Third Party Agreements. As between
Palatin and Fosun, Palatin shall be solely responsible for (i) all
obligations (including any royalty or other obligations that relate
to the Palatin Technology) under its agreements with Third Parties
that are in effect as of the Effective Date or that Palatin enters
into during the Term and (ii) all payments to inventors (other than
inventors that are Representatives of Fosun) of Palatin Technology,
including payments under inventorship compensation
Laws.

 

(c)           Generic
Entry. As used in this Section 3.4(c), “Generic
Competition” means, with respect to a given Product in a
given Jurisdiction in the Territory, that (a) one or more Generic
Products to such Product are available in such Jurisdiction and (b)
[...***...]. Notwithstanding any provision of this
Agreement to the contrary, upon the occurrence of Generic
Competition with respect to a Product in a given Jurisdiction in
the Territory, any royalty payments owed with respect to such
Product in such Jurisdiction pursuant to this Section 3.4 shall be
reduced by [...***...].

 

3.4.4.               Limitations
on Adjustments. Notwithstanding anything herein to the
contrary, in no event shall the royalties payable to Palatin for
any Product under this Agreement be less than an amount equal to
[...***...].

 

 

5

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

3.5.                 
Reports and
Payments.

 

3.5.1.               Cumulative
Royalties. The obligation to pay royalties under this
Agreement shall be imposed only once with respect to any sale of
any given unit of a Product.

 

3.5.2.             
Royalty Statements and
Payments. Within [...***...] of the end of each
Calendar Quarter, Fosun shall deliver to Palatin a report setting
forth the following information for such Calendar Quarter, on a
Product-by-Product, Jurisdiction-by-Jurisdiction and Territory-wide
basis: (a) gross sales of each Product, (b) Net Sales of each
Product, (c) deductions taken from gross sales (by category as
set forth in the definition of Net Sales) to arrive at the Net
Sales calculation, (d) the basis for any adjustments to the royalty
payable for the sale of any such Product and (e) the royalty due
hereunder for the sale of each such Product. No such reports shall
be due for any such Product (i) before the First Commercial Sale of
such Product or (ii) after the Royalty Term for such Product has
expired in all Jurisdictions in the Territory. The total royalty
due for the sale of all such Products during such Calendar Quarter
shall be remitted within [...***...] following the delivery
of such report and confirmation by Palatin as to the amount of
royalty due.

 

3.5.3.               Taxes
and Withholding. To the extent any payments made by Fosun
pursuant to this Agreement become subject to withholding taxes
under the Laws or regulations of any jurisdiction or Governmental
Authority, Fosun shall deduct and withhold the amount of such taxes
for the account of Palatin to the extent required by applicable
Laws or regulations; such amounts payable to Palatin shall be
reduced by the amount of taxes deducted and withheld; and Fosun
shall pay the amounts of such taxes to the proper Governmental
Authority in a timely manner and transmit to Palatin an official
tax certificate or other evidence of such tax obligations together
with proof of payment from the relevant Governmental Authority of
all amounts deducted and withheld sufficient to enable Palatin to
claim such payment of taxes. Any such withholding taxes required
under applicable Laws or regulations to be paid or withheld shall
be an expense of, and borne solely by, Palatin. Except as provided
in this Section 3.5.3, all taxes or duties in connection with
payments made by Fosun, including any value added or similar tax or
local tax or surcharge on value added taxes and any import duty or
fees, shall be borne by Fosun.

 

3.5.4.               Currency.
All amounts payable and calculations under this Agreement shall be
in United States dollars. As applicable, Net Sales and any
adjustments to payments under this Agreement shall be translated
into United States dollars at the exchange rate used by Fosun for
public financial accounting purposes. If, due to restrictions or
prohibitions imposed by national or international authority, a
given payment cannot be made as provided in this Section 3, Fosun
shall promptly notify Palatin and the Parties shall consult with a
view to finding a prompt and acceptable solution. If the Parties
are unable to identify a mutually acceptable solution regarding
such payment, then Fosun may elect, in its sole discretion and upon
60 days’ advance written notice to Palatin, to deposit such
payment in local currency in the relevant jurisdiction to the
credit of Palatin in a recognized banking institution designated by
Palatin or, if none is designated by Palatin, within such 60 day
period, in a recognized banking institution selected by Fosun and
identified in a written notice given to Palatin.

 

 

6

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

3.5.5.               Method
of Payment. Except as permitted pursuant to Section 3.5.4,
each payment hereunder shall be made by electronic transfer in
immediately available funds via either a bank wire transfer, an ACH
(automated clearing house) mechanism, or any other means of
electronic funds transfer, at Fosun’s election, to such bank
account as Palatin shall designate in writing to Fosun at least
[...***...] before the payment is due.

 

3.5.6.             
Record Keeping. Fosun shall
keep and shall cause its Affiliates and Sublicensees to keep books
and accounts of record in connection with the sale of Products in
sufficient detail to permit accurate determination of all figures
necessary for verification of royalties and Sales Milestone
Payments to be paid
hereunder. Fosun and its Affiliates shall maintain such records for
a period of at least [...***...] after the end of the
Calendar Quarter in which they were generated.

 

3.5.7.               Audits.
Upon
[...***...] prior notice from Palatin, Fosun shall permit
an independent certified public accounting firm of nationally
recognized standing selected by Palatin and Fosun, to examine, at
Palatin’s sole expense, the relevant books and records of
Fosun and its Affiliates as may be reasonably necessary to verify
the amounts reported by Fosun in accordance with Section 3.5.2 and
the payment of royalties and Sales Milestone Payments hereunder. An examination by
Palatin under this Section 3.5.7 shall occur not more than once in
any Calendar Year and shall be limited to the pertinent books and
records for any Calendar Year ending not more than
[...***...] before the date of the request. The accounting
firm shall be provided access to such books and records at
Fosun’s or its Affiliates’ or any Sublicensee’s
facility(ies) where such books and records are normally kept and
such examination shall be conducted during Fosun’s normal
business hours. Fosun may require the accounting firm to sign a
reasonably acceptable non-disclosure agreement before providing the
accounting firm with access to Fosun’s or its
Affiliates’ facilities or records. Upon completion of the
audit, the accounting firm shall provide both Fosun and Palatin a
written report disclosing any discrepancies in the reports
submitted by Fosun or the royalties or Sales Milestone
Payments paid by Fosun,
and, in each case, the specific details concerning any
discrepancies. Upon [...***...] from Fosun, Palatin shall
permit an independent certified public accounting firm of
nationally recognized standing selected by Fosun and Palatin, to
examine, at Fosun’s sole expense, the relevant books and
records of Palatin and its Affiliates as may be reasonably
necessary to verify the amounts reported by Palatin related to COGS
and price of Product supplied by Palatin in accordance with Section
4.6.4. The accounting firm shall be provided access to such books
and records at Palatin’s or its Affiliates’
facility(ies) where such books and records are normally kept and
such examination shall be conducted during Palatin’s normal
business hours. Palatin may require the accounting firm to sign a
reasonably acceptable non-disclosure agreement before providing the
accounting firm with access to Palatin’s or its
Affiliates’ facilities or records. Upon completion of the
audit, the accounting firm shall provide both Fosun and Palatin a
written report disclosing any discrepancies in the reports
submitted by Palatin on the COGS and price of Product supplied by
Palatin in accordance with Section 4.6.4, and the specific details
concerning any discrepancies.

 

 

7

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

3.5.8.               Underpayments/Overpayments.
If any audit conducted pursuant to Section 3.5.7 concludes that
additional royalties or Sales Milestone Payments were due to Palatin, then Fosun
will pay to Palatin the additional royalties or Sales Milestone
Payments, plus interest on the deficient amount, as calculated
pursuant to Section 3.5.9, within [...***...] of the date
Fosun receives such accountant’s written report.
[...***...]. If any audit conducted pursuant to Section
3.5.7 concludes that the price actually paid by Fosun with respect
to Product supplied by Palatin in accordance with Section 4.6.4
exceeded the amount Fosun should pay to Palatin, then Fosun shall
have the right to deduct the gap from the next royalty or goods
payment to Palatin. [...***...].

 

3.5.9.               Late
Payments. Any payments due under this Agreement shall be due
on such date as specified in this Agreement and, in the event such
date is not a Business Day, then the next succeeding Business Day.
In the event that any payment due under this Agreement is not made
when due, except any delay caused by Force Majeure as provided in
Section 10.3 (including, for the avoidance of doubt, any
unanticipated and unusual examination by the Government Authority
controlling foreign currency in the Territory), the amount due
shall accrue interest beginning on the [...***...]
following the date on which such payment was due, calculated at the
[...***...] for the due date, calculated from the due date
until paid in full. Each payment made after the due date shall be
accompanied by all interest so accrued. Notwithstanding the
foregoing, a Party shall have recourse to any other remedy
available at law or in equity with respect to any delinquent
payment, subject to the terms of this Agreement.

 

3.5.10.          
Confidentiality.
Notwithstanding any provision of this Agreement to the contrary,
all reports and financial information of the Parties, their
Affiliates or their Sublicensees which are provided to or subject
to review by the other Party under this Section 3 shall be deemed
to be the Confidential Information of the reporting or audited
Party, as applicable, and subject to the provisions of Section
6.

 

4. 

PRODUCT DEVELOPMENT AND
COMMERCIALIZATION.

 

4.1.           General.
Fosun shall have sole authority over and control of the Regulatory
Approval and Commercialization of Compounds, Products,
Pharmaceutical Products and Product Delivery Devices for
Commercialization in the Territory. Palatin shall cooperate, and
take Commercially Reasonable Efforts to secure the United States
Certificate of Pharmaceutical Product holder (the “U.S. CPP
Holder”) to cooperate, with Fosun such that the application
for Regulatory Approval shall be filed in the U.S. CPP
Holder’s name as required by the Regulatory Authority in the
Territory.

 

 

8

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

4.2.           Diligence.

 

4.2.1.         
Regulatory Approval. Fosun
will use Commercially Reasonable Efforts to file an NDA for a
Product for the Initial Indication in the Territory and secure
Regulatory Approval of such NDA in the Territory.

 

(a)           Without
limiting the foregoing, the Clinical Trial application submission
to the relevant Regulatory Authority for the Initial Indication
shall occur [...***...].

 

(b)           The
Clinical Trial(s) shall be initiated
[...***...].

 

(c)           Without
limiting the foregoing, Fosun shall file an NDA,
[...***...].

 

4.2.2.        
Commercial Diligence. Once
the NDA described in Section 4.2.1 has received Regulatory Approval
in China with respect to the Initial Indication, Fosun will use
Commercially Reasonable Efforts to Commercialize the Product
covered by such NDA in China with respect to the Initial
Indication. The First Commercial Sale in China shall be
[...***...] following Regulatory Approval in China and
[...***...].

 

4.2.3.         
Exceptions to Diligence
Obligations. Notwithstanding any provision of this Agreement
to the contrary, Fosun will be relieved of all Fosun Diligence
Obligations to the extent that:

 

(a)           Fosun
or Palatin receives or generates any safety, tolerability or other
data indicating or signaling that a Product has or would have an
unacceptable risk-benefit profile or is otherwise not suitable for
initiation or continuation of Clinical Trials; or

 

(b)           Fosun
or Palatin receive any notice, information or correspondence from
an applicable Regulatory Authority, or an applicable Regulatory
Authority takes any action, that indicates that a Product is
unlikely to receive Regulatory Approval in the Territory with
respect to the Initial Indication.

 

4.2.4.        
Assertion of Fosun Diligence
Obligation Claims. If Palatin is, becomes or reasonably
should be aware of facts that might form a reasonable basis to
allege that Fosun has failed to meet any of its obligations under
Section 4.2.1 or Section 4.2.2, then Palatin will promptly notify
Fosun in writing of such potential alleged performance failure
(each such potential alleged performance failure, a
“Diligence Issue”). Promptly upon Fosun’s
receipt of any notice of a Diligence Issue pursuant to this Section
4.2.4, Fosun will contact Palatin to discuss the specific nature of
such Diligence Issue and seek to identify an appropriate corrective
course of action. If,
[...***...], (a) the Parties have not reached consensus
regarding whether Fosun has failed to satisfy its obligations
pursuant to Section 4.2.1 or Section 4.2.2 and (b) the Parties have
not agreed upon an appropriate corrective course of action for such
Diligence Issue, then such Diligence Issue will be escalated and
resolved pursuant to the dispute resolution provisions set forth in
Section 10.9.

 

4.2.5.         
Remedies for Breach of Fosun
Diligence Obligations. If Fosun materially breaches any
Fosun Diligence Obligation and fails to remedy such breach
[...***...] of such breach from Palatin, then Palatin may,
in its sole discretion, elect to either (a) terminate this
Agreement pursuant to the provisions of Section 8.5.1(a) on a
Product-by-Product and Jurisdiction-by-Jurisdiction basis, but only
to the extent that a Product in a given Jurisdiction in the
Territory is directly and adversely impacted by such uncured
material breach or (b) convert any exclusive license granted to
Fosun under this Agreement with respect to a Product in a given
Jurisdiction in the Territory into non-exclusive license, but only
to the extent that such Product in such Jurisdiction is directly
and adversely impacted by such uncured material
breach.

 

 

9

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

4.2.6.        
No Other Covenants. Except
as expressly set forth in Section 4.2, Fosun makes no
representation, warranty or covenant, either express or implied,
that (A) it will successfully Commercialize or continue to
Commercialize any Product in any Jurisdiction, (B) if
Commercialized, that any Product will achieve any particular sales
level, whether in any individual Jurisdiction or cumulatively
throughout the Territory.

 

4.3.           Regulatory
Approvals. Fosun or its designated Affiliate(s) or
Sublicensee(s) shall have the sole authority, at their sole
expense, to file applications for Regulatory Approval of Products,
Pharmaceutical Products and Product Delivery Devices in the Field
in the Territory, including communicating with any Regulatory
Authority both prior to and following Regulatory Approval. As
between the Parties, Fosun shall be the sole and exclusive owner of
all such Regulatory Approval applications (including NDAs) and all
regulatory correspondence and filings with respect to such
Regulatory Approval applications and Regulatory Approvals granted
thereon. Fosun shall consult and reasonably cooperate with Palatin
and its other licensees (including, without limitation, AMAG) with
respect to all applications for Regulatory Approval of any
Products, Pharmaceutical Products or Product Delivery Devices in
the Territory, including allowing Palatin and such licensees a
reasonable opportunity and reasonable time to review and comment
regarding relevant communications with applicable Regulatory
Authorities in the Territory.

 

4.4.           Adverse
Event Reporting; Pharmacovigilance Agreement. Fosun
acknowledges that Palatin has agreed with AMAG Pharmaceuticals,
Inc., (“AMAG”) Palatin’s exclusive licensee for
North America, that AMAG shall be solely responsible for
maintaining the global safety database for Products. Fosun agrees
to negotiate in good faith and enter into such pharmacovigilance
agreements as are reasonably necessary in further of AMAG
maintaining the global safety database for Products.
[...***...]. As between the Parties: (a) Fosun shall
be responsible for the pharmacovigilance surveillance and timely
reporting of all relevant adverse drug reactions/experiences,
Product quality, Product complaints and Safety Data relating to any
Compound, Product, Pharmaceutical Product or Product Delivery
Device to the appropriate Regulatory Authorities in the Territory;
and (b) AMAG and Palatin shall be responsible for the
pharmacovigilance surveillance and timely reporting of all relevant
adverse drug reactions/experiences, Product quality, Product
complaints and Safety Data relating to any Compound, Product,
Pharmaceutical Product or Product Delivery Device to the
appropriate Regulatory Authorities outside the Territory, in each
case in accordance with applicable Laws. The Parties shall
cooperate with each other and with AMAG with respect to their
respective pharmacovigilance responsibilities, and each Party shall
be solely responsible for costs relating to its respective
pharmacovigilance responsibilities, except to the extent agreed
otherwise by the Parties in writing. [...***...], Fosun and
AMAG (or, at Palatin’s option, Fosun, Palatin and AMAG) shall
enter into a pharmacovigilance agreement, pursuant to which AMAG
will maintain the global safety database for Products, on terms
that comply with ICH guidelines, including: (i) providing
detailed procedures regarding the maintenance of core safety
information and the exchange of Safety Data relating to all
Compounds, Products, Pharmaceutical Products and Product Delivery
Devices worldwide within appropriate timeframes and in an
appropriate format to enable each Party, as applicable, and AMAG to
meet both expedited and periodic regulatory reporting requirements;
and (ii) ensuring compliance with the reporting requirements
of all applicable Regulatory Authorities on a worldwide basis for
the reporting of Safety Data in accordance with standards
stipulated in the ICH guidelines, and all applicable regulatory and
legal requirements regarding the management of Safety
Data.

 

 

10

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

4.5.           Commercialization
Activities.

 

4.5.1.        
General. Fosun shall have
sole and exclusive control, at its sole expense, over all matters
relating to the Commercialization of Compounds, Products,
Pharmaceutical Products and Product Delivery Devices in the Field
in the Territory, including sole and exclusive control over (a)
pricing of Products and (b) the negotiation of Product pricing with
Regulatory Authorities and other Third Parties.

 

4.5.2.       
Branding. Fosun and its
designated Affiliates or Sublicensees shall have the right to brand
all Products in the Territory using any one or more Trademarks
which may vary by Jurisdiction or within a Jurisdiction in the
Territory. Fosun or its designated Affiliates or Sublicensees shall
own all rights, title and interests in and to such Trademarks and
Fosun or such Affiliates or Sublicensees may file, seek
registration of and maintain such Trademarks in the countries and
regions they determine reasonably necessary. In the event that
Fosun intends to register any Trademarks in the name of Palatin in
a Jurisdiction in the Territory, Palatin shall reasonably cooperate
to provide assistance, execute and deliver to Fosun any documents
required for the registration of the Trademarks. Palatin also
agrees to grant an exclusive license (exclusive even as to Palatin)
to Fosun of any Trademarks which are applied for by Fosun in
Palatin’s name in the Territory without additional
consideration until this Agreement is terminated.

 

4.5.3.       
Ex-Territory Sales. Subject
to applicable Law, Palatin, its Affiliates and its licensees shall
not engage in any advertising or promotional activities relating to
any Product directed primarily to customers or other buyers or
users of any Product located in the Territory, or accept orders for
Compounds, Products, Pharmaceutical Products or Product Delivery
Devices from or sell Compounds, Products, Pharmaceutical Products
or Product Delivery Devices into the Territory, and if Palatin, its
Affiliates or its licensees receive any such order it shall refer
such order to Fosun.

 

 

11

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

4.5.4.    
   Export Monitoring.

 

(a)           Fosun
shall not, and shall use reasonable efforts to not permit its
Affiliates and its Sublicensees to, export Compounds, Products,
Pharmaceutical Products or Product Delivery Devices from in the
Territory for Commercialization outside the Territory, provided
that, Fosun may export Compounds, Products, Pharmaceutical Products
or Product Delivery Devices to Palatin or its designated parties.
Fosun shall promptly inform Palatin of any such exports of
Compounds, Products, Pharmaceutical Products or Product Delivery
Devices and the actions taken to prevent such exports. Fosun will
take all reasonable actions requested in writing by Palatin that
are consistent with applicable Law to prevent Third Party exports
of Compounds, Products, Pharmaceutical Products or Product Delivery
Devices from in the Territory for Commercialization outside the
Territory.

 

(b)           Palatin
shall not, and shall use reasonable efforts to not permit its
Affiliates and its licensees to, export Compounds, Products,
Pharmaceutical Products or Product Delivery Devices from outside
the Territory for Commercialization in the Territory, and shall
promptly inform Fosun of any such exports of Compounds, Products,
Pharmaceutical Products or Product Delivery Devices and the actions
taken to prevent such exports. Palatin will take all reasonable
actions requested in writing by Fosun that are consistent with
applicable Law to prevent Third Party exports of Compounds,
Products, Pharmaceutical Products or Product Delivery Devices from
outside the Territory for Commercialization in the
Territory.

 

4.6.           Manufacturing.

 

4.6.1.       
Clinical Trial Materials.
Palatin will supply to Fosun up to [...***...] following
the scheduled manufacture of the same, for Development of the
Product by Fosun in the Territory. The units of bremelanotide will
be provided as part of a scheduled production run, which run is
currently planned for [...***...]. Fosun shall pay the
[...***...].

 

4.6.2.      
Manufacturing Technology
Transfer. Without limiting Palatin’s obligations under
Section 2.5, within [...***...] following the Initial
Payment Date, Palatin shall disclose to Fosun all Know-How and
physical embodiments thereof then Controlled by Palatin or its
Affiliates that are necessary or useful to enable Fosun to
Manufacture Compounds, Products, Pharmaceutical Products and
Product Delivery Devices for clinical or commercial use in
accordance with all applicable product specifications, requirement
of applicable regulatory filings, and current Good Manufacturing
Practices and equivalent Laws outside the United States
(“cGMP”) (such Know-How collectively referred to herein
as “Manufacturing Know-How”). For the avoidance of
doubt, and without limitation, Manufacturing Know-How shall include
copies or samples, as applicable, of all relevant documentation,
regulatory filings, specifications, processes, materials and other
embodiments of such Know-How, all to the extent that such
documentation and materials are within the Control of Palatin.
Thereafter, throughout the Term and at Fosun’s request,
Palatin will make available to Fosun Palatin’s qualified
technical personnel to assist Fosun in understanding and applying
the Manufacturing Know-How to enable Fosun to Manufacture
Compounds, Products, Pharmaceutical Products and Product Delivery
Devices for clinical or commercial use (including qualification of
facilities used to Manufacture Compounds, Products, Pharmaceutical
Products or Product Delivery Devices).

 

 

12

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

4.6.3.      
General. Fosun shall have
the non-exclusive right in the Territory, and the non-exclusive
right outside the Territory (subject to the limitations in Section
2.1), to Manufacture Compounds, Products, Pharmaceutical Products
and Product Delivery Devices itself or through one or more
Affiliates or Third Parties selected by Fosun in its sole
discretion solely for use in the Territory. Fosun shall not use for
any Clinical Trial or Commercialize any Compounds, Products,
Pharmaceutical Products and Product Delivery Devices until and
unless (a) [...***...], and (b)(i) [...***...]
and (ii) [...***...]. Palatin shall have the right to
[...***...] However, in the event that [...***...],
Palatin shall not [...***...]. No inspection or
authorization by Palatin pursuant to this Section 4.6.3 shall
relieve Fosun of its obligations under this Agreement, including,
without limitation, Fosun’s indemnification obligations
pursuant to Section 9.2.

 

4.6.4.       
Supply to Fosun. Upon the
request of Fosun, [...***...] will negotiate in good faith
the terms of a supply agreement, pursuant to which
[...***...]. Fosun will pay costs and expenses incurred by
[...***...] relating to packaging, shipping costs or fees,
customs or duty expenses and any taxes, including excise and value
added taxes. For the avoidance of doubt, in the event that any
costs and expenses are already included in [...***...], any
such costs and expenses shall not be separately payable by Fosun
pursuant to the preceding sentence. The Parties recognize that
there is [...***...].

 

4.6.5.       
Second Source Supply
[...***...]. Upon Palatin’s request and following the
transfer of Manufacturing Know-How, the Parties will
[...***...]. [...***...] is conditioned upon
negotiation of terms and conditions that are mutually acceptable to
[...***...].

 

5. 

INTELLECTUAL
PROPERTY.

 

5.1.           Ownership
of Intellectual Property.

 

5.1.1.      
Ownership of Inventions.
Subject to the grant of licenses to Fosun under Section 2 and the
Parties’ other rights and obligations under this Agreement,
each Party shall own all rights, title and interests in and to: (a)
any and all Know-How, Compounds and Products (i) owned by such
Party prior to the Effective Date or (ii) made solely by or on
behalf of such Party or its Representatives in connection with
their activities under this Agreement and (b) any and all Patent
Rights claiming any such Know-How, Compounds or Products described
in clause (a) of this Section 5.1.1. Jointly made inventions, with
inventorship determined in accordance with United States or Chinese
patent laws, shall be jointly owned.

 

 

13

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

5.1.2.     
Improvements in Know-How, Compounds
and Products After Effective Date. Any improvements made by
Palatin in Know-How, Compounds and Products made after the
Effective Date by a Party shall be and hereby is subject to the
licenses granted to Fosun pursuant to Sections 2.1 and 2.2, without
any additional consideration, for the term of this Agreement, with
the right to grant sublicenses, directly or indirectly. Any
improvements made by Fosun in Know-How, Compounds and Products made
after the Effective Date shall be solely owned by
Fosun.

 

5.2.           Patent
Rights.

 

5.2.1.     
Filing, Prosecution and Maintenance
of Palatin Patent Rights. Palatin shall be responsible, at
its sole cost and expense, for preparing, filing, prosecuting and
maintaining (including conducting any interferences,
re-examinations, reissues and oppositions) the Palatin Patent
Rights in the Territory, by itself or with Third Parties. Palatin
shall consult and reasonably cooperate with Fosun with respect to
the preparation, filing, prosecution and maintenance of the Palatin
Patent Rights, including: (i) allowing Fosun a reasonable
opportunity and reasonable time to review and comment regarding
relevant communications to Palatin and drafts of any responses or
other proposed filings by Palatin before any applicable filings are
submitted to any relevant patent office or Governmental Authority
and (ii) considering in good faith any reasonable comments offered
by Fosun with respect to any final filings submitted by Palatin to
any relevant patent office or Governmental Authority. If Palatin
elects not to file a patent application for an invention or
application included in the Palatin Patent Rights in a given
Jurisdiction in the Territory or elects to cease the prosecution or
maintenance of any Palatin Patent Right in a given Jurisdiction in
the Territory, then Palatin shall provide Fosun with written notice
promptly, but not less than [...***...] before any action
is required or any Palatin Patent Rights becomes patentable in the
Territory, upon the decision to not file or continue the
prosecution of such patent application or maintenance of such
patent. In such event, Fosun shall have the right, but not the
obligation, to file the patent application or continue prosecution
or maintenance of any such Palatin Patent Right in such
Jurisdiction and at Palatin’s expense. Fosun shall not, and
shall not permit any of its Affiliates or sublicensees to, take any
action with respect to the filing, prosecution, maintenance or
enforcement of any Palatin Patent Right in the Territory that may
reasonably be expected to adversely impact the rights of Palatin or
its other licensees. Without limiting the foregoing, Fosun shall
consult and reasonably cooperate with Palatin and, at
Palatin’s request, Palatin’s other licensees
(including, without limitation, AMAG) with respect to the
preparation, filing, prosecution and maintenance of the Palatin
Patent Rights in the Territory, including: (A) allowing Palatin and
such licensees a reasonable opportunity and reasonable time to
review and comment regarding relevant communications to Fosun and
drafts of any responses or other proposed filings by Fosun before
any applicable filings are submitted to any relevant patent office
or Governmental Authority and (B) considering in good faith
any reasonable comments offered by Palatin and such licensees with
respect to any final filings submitted by Fosun to any relevant
patent office or Governmental Authority.

 

 

14

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

5.2.2.      
Filing, Prosecution and Maintenance
of Fosun Patent Rights. Fosun shall have the sole right, but
no obligation, to file, prosecute and maintain the Patent Rights
that it owns or to which it otherwise has Control of prosecution
rights, including the Fosun Patent Rights, in its sole
discretion.

 

5.2.3.      
Filing, Prosecution and Maintenance
of Joint Patent Rights. In the event that any joint
invention is made and it is determined by the Parties to file,
prosecute and maintain a patent application on such Patent Rights,
the Parties shall meet and determine responsibility for such
filing, prosecution and maintenance, provided that Palatin shall be
responsible for any such filing, prosecution and maintenance
outside of the Territory, and Fosun may, in its discretion, elect
to be responsible for any such filing, prosecution and maintenance
within the Territory.

 

5.2.4.        Enforcement
and Defense of Patent Rights.

 

(a)           Enforcement
of Palatin Patent Rights. Each Party will promptly notify
the other in the event of any actual, potential or suspected
infringement of a patent under the Palatin Patent Rights in the
Territory. As between Fosun and Palatin, Palatin shall have the
first right, except as otherwise provided in this Section 5.2.4,
but not the obligation, to institute litigation or take other steps to remedy
infringement in
connection therewith, and any such litigation or steps [...***...].
Palatin shall not, without the prior written consent of Fosun,
enter into any compromise or settlement relating to such litigation
that (i) admits the invalidity or unenforceability of any Palatin
Patent Right in the Territory or (ii) requires Fosun or Palatin to
abandon or relinquish any Palatin Patent Right in the Territory. If
Palatin fails to institute such litigation or otherwise take steps
to remedy the actual, potential or suspected infringement of a
Palatin Patent Right in the Territory within [...***...] of
its receipt of notice thereof, then Fosun shall have the right, but
not the obligation, upon [...***...] prior notice to
Palatin, at [...***...]
expense, to institute any such litigation, however
[...***...]. Fosun will have the right to consult with
Palatin about such litigation and to participate in and be
represented by independent counsel in such litigation at Fosun's
own expense. Except in the case of a breach of a term of this
Agreement, neither Party shall incur any liability to the other
Party as a consequent of any litigation initiated or pursued
pursuant to this Section 5.2.4(a) or any unfavorable decision
resulting therefrom, including any decision holding any Palatin
Patent Right.

 

(b)           Enforcement
of Fosun Patent Rights. Fosun shall have the sole right, but
no obligation, to take action to obtain a discontinuance of
infringement or bring suit against a Third Party infringing or
challenging the validity or enforceability of any Fosun Patent
Right.

 

 

15

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

(c)           Enforcement
of Palatin Patent Rights Outside the Territory. Palatin
shall have the sole right, but no obligation, to take action to
obtain a discontinuance of infringement or bring suit against a
Third Party infringing or challenging the validity or
enforceability of any Palatin Patent Right outside the
Territory.

 

5.2.5.       
Allegations of Infringement and
Right to Seek Third Party Licenses.

 

(a)           Notice.
If the Development, Manufacture, Commercialization or use of any
Compound, Product, Pharmaceutical Product or Product Delivery
Device, the practice of any Palatin Technology, or the exercise of
any other right granted by Palatin to Fosun hereunder
(collectively, the “Licensed Activities”) by Fosun or
any of its Affiliates or Sublicensees is alleged by a Third Party
to infringe, misappropriate or otherwise violate such Third
Party’s Patent Rights or other intellectual property rights,
then the Party discovering the same shall, promptly upon becoming
aware of such allegation, notify the other Party in writing.
Additionally, if either Party determines that, based upon the
review of any Third Party Patent Right or other Third Party
intellectual property rights, it may be desirable to obtain a
license from such Third Party with respect thereto so as to avoid
any potential claim of infringement by such Third Party against
either Party or their respective Affiliates or Sublicensees, then
such Party shall promptly notify the other Party of such
determination.

 

(b)           Fosun
Option to Negotiate. If Fosun determines, in its sole
discretion, that, in order for Fosun, its Affiliates or
Sublicensees to engage in the Licensed Activities, it is necessary
or desirable to obtain a license under one or more Patent Rights or
other intellectual property rights Controlled by a Third Party,
then Fosun shall have the sole right, but not the obligation, to
negotiate and enter into a license or other agreement with such
Third Party. All amounts payable under any such license or
agreement with a Third Party shall reduce Fosun’s royalty
obligations under this Agreement as and to the extent provided in
Section 3.4.3(a).

 

 

 

16

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

5.2.6.      
Third Party Infringement
Suits. Each of the Parties shall promptly notify the other
in the event that any Third Party files any suit or brings any
other action alleging patent infringement by Fosun or Palatin or
any of their respective Affiliates or Sublicensees with respect to
the Development,
Manufacture, Commercialization or use of any Compound, Product,
Pharmaceutical Product or Product Delivery Device or the practice
of any Palatin Technology in the Territory (any such suit or other
action referred to herein as an “Infringement Claim”)
or outside the Territory. In the case of any Infringement Claim
against Fosun (including its Affiliates or Sublicensees) alone or
against both Fosun and Palatin (including its Affiliates), Fosun
shall have the right, but not the obligation, at Fosun’s sole
cost and expense subject to the provisions of this Section 5.2.6,
to control the defense of such Infringement Claim, including
control over any related litigation, settlement, appeal or other
disposition arising in connection therewith. Palatin, upon request
of Fosun, agrees to join in any litigation associated with any
Infringement Claim at Palatin’s expense and in any event to
reasonably cooperate with Fosun at Palatin’s expense (in all
cases subject to Palatin’s indemnification obligations under
Section 9.3). Palatin will have the right to consult with Fosun
concerning any Infringement Claim and to participate in and be
represented by independent counsel in any associated litigation in
which Palatin is a party at Palatin’s own expense. Fosun
shall not, without the prior written consent of Palatin, enter into
any compromise or settlement relating to such litigation that (i)
admits the invalidity or unenforceability of any Palatin Patent
Right in the Territory or (ii) requires Fosun or Palatin to abandon
or relinquish any Palatin Patent Right in the Territory. If Fosun
elects to control the defense of any Infringement Claim and Palatin
is obligated under Section 9.3 to indemnify Fosun (including any
Fosun Indemnified Party) with respect to such Infringement Claim,
then (a) [...***...] and (b) Palatin will otherwise
indemnify Fosun and any applicable Fosun Indemnified Parties to the
full extent provided for under Section 9.3. In the case of any
Infringement Claim against Palatin (including Palatin’s
Affiliates) alone, Palatin shall have the right, but not the
obligation, at Palatin’s sole cost and expense, to control
the defense of such Infringement Claim, including control over any
related litigation, settlement, appeal or other disposition arising
in connection therewith; provided that Palatin shall not,
without the prior written consent of Fosun, enter into any
compromise or settlement relating to such litigation that (i)
admits the invalidity or unenforceability of any Palatin Patent
Right in the Territory or (ii) requires Fosun or Palatin to abandon
or relinquish any Palatin Patent Right in the Territory. Fosun
shall have the right to consult with Palatin concerning such
Infringement Claim and Fosun, upon request of Palatin, will
reasonably cooperate with Palatin at Palatin’s expense (but
Fosun shall have no obligation to join any Infringement Claim or
associated litigation).

 

5.2.7.     
Other Actions by Third
Parties. Each Party shall promptly notify the other Party in
the event of any legal or administrative action by any Third Party
involving any Palatin Patent Right in the Territory of which it
becomes aware, including any nullity, revocation, interference,
reexamination or compulsory license proceeding. Fosun shall have
the first right, but no obligation, to defend against any such
action involving any Palatin Patent Right in the Territory, in its
own name (to the extent permitted by applicable Law), and any such
defense shall be at Fosun’s reasonable expense, subject to
Palatin’s indemnification obligations under Section 9.
Palatin, upon Fosun’s request, agrees to join in any such
action at Fosun’s expense and in any event to cooperate with
Fosun at Fosun’s expense. If Fosun fails to defend against
any such action involving a Palatin Patent Right, then Palatin
shall have the right to defend such action, in its own name, and
any such defense shall be at Palatin’s expense. In such
event, Fosun, upon Palatin’s request, shall reasonably
cooperate with Palatin in any such action at Palatin’s
expense.

 

5.2.8.      
Orange Book Information.
Fosun shall have the sole right, but not the obligation, to submit
to all applicable Governmental Authorities patent information
pertaining to each Product pursuant to any statutory or regulatory
requirement similar to 21 U.S.C. § 355(b)(1)(G) in any
Jurisdiction or regulatory jurisdiction in the
Territory.

 

 

17

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

5.2.9.     
Paragraph IV Type Notices.
Notwithstanding any provision of this Agreement to the contrary,
each Party shall immediately (but in no event later than two (2)
Business Days following receipt or discovery, whichever occurs
first) give written notice to the other of any certification of
which it becomes aware filed pursuant to any statutory or
regulatory requirement in any Jurisdiction in the Territory similar
to 21 U.S.C. § 355(b)(2)(A)(iv) or §
355(j)(2)(A)(vii)(IV) (or any amendment or successor statute
thereto) claiming that any Palatin Patent Right in the Territory
covering any Compound, Product or Pharmaceutical Product is invalid
or that infringement will not arise from the Development,
Manufacture, use or Commercialization of such Compound, Product or
Pharmaceutical Product by a Third Party. Upon the giving or receipt
of such notice, Fosun shall have the sole right, but not the
obligation, to bring an infringement action against such Third
Party at Fosun’s sole cost and expense. If necessary in order
to establish standing in connection with any action brought by
Fosun under this Section 5.2.9, Palatin, upon Fosun’s
request, shall reasonably cooperate with Fosun in any such action
at Fosun’s expense and shall timely commence or join in any
such action at Fosun’s request and expense. In the event of
any conflict between the terms of this Section 5.2.9 and the terms
of Section 5.2.4(a), the terms of this Section 5.2.9 shall control
and govern.

 

5.2.10.    Patent Term Restoration and Extension.
Fosun shall have the exclusive right, but not the obligation, to
seek, in Palatin’s name if so required, patent term
extensions, and supplemental protection certificates and the like
available under Law, in any Jurisdiction in the Territory in
relation to the Palatin Patent Rights. Any costs or expenses
associated with the above shall be shared by Fosun and Palatin
equally. Palatin and Fosun shall cooperate in connection with all
such activities. Fosun, its agents and attorneys will give due
consideration to all suggestions and comments of Palatin regarding
any such activities, but in the event of a disagreement between the
Parties, Fosun will have the final decision-making authority;
provided, however, that Fosun shall seek (or allow Palatin to seek)
to extend any Palatin Patent Right at Palatin’s request,
including through the use of supplemental protection certificates
and the like, unless in Fosun’s reasonable legal
determination such Palatin Patent Right may not be extended under
Law without limiting Fosun’s right to extend any other Patent
Right.

 

 

18

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

5.3.           Enforcement
and Defense of Know-How.

 

5.3.1.     
Misappropriation Actions Relating
to Palatin Know-How. Each Party will promptly notify the
other in the event of any actual, potential or suspected
misappropriation of any Palatin Know-How by any Third Party. As
between Fosun and Palatin, Fosun shall have the first right, except
as otherwise provided in this Section 5.3.1, but not the
obligation, to institute litigation or take other steps to remedy
misappropriation of the Palatin Know-How in the Territory in
connection therewith. If [...***...]. If
[...***...]. If [...***...]. Fosun shall not,
without the prior written consent of Palatin, enter into any
compromise or settlement relating to such litigation that (a)
admits that all or any portion of the Palatin Know-How is not
protectable under relevant trade secret Laws or (b) requires Fosun
or Palatin to abandon or relinquish trade secret protection for any
Palatin Know-How. If necessary in order to establish standing for
Fosun, Palatin, upon request of Fosun, agrees to timely commence or
to join in any such litigation, provided that any costs or expenses
associated with the above shall be shared by Fosun and Palatin
equally. Palatin will have the right to consult with Fosun about
such litigation and to participate in and be represented by
independent counsel in such litigation at Palatin’s own
expense. If Fosun fails to institute such litigation or otherwise
take steps to remedy the actual, potential or suspected
misappropriation of any Palatin Know-How in the Territory
[...***...] of its receipt of notice thereof, then Palatin
shall have the right, but not the obligation, upon
[...***...] to Fosun, at Palatin’s expense, to
institute any such litigation. If necessary in order to establish
standing for Palatin, Fosun, upon request of Palatin, agrees to
timely commence or to join in any such litigation, and in any event
to cooperate with Palatin in such litigation or steps at
Palatin’s expense. Fosun will have the right to consult with
Palatin about such litigation and to participate in and be
represented by independent counsel in such litigation at Fosun's
own expense. Palatin shall not, without the prior written consent
of Fosun, enter into any compromise or settlement relating to such
litigation that (a) admits that all or any portion of the Palatin
Know-How is not protectable under relevant trade secret Laws or (b)
requires Fosun or Palatin to abandon or relinquish trade secret
protection for any Palatin Know-How. Palatin shall have the sole
right, but not the obligation, to institute litigation or take
other steps to remedy misappropriation of the Palatin Know-How
outside the Territory.

 

5.3.2.    
Misappropriation Actions Relating
to Fosun Know-How. Fosun shall have the sole right, but no
obligation, to take action to obtain a discontinuance of
misappropriation or bring suit against a Third Party that is
misappropriating, or that is suspected of misappropriating, any
Fosun Know-How.

 

5.4.     
Recording. If registration
or recordation is required by applicable Law, of if Fosun otherwise
deems it necessary or desirable to register or record this
Agreement or evidence of this Agreement with any patent office or
other appropriate Governmental Authority(ies) in one or more
jurisdictions in the Territory, Palatin shall reasonably cooperate
to provide assistance, execute and deliver to Fosun any documents
accurately reflecting or evidencing this Agreement that are
necessary or desirable, in Fosun’s reasonable judgment, to
complete such registration or recordation. Upon successful
registration of this Agreement with each applicable Governmental
Authority in the Territory, Fosun shall promptly forward to Palatin
copies of any registration certificates as well as any other
documentation received by Fosun in connection therewith. Fosun
shall reimburse Palatin for all reasonable out-of-pocket expenses,
including attorneys’ fees, incurred by Palatin in complying
with the provisions of this Section 5.4.

 

6. 

CONFIDENTIALITY.

 

6.1.    Confidentiality. Except to the extent
expressly authorized by this Agreement, the Parties agree that,
during the Term and for [...***...], each Party (the
“Receiving Party”) receiving any Confidential
Information of the other Party (the “Disclosing Party”)
hereunder shall: (a) keep the Disclosing Party’s Confidential
Information confidential; (b) not disclose, or permit the
disclosure of, the Disclosing Party’s Confidential
Information; and (c) not use, or permit to be used, the Disclosing
Party’s Confidential Information for any purpose other than
as expressly permitted under the terms of this Agreement. For the
avoidance of doubt, the Confidential Information Disclosure
Agreement dated [...***...] between Palatin and Fosun shall
be terminated as of the Effective Date of this
Agreement.

 

 

19

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

6.2.    
Authorized
Disclosure.

 

6.2.1.   Disclosure to Party Representatives.
Notwithstanding the foregoing provisions of Section 6.1, the
Receiving Party may disclose Confidential Information belonging to
the Disclosing Party to the Receiving Party’s Representatives
who (a) have a need to know such Confidential Information in
connection with the performance of the Receiving Party’s
obligations or the exercise of the Receiving Party’s rights
under this Agreement and (b) have agreed in writing to
non-disclosure and non-use provisions with respect to such
Confidential Information that are at least as restrictive as those
set forth in this Section 6.

 

6.2.2.  Disclosure to Third Parties.
Notwithstanding the foregoing provisions of Section 6.1, each
Party may disclose Confidential Information belonging to the other
Party to the extent such disclosure is reasonably
necessary:

 

(a)           to
Governmental Authorities (i) to the extent desirable to obtain or
maintain INDs or Regulatory Approvals for any Compound, Product,
Pharmaceutical Product or Product Delivery Device within the
Territory, and (ii) in order to respond to inquiries, requests or
investigations relating to Compounds or Products in the Territory
or this Agreement;

 

(b)           in
connection with filing or prosecuting Palatin Patent Rights as
permitted by this Agreement;

 

(c)           in
connection with prosecuting or defending litigation as permitted by
this Agreement;

 

(d)           to
the extent necessary or desirable in order to enforce its rights
under this Agreement; or

 

(e)           to
the extent required by relevant laws, regulations, or stock
exchanges rules.

 

If the
Receiving Party deems it reasonably necessary to disclose
Confidential Information belonging to the Disclosing Party pursuant
to this Section 6.2.2, then the Receiving Party shall to the extent
possible give reasonable advance written notice of such disclosure
to the Disclosing Party and take such measures to ensure
confidential treatment of such information as is reasonably
requested by the Disclosing Party, at the Disclosing Party’s
expense.

 

 

 

20

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

6.3.    
SEC Filings and Other
Disclosures. Either Party may disclose Confidential
Information, or the terms of this Agreement, to the extent
required, in the reasonable opinion of such Party’s legal
counsel, to comply with applicable Law, including the rules and
regulations promulgated by the United States Securities and
Exchange Commission (“SEC”), stock exchanges, or any
equivalent governmental agency in any Jurisdiction in the
Territory. Before disclosing this Agreement or any of the terms
hereof pursuant to this Section 6.3, the Parties will consult with
one another on the terms of this Agreement to be redacted in making
any such disclosure (which, at a minimum, shall include redaction
of all financial terms), with the disclosing Party providing as
much advanced notice as is feasible under the circumstances, and
giving consideration to the comments of the other Party. Further,
if a Party discloses this Agreement or any of the terms hereof in
accordance with this Section 6.3, the other Party may, at its own
expense, seek such confidential treatment of confidential portions
of this Agreement and such other terms.

 

6.4.      
Public Announcements. Except
as may be expressly permitted under Section 6.2, neither Party
will make any public announcement regarding this Agreement without
the prior written approval of the other Party. For the sake of
clarity, nothing in this Agreement shall prevent Fosun from making
any scientific publication or public announcement with respect to
any product under this Agreement; provided, however, that, except as
permitted under Section 6.2, Fosun shall not disclose any of
Palatin’s Confidential Information in any such publication or
announcement without obtaining Palatin’s prior written
consent to do so. Notwithstanding the foregoing, without prior
consent of the other Party, each Party may disseminate material
substantially similar to material included in a press release or
other document previously approved for external distribution by the
other Party. The Parties agree to coordinate timing of any public
announcement regarding this Agreement, and to exchange proposed
public announcements prior to making such
announcements.

 

7. 

REPRESENTATIONS AND WARRANTIES; COVENANTS;
SECURITY INTEREST.

 

7.1.           Mutual
Representations and Warranties. Each of Palatin and Fosun
hereby represents and warrants to the other Party
that:

 

7.1.1.      
it is duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization;

 

7.1.2.      
the execution, delivery and performance of this Agreement by such
Party has been duly authorized by all requisite action under the
provisions of its charter, bylaws and other organizational
documents, and does not require any action or approval by any of
its shareholders or other holders of its voting securities or
voting interests;

 

7.1.3.      
it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder;

 

 

21

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

7.1.4.     
this Agreement has been duly executed and is a legal, valid and
binding obligation on each Party, enforceable against such Party in
accordance with its terms; and

 

7.1.5.      the
execution, delivery and performance by such Party of this Agreement
and its compliance with the terms and provisions hereof does not
and will not conflict with or result in a breach of or default
under any Binding Obligation existing as of the Effective
Date.

 

7.2.           Mutual
Covenants. Each of Palatin and Fosun hereby covenants to the
other Party that, from the Effective Date until expiration or
termination of this Agreement, it will:

 

7.2.1.      
perform its obligations under this Agreement in compliance with
applicable Laws;

 

7.2.2.       
comply with all applicable laws, including any U.S. laws and
regulations including, but without limitation, U.S. export
controls, U.S. economic sanctions, and anti-bribery laws (e.g., the
U.S. Foreign Corrupt Practices Act, the UK Bribery
Act);

 

7.2.3.        
not take any actions that would cause the other Party to be in
violation of any of any applicable laws, including, but without
limitation, U.S. export controls, U.S. economic sanctions, and
anti-bribery laws;

 

7.2.4.        
not, directly or indirectly, offer, pay, give, promise to pay or
give, or authorize the payment or giving of, money, benefit or
anything else of value to any foreign official or private
individual, while knowing or having reason to know that all or a
portion of such money, benefit or thing of value will be
used:

 

(a)           to
seek, obtain, or retain business for the a Party, or

 

(b)           to
induce or seek to induce consideration or action by any individual,
or any employee or officer of a customer or prospective customer,
public or private, on any basis other than the merits of Products
or other Palatin Technology.

 

As used
in Section 7.2.4, the term “foreign official” means:
(i) any officer or employee of any government or any department,
agency, or instrumentality of a government, including entities
owned or controlled by a government; (ii) any person acting in an
official capacity for or on behalf of such government or
department, agency or instrumentality; (iii) any member of a
foreign political party or international organization; or (iv) any
person related to or affiliated with the above.

 

 

 

22

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

7.3.           Representations
and Warranties of Palatin. Palatin hereby represents and
warrants to Fosun that:

 

7.3.1.      
Palatin is the sole and exclusive owner of the Palatin Technology,
all of which is free and clear of any claims, liens, charges or
encumbrances other than the North American license agreement with
AMAG and agreements incidental thereto, including without
limitation any agreement relating to a global safety database for
Products;

 

7.3.2.       
Palatin has and will have the full right, power and authority to
grant all of the rights, title and interests in and to the licenses
and other rights granted or to be granted to Fosun, Fosun’s
Affiliates or Fosun’s Sublicensees under this
Agreement;

 

7.3.3.     
  Exhibit C sets forth a true and complete list of all
Compounds discovered or developed by Palatin or its Affiliates on
or prior to the Effective Date;

 

7.3.4.      
as of the Effective Date (a) Exhibit B sets forth a true and
complete list of all Patent Rights owned or otherwise Controlled by
Palatin or its Affiliates that relate to the Compounds or Products,
(b) each such Patent Right remains in full force and effect and (c)
Palatin or its Affiliates have timely paid all filing and renewal
fees payable with respect to such Patent Rights;

 

7.3.5.     
Except as disclosed in Exhibit D, there are no settled, unsettled,
pending or threatened claims or lawsuits or legal proceedings by a
third party against Palatin alleging that Palatin Technology
infringes, uses without authorization, misappropriates or otherwise
violates in part or in whole the intellectual property or
intellectual property rights of such third party;

 

7.3.6.      
Palatin has no knowledge that any claims of any Palatin Technology
or any claims directed to any Compound, Product, Pharmaceutical
Product or Product Delivery Device covered in such patents are
unpatentable, invalid or unenforceable;

 

7.3.7.      
the Products supplied by Palatin or AMAG under this Agreement
and/or the supply agreement as provided in section 4.6.4 will be in
full compliance with applicable Laws; and

 

7.3.8.     
Palatin has not granted any exclusive or non-exclusive license in
the Territory under the Palatin Technology, to Commercialize and
have Commercialized (but not to use, have used, Develop, have
Developed, Manufacture and have Manufactured) Compounds, Products,
Pharmaceutical Products and Product Delivery Devices, and otherwise
practice and exploit the Palatin Technology.

 

7.4.      
Disclaimer. THE FOREGOING
REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ALL
OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES
OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY
SPECIFICALLY EXCLUDED AND DISCLAIMED.

 

 

 

23

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

8. 

GOVERNMENT APPROVALS; REMEDY; TERM AND
TERMINATION.

 

8.1.     
Other Government Approvals.
Each of Palatin and Fosun shall cooperate with the other Party and
use Commercially Reasonable Efforts to make all registrations,
filings and applications, to give all notices and to obtain as soon
as practicable all governmental or other consents, transfers,
approvals, orders, qualifications authorizations, permits and
waivers, if any, and to do all other things necessary or desirable
for the consummation of the transactions as contemplated
hereby.

 

8.2.      
Term. The term of this
Agreement (the “Term”) will commence on the Effective
Date and extend on a Jurisdiction-by-Jurisdiction basis (in the
Territory), unless this Agreement is terminated earlier in
accordance with this Section 8, until the last to expire of any
Royalty Term for any Product in such Jurisdiction in the Territory;
provided, however, that the
Agreement shall be automatically extended for successive
[...***...] unless and until either Party gives at least
[...***...] prior written notice to terminate the
Agreement.

 

8.3.      
Termination by Palatin.
Palatin may terminate this Agreement for cause, at any time during
the Term, by giving written notice to Fosun in the event that Fosun
commits a material breach of its obligations under this Agreement
and such material breach remains uncured for [...***...],
measured from the date written notice of such material breach is
given to Fosun; provided,
however, that if any breach is not reasonably curable within
[...***...] and if Fosun is making a bona fide effort to
cure such breach, such termination shall be delayed for a time
period to be agreed by both Parties in order to permit Fosun a
reasonable period of time to cure such breach. If the alleged
material breach relates to non-payment of any amount due under this
Agreement, the cure period shall be tolled pending resolution of
any bona fide dispute between the Parties as to whether such
payment is due.

 

8.4.      
Termination by
Fosun.

 

8.4.1.    Termination for Convenience. Upon at
least [...***...] written notice to Palatin, Fosun may
terminate this Agreement on a Product-by-Product and
Jurisdiction-by-Jurisdiction basis, or in its entirety, without
cause, for any or no reason.

 

8.4.2.    Termination for Cause. Fosun may
terminate this Agreement for cause with respect to one or more
Products in one or more Jurisdictions in the Territory or may
terminate this Agreement in its entirety, at any time during the
Term, by giving written notice to Palatin in the event that Palatin
commits a material breach of its obligations under this Agreement
and such material breach remains uncured [...***...],
measured from the date written notice of such material breach is
given to Palatin; provided,
however, that if any breach is not reasonably curable within
[...***...] and if Palatin is making a bona fide effort to
cure such breach, such termination shall be delayed for a time
period to be agreed by both Parties in order to permit Palatin a
reasonable period of time to cure such breach.

 

 

24

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

8.5.     
Effects of
Termination.

 

8.5.1.   Effect of Termination.

 

(a)           Termination
for Cause by Palatin. In the event that Palatin terminates
this Agreement for cause pursuant to Section 8.3, the following
will apply (with respect to the terminated Jurisdictions in the
Territory, in the event of partial termination, and with respect to
the entire Territory, in the event of termination of the Agreement
in its entirety):

 

(i)           Except
as otherwise expressly provided herein, all rights and obligations
of each Party hereunder shall cease (including all rights and
licenses granted by either Party to the other Party hereunder) in
the relevant Jurisdiction or Territory, as applicable;

 

(ii)           To
the extent permitted by applicable law, Fosun will assign and
transfer to Palatin all Regulatory Approvals owned by Fosun or its
Affiliates with respect to all Continuation Products in the
relevant Jurisdiction (or the Territory in the event of termination
of this Agreement in its entirety);

 

(iii)           To
the extent permitted by applicable law, Fosun will assign all
applications and registrations for the Product Brands that are
Controlled by Fosun or its Affiliates in the relevant Jurisdiction
(or the Territory in the event of termination of this Agreement in
its entirety) to Palatin;

 

(iv)           Fosun
will transfer to Palatin all development data and regulatory
filings specifically relating to such Continuation Product in the
relevant Jurisdiction (or the Territory in the event of termination
of this Agreement in its entirety) and grant to Palatin rights of
reference with respect to such data and filings in each other
Jurisdiction in the Territory (if any); and

 

(v)           On
Palatin’s written notice to Fosun, which notice may only be
delivered within [...***...] following the effective date
of termination, the Parties will negotiate in good faith mutually
agreeable terms regarding (A) the grant by Fosun to Palatin of a
license under the Applicable Fosun Technology for Palatin to
continue to Develop, Commercialize and Manufacture any Product (in
the relevant Jurisdiction or Territory, as applicable) that is
under Development or Commercialization by Fosun under this
Agreement at the time of termination, in the form in which such
Product then exists (a “Continuation Product”), and (B)
the provision of transitional supplies of such Continuation Product
to Palatin. Neither Party will be obligated to enter into any
transaction described in this Section 8.5.1(a)(v), and neither
Party will have any liability to the other for failure to do
so.

 

 

25

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

(b)           Termination
for Convenience by Fosun. In the event that Fosun terminates
this Agreement without cause pursuant to Section 8.4.1, the
following will apply (with respect to the terminated Jurisdictions
in the Territory, in the event of partial termination, and with
respect to the entire Territory, in the event of termination of the
Agreement in its entirety):

 

(i)         Except
as otherwise expressly provided herein, all rights and obligations
of each Party hereunder shall cease (including all rights and
licenses granted by either Party to the other Party hereunder) in
the relevant Jurisdiction or Territory, as applicable;

 

(ii)         To
the extent permitted by applicable law, Fosun will assign and
transfer to Palatin all Regulatory Approvals owned by Fosun or its
Affiliates with respect to all Continuation Products in the
relevant Jurisdiction (or the Territory in the event of termination
of this Agreement in its entirety);

 

(iii)      
To the extent permitted by applicable law, Fosun will assign all
applications and registrations for the Product Brands that are
Controlled by Fosun or its Affiliates in the relevant Jurisdiction
(or the Territory in the event of termination of this Agreement in
its entirety) to Palatin; and

 

(iv)        
Fosun will grant to Palatin a royalty-free, non-exclusive license
under the Applicable Fosun Technology, with the right to
sublicense, to Develop, Commercialize, Manufacture and use the
Continuation Products (in the relevant Jurisdiction or Territory,
as applicable).

 

(c)           Termination
for Cause by Fosun; Alternative Remedy for
Breach.

 

(i)           Partial
Termination. In the event that Fosun terminates this
Agreement pursuant to Section 8.4.2 with respect to any Product in
any Jurisdiction in the Territory, except as otherwise expressly
provided herein, all rights and obligations of each Party hereunder
with respect to such Product in such Jurisdiction shall cease
(including all relevant rights and licenses granted by either Party
to the other Party hereunder);

 

(ii)       
Complete Termination. In
the event that Fosun terminates this Agreement in its entirety
pursuant to Section 8.4.2, except as otherwise expressly provided
herein, all rights and obligations of each Party hereunder shall
cease (including all rights and licenses granted by either Party to
the other Party hereunder); and

 

 

 

26

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

(iii)    
For a period of [...***...] after any such termination for
cause by Fosun, Palatin shall not grant development and
commercialization rights as to the Product in any Jurisdiction in
the Territory to any Third Party (including Palatin itself and its
affiliates) [...***...]. After this
[...***...].

 

8.5.2.      
Accrued Rights. Expiration
or termination of this Agreement for any reason shall be without
prejudice to any right which shall have accrued to the benefit of
either Party prior to such termination, including damages arising
from any breach under this Agreement and shall not preclude either
Party from pursuing any remedies it may have hereunder or at law or
in equity which accrued or are based upon any event occurring prior
to such termination or expiration. Expiration or termination of
this Agreement shall not relieve either Party from any obligation
which is expressly indicated to survive such expiration or
termination.

 

8.5.3.     
Survival Period. The
following sections, together with any sections that expressly
survive (including any perpetual licenses granted hereunder), shall
survive expiration or termination of this Agreement for any reason:
Sections 1.1 (together with Exhibit A); 1.2; 3.4.2 (with respect to
any licenses that accrue thereunder on or prior to the end of the
Term); 3.5.6 [...***...]; 3.5.7 [...***...]; 3.5.8
[...***...]; 3.5.10; 6 [...***...]; 8.5; 9.1; 9.2;
9.3; 9.4 and 10.

 

9. 

LIMITATION
ON LIABILITY, INDEMNIFICATION AND INSURANCE.

 

9.1.           No
Consequential Damages. [...***...], in
no event will either Party or its Representatives be liable under
this Agreement for any special, indirect, incidental, consequential
or punitive damages, whether in contract, warranty, tort,
negligence, strict liability or otherwise, including loss of
profits or revenue suffered by either Party or any of its
Representatives. Without limiting the generality of the foregoing,
“consequential damages” will be deemed to include, and
neither Party will be liable to the other Party or any of such
other Party’s Representatives or stockholders for any damages
based on or measured by loss of projected or speculative future
sales of the Products, any Development Milestone Payment due upon
any unachieved Development Event under Section 3.2, any Sales
Milestone Payment due upon any unachieved Total Annual Net Sales
level under Section 3.3, any unearned royalties under Section 3.4
or any other unearned, speculative or otherwise contingent payments
provided for in this Agreement.

 

9.2.           Indemnification
by Fosun. Fosun will indemnify, defend and hold harmless
Palatin, each of its Affiliates, and each of its and its
Affiliates’ employees, officers, directors and agents (each,
a “Palatin Indemnified Party”) from and against any and
all liability, loss, damage, expense (including reasonable
attorneys’ fees and expenses) and cost (collectively, a
“Liability”) that the Palatin Indemnified Party may be
required to pay to one or more Third Parties (other than
shareholders of Palatin or its Affiliates) resulting from or
arising out of:

 

 

 

27

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

(a)
Development, Manufacture, Commercialization or use of any Product
by, on behalf of, or under the authority of, Fosun (other than by
any Palatin Indemnified Party), other than (i) claims by Third
Parties relating to patent infringement arising out of the exercise
of rights under the Palatin Patent Rights, (ii) claims by Third
Parties relating misappropriation of trade secrets arising out of
the exercise of rights under the Palatin Know-How, or (iii) claims
for which Palatin is required to indemnify Fosun pursuant to
Section 9.3; or

 

(b) the
material breach by Fosun of any of its representations, warranties
or covenants set forth in Section 7.1;

 

except,
in each case, to the extent caused by the negligence, recklessness
or intentional acts of Palatin or any Palatin Indemnified
Party.

 

9.3.    Indemnification by Palatin. Palatin will
indemnify, defend and hold harmless Fosun, its Affiliates,
Sublicensees, contractors, distributors and each of its and
their respective employees, officers, directors and agents (each, a
“Fosun Indemnified Party”) from and against any and all
Liabilities that the Fosun Indemnified Party may be required to pay
to one or more Third Parties resulting from or arising out
of:

 

(a)
gross negligence in the manufacture and quality control of any
Product supplied by Palatin; or

 

(b) the
material breach by Palatin of any of its representations,
warranties or covenants, obligations and other provisions
hereof;

 

except,
in each case, to the extent caused by the negligence, recklessness
or intentional acts of Fosun or any Fosun Indemnified
Party.

 

9.4.    
Procedure.

 

9.4.1.  Notice. Each Party will notify the other
Party in writing in the event it becomes aware of a claim for which
indemnification may be sought hereunder. In the event that any
Third Party asserts a claim or other proceeding (including any
governmental investigation) with respect to any matter for which a
Party (the “Indemnified Party”) is entitled to
indemnification hereunder (a “Third Party Claim”), then
the Indemnified Party shall promptly notify the Party obligated to
indemnify the Indemnified Party (the “Indemnifying
Party”) thereof; provided,
however, that no delay on the part of the Indemnified Party
in notifying the Indemnifying Party shall relieve the Indemnifying
Party from any obligation hereunder unless (and then only to the
extent that) the Indemnifying Party is prejudiced
thereby.

 

 

28

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

9.4.2.   Control. Subject to Fosun’s right
to control any actions described in Sections 5.2.2, 5.2.6, 5.2.7,
5.2.9 or 5.3 (even where Palatin is the Indemnifying Party), the
Indemnifying Party shall have the right, exercisable by notice to
the Indemnified Party within [...***...] after receipt of
notice from the Indemnified Party of the commencement of or
assertion of any Third Party Claim, to assume direction and control
of the defense, litigation, settlement, appeal or other disposition
of the Third Party Claim (including the right to settle the claim
solely for monetary consideration) with counsel selected by the
Indemnifying Party and reasonably acceptable to the Indemnified
Party; provided that (a) the Indemnifying Party has sufficient
financial resources, in the reasonable judgment of the Indemnified
Party, to satisfy the amount of any adverse monetary judgment that
is sought, (b) the Third Party Claim seeks solely monetary damages
and (c) the Indemnifying Party expressly agrees in writing that as
between the Indemnifying Party and the Indemnified Party, the
Indemnifying Party shall be solely obligated to satisfy and
discharge the Third Party Claim in full (the conditions set forth
in clauses (a), (b) and (c) above are collectively referred to as
the “Litigation Conditions”). Within

[...***...] after the Indemnifying Party has given
notice to the Indemnified Party of its exercise of its right to
defend a Third Party Claim, the Indemnified Party shall give notice
to the Indemnifying Party of any objection thereto based upon the
Litigation Conditions. If the Indemnified Party reasonably so
objects, the Indemnified Party shall continue to defend the Third
Party Claim, at the expense of the Indemnifying Party, until such
time as such objection is withdrawn. If no such notice is given, or
if any such objection is withdrawn, the Indemnifying Party shall be
entitled, at its sole cost and expense, to assume direction and
control of such defense, with counsel selected by the Indemnifying
Party and reasonably acceptable to the Indemnified Party. During
such time as the Indemnifying Party is controlling the defense of
such Third Party Claim, the Indemnified Party shall cooperate, and
shall cause its Affiliates and agents to cooperate upon request of
the Indemnifying Party, in the defense or prosecution of the Third
Party Claim, including by furnishing such records, information and
testimony and attending such conferences, discovery proceedings,
hearings, trials or appeals as may reasonably be requested by the
Indemnifying Party. In the event that the Indemnifying Party does
not satisfy the Litigation Conditions or does not notify the
Indemnified Party of the Indemnifying Party’s intent to
defend any Third Party Claim within [...***...] after
notice thereof, the Indemnified Party may (without further notice
to the Indemnifying Party) undertake the defense thereof with
counsel of its choice and at the Indemnifying Party’s expense
(including reasonable, out-of-pocket attorneys’ fees and
costs and expenses of enforcement or defense). The Indemnifying
Party or the Indemnified Party, as the case may be, shall have the
right to join in (including the right to conduct discovery,
interview and examine witnesses and participate in all settlement
conferences), but not control, at its own expense, the defense of
any Third Party Claim that the other party is defending as provided
in this Agreement.

 

 

29

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

9.4.3.    Settlement. The Indemnifying Party shall
not, without the prior written consent of the Indemnified Party,
enter into any compromise or settlement that commits the
Indemnified Party to take, or to forbear to take, any action. The
Indemnified Party shall have the sole and exclusive right to settle
any Third Party Claim, on such terms and conditions as it deems
reasonably appropriate, to the extent such Third Party Claim
involves equitable or other non-monetary relief, but shall not have
the right to settle such Third Party Claim to the extent such Third
Party Claim involves monetary damages without the prior written
consent of the Indemnifying Party. Each of the Indemnifying Party
and the Indemnified Party shall not make any admission of liability
in respect of any Third Party Claim without the prior written
consent of the other party, and the Indemnified Party shall use
reasonable efforts to mitigate liabilities arising from such Third
Party Claim.

 

9.5.    
Insurance. Each Party shall
purchase insurance at its own expense with respect to its potential
liability under this Agreement. Such insurance shall be in
reasonable amounts to meet its indemnity obligations under this
Agreement and on reasonable terms in the circumstances in
accordance with common practice and applicable laws and regulations
regarding the development and sales of the Product.

 

10. 

MISCELLANEOUS.

 

10.1.    
Assignment. Neither this
Agreement nor any interest hereunder shall be assignable by a Party
without the prior written consent of the other Party, except as
follows: a Party may assign its rights and obligations under this
Agreement by way of sale of itself or the sale of the portion of
its business to which this Agreement relates, through merger, sale
of assets or sale of stock or ownership interest, provided that the assignee shall
expressly agree to be bound by such Party’s obligations under
this Agreement and that such sale is not primarily for the benefit
of its creditors, (b) such Party may assign its rights and
obligations under this Agreement to any of its Affiliates,
provided that the assignee
shall expressly agree to be bound by such Party’s obligations
under this Agreement and that such Party shall remain liable for
all of its rights and obligations under this Agreement. Each Party
shall promptly notify the other Party of any assignment or transfer
under the provisions of this Section 10.1. This Agreement shall be
binding upon the successors and permitted assigns of the Parties
and the name of a Party appearing herein shall be deemed to include
the names of such Party’s successors and permitted assigns to
the extent necessary to carry out the intent of this Agreement. Any
assignment not in accordance with this Section 10.1 shall be
void.

 

10.2.    Further Actions. Each Party agrees to
execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order
to carry out the purposes and intent of the Agreement.

 

10.3.    
Force Majeure. Each Party
shall be excused from the performance of its obligations under this
Agreement to the extent that such performance is prevented by force
majeure (defined below) and the nonperforming Party promptly
provides notice of the prevention to the other Party. Such excuse
shall be continued so long as the condition constituting force
majeure continues and the nonperforming Party takes Commercially
Reasonable Efforts to remove the condition. For purposes of this
Agreement, “force majeure” shall include conditions
beyond the control of the Parties, including an act of God,
voluntary or involuntary compliance with any regulation, Law or
order of any government, war, act of terror, civil commotion, labor
strike or lock-out, epidemic, failure or default of public
utilities or common carriers, destruction of production facilities
or materials by fire, earthquake, storm or like
catastrophe.

 

 

30

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

10.4.    Notices. Any notice or notification
required or permitted to be provided pursuant to the terms and
conditions of this Agreement (including any notice of force
majeure, breach, termination, change of address, etc.) shall be in
writing and shall be deemed given upon receipt if delivered
personally, on the next Business Day if sent by facsimile
transmission (receipt verified) or email, five(5) days after
deposited in the mail if mailed by registered or certified mail
(return receipt requested) postage prepaid, or on the next Business
Day if sent by overnight delivery using an internationally
recognized express courier service and specifying next Business Day
delivery (receipt verified), to the Parties at the following
addresses, email addresses or facsimile numbers (or at such other
address or facsimile number for a Party as shall be specified by
like notice, provided,
however, that notices of a change of address shall be
effective only upon receipt thereof):

 

All
correspondence to Fosun shall be addressed as follows:

 

Strategic Product
Development Center

Shanghai Fosun
Pharmaceutical Industrial Development Co., Ltd

Building A, 1289
Yishan Road

Minhang
District, Shanghai 200030

P.R.China

[...***...]

[...***...]

[...***...]

 

with a
copy to:

 

Legal
Department

Shanghai Fosun
Pharmaceutical (Group) Co., Ltd

Building A, 1289
Yishan Road

Minhang
District, Shanghai 200030

P.R.China

[...***...]

[...***...]

[...***...]

 

All
correspondence to Palatin shall be addressed as
follows:

 

Palatin
Technologies, Inc.

4-B
Cedar Brook Drive

Cranbury, NJ
08512

[...***...]

[...***...]

[...***...]

 

with a
copy to:

 

Thompson Hine
LLP

335
Madison Avenue, 12th Floor

New
York, NY 10017

[...***...]

[...***...]

[...***...]

 

 

31

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

10.5.               Amendment.
No amendment, modification or supplement of any provision of this
Agreement shall be valid or effective unless made in writing and
signed by a duly authorized officer of each Party.

 

10.6.               Waiver.
No provision of this Agreement shall be waived by any act, omission
or knowledge of a Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed
by a duly authorized officer of the waiving Party. The waiver by
either of the Parties of any breach of any provision hereof by the
other Party shall not be construed to be a waiver of any succeeding
breach of such provision or a waiver of the provision
itself.

 

10.7.               Severability.
If any clause or portion thereof in this Agreement is for any
reason held to be invalid, illegal or unenforceable, the same shall
not affect any other portion of this Agreement, as it is the intent
of the Parties that this Agreement shall be construed in such
fashion as to maintain its existence, validity and enforceability
to the greatest extent possible. In any such event, this Agreement
shall be construed as if such clause of portion thereof had never
been contained in this Agreement, and there shall be deemed
substituted therefor such provision as will most nearly carry out
the intent of the Parties as expressed in this Agreement to the
fullest extent permitted by applicable Law.

 

10.8.               Descriptive
Headings. The descriptive headings of this Agreement are for
convenience only and shall be of no force or effect in construing
or interpreting any of the provisions of this
Agreement.

 

10.9.               Dispute
Resolution. If any dispute or disagreement arises between
Fosun and Palatin in respect of this Agreement, they shall follow
the following procedures in an attempt to resolve the dispute or
disagreement:

 

10.9.1.          
The Party claiming that such a dispute exists shall give notice in
writing (“Notice of Dispute”) to the other Party of the
nature of the dispute.

 

10.9.2.        
  Within [...***...] of receipt of a Notice of
Dispute, the CEO (or his or her designee) of Fosun and the CEO (or
his or her designee) of Palatin shall meet at a mutually
agreed-upon time and location for the purpose of resolving such
dispute.

 

 

32

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

10.9.3.           
If, within a further period of [...***...], or if in any
event within [...***...] of initial receipt of the Notice
of Dispute, the dispute has not been resolved, or if, for any
reason, the meeting described in Section 10.9.2 has not been held
within [...***...] of initial receipt of the Notice of
Dispute, then the Parties agree that either Party may initiate
arbitration under the rules of Conciliation and Arbitration of the
International Chamber of Commerce to resolve the dispute. Such
Arbitration shall be held in the English language, and shall be
conducted in New York City if arbitration is demanded by Fosun and
in Hong Kong if arbitration is demanded by Palatin. The award
rendered by the arbitrator(s) shall be final and binding upon the
Parties hereto.

 

10.10.               Governing
Law. This Agreement, and all claims arising under or in
connection therewith, shall be governed by and interpreted in
accordance with the substantive laws of the State of New York,
U.S.A., without regard to conflict of law principles thereof and
without regard to the United Nations Convention on Contracts for
the International Sale of Goods.

 

10.11.               Entire
Agreement. This Agreement constitutes and contains the
complete, final and exclusive understanding and agreement of the
Parties and cancels and supersedes any and all prior negotiations,
correspondence, understandings and agreements, whether oral or
written, between the Parties respecting the subject matter hereof
and thereof.

 

10.12.             
Representation by Legal
Counsel. Each Party hereto represents that it has been
represented by legal counsel in connection with this Agreement and
acknowledges that it has participated in the drafting hereof. In
interpreting and applying the terms and provisions of this
Agreement, the Parties agree that no presumption shall exist or be
implied against the Party which drafted such terms and
provisions.

 

10.13.               Independent
Contractors. Both Parties are independent contractors under
this Agreement. Nothing herein contained shall be deemed to create
an employment, agency, joint venture or partnership relationship
between the Parties hereto or any of their agents or employees, or
any other legal arrangement that would impose liability upon one
Party for the act or failure to act of the other Party. Neither
Party shall have any express or implied power to enter into any
contracts or commitments or to incur any liabilities in the name
of, or on behalf of, the other Party, or to bind the other Party in
any respect whatsoever.

 

10.14.               Counterparts.
This Agreement may be executed in two counterparts, each of which
shall be an original and both of which shall constitute together
the same document. Counterparts may be signed and delivered by
facsimile or PDF file, each of which shall be binding when received
by the applicable Party.

 

10.15.               No
Third Party Rights or Obligations. No provision of this
Agreement shall be deemed or construed in any way to result in the
creation of any rights or obligation in any Person not a Party to
this Agreement. However, Fosun may decide, in its sole discretion,
to use one or more of its Affiliates to perform its obligations and
duties hereunder, provided
that Fosun shall remain liable hereunder for the performance
by any such Affiliates of any such obligations.

 

(Signature page follows.)

 

 

33

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

IN
WITNESS WHEREOF, authorized representatives of the Parties have
duly executed this Agreement as of the Effective Date to be
effective as of the Effective Date.

 

	

SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO.
LTD.

	
 

	

PALATIN TECHNOLOGIES, INC.

	

 

        

By
/s/ Yifang
Wu

	
 

	

 

         

By
/s/ Stephen T.
Wills

	

Name:  
Yifang Wu

Title:     
President

	
 

	

Name:   
Stephen T. Wills

Title:      
Chief Financial Officer, Chief Operating Officer and Executive Vice
President

Signature
Page to License Agreement

 

34

 

 CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

Exhibit A

 

Defined Terms

 

“Affiliate”
means, as of any point in time and for so long as such relationship
continues to exist with respect to any Person, any other Person
that controls, is controlled by or is under common control with
such Person. A Person shall be regarded as in control of another
Person if it (a) owns or controls at least fifty percent (50%) of
the equity securities of the subject Person entitled to vote in the
election of directors or (b) possesses, directly or indirectly, the
power to direct or cause the direction of the management or
policies of any such Person (whether through ownership of
securities or other ownership interests, by contract or
otherwise).

 

 “Applicable
Fosun Technology” means any (a) Know-How Controlled by Fosun
or its Affiliates that was invented, discovered or developed during
the Term and in connection with Fosun’s or its
Affiliates’ activities under the Agreement and (b) Patent
Right Controlled by Fosun or its Affiliates, to the extent that
such Patent Right claims any Know-How described in clause (a),
above.

 

“Bankruptcy
Code” means Section 101(35A) of Title 11 of the United
States Code, as amended.

 

“Binding
Obligation” means, with respect to a Party (a) any oral or
written agreement, arrangement or settlement that binds or affects
such Party’s operations or property, including any
assignment, license agreement, loan agreement, guaranty, or
financing agreement, (b) the provisions of such Party’s
charter, bylaws or other organizational documents or (c) any order,
writ, injunction, decree or judgment of any court or Governmental
Authority entered against such Party or by which any of such
Party’s operations or property are bound.

 

“Business
Day” means a day other than a Saturday, Sunday or bank or
other public national holiday in the United States and the
People’s Republic of China.

 

“Calendar
Quarter” means the respective periods of three consecutive
calendar months ending on March 31, June 30, September 30 and
December 31.

 

“Calendar
Year” means each successive period of twelve (12) months
commencing on January 1 and ending on December 31; provided that
the first Calendar Year of the Term shall begin on the Effective
Date and end on the first December 31 thereafter and the last
Calendar Year of the Term shall end on the last day of the
Term.

 

“CDE”
means the Chinese Center for Drug Evaluation.

 

“CFDA”
means the China Food and Drug Administration, or any successor
agency with a similar scope of responsibility regarding the
regulation of human pharmaceutical products in China.

 

Exhibits-1

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“China”
means the People’s Republic of China, for the purpose of this
Agreement excluding Taiwan, Hong Kong S.A.R. and Macau
S.A.R...

 

“Clinical
Trial” means a human clinical study conducted on sufficient
numbers of human subjects that is designed to (a) establish that a
pharmaceutical product is reasonably safe for continued testing,
(b) investigate the safety and efficacy of the pharmaceutical
product for its intended use, and to define warnings, precautions
and adverse reactions that may be associated with the
pharmaceutical product in the dosage range to be prescribed or (c)
support Regulatory Approval of such pharmaceutical product or label
expansion of such pharmaceutical product.

 

“Commercialize”
or “Commercializing” means to market, promote,
distribute, offer for sale, sell, have sold, import, have imported,
export, have exported or otherwise commercialize a compound or
product. When used as a noun, “Commercialization” means
any and all activities involved in Commercializing.

 

“Commercially
Reasonable Efforts” means, with respect to the efforts to be
expended by a Party with respect to any objective, those
reasonable, good faith efforts to accomplish such objective
[...***...]. With respect to any efforts relating to the
Development, Regulatory Approval or Commercialization of a
Compound, Product, Pharmaceutical Product or Product Delivery
Device by a Party, generally or with respect to any particular
Jurisdiction in the Territory, a Party will be deemed to have
exercised Commercially Reasonable Efforts [...***...] as
applicable (a) of similar modality Controlled by such Party, or (b)
(i) to which such Party has similar rights, (ii) which is of
similar market potential in such Jurisdiction, and (iii) which is
at a similar stage in its development or product life cycle, as the
Compound, Product, Pharmaceutical Product or Product Delivery
Device, in each case, taking into account all Relevant Factors in
effect at the time such efforts are to be expended. Further, to the
extent that the performance of a Party’s obligations
hereunder is adversely affected by the other Party’s failure
to perform its obligations hereunder, the impact of such
performance failure will be taken into account in determining
whether such Party has used its Commercially Reasonable Efforts to
perform any such affected obligations.

 

“Compound”
means bremelanotide, a generic name adopted and defined by the
United States Adopted Name (USAN) Council, including any and all
[...***...]. Those Compounds known to be existing as of the
Effective Date are listed in Exhibit C.

 

Exhibits-2

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“Confidential
Information” means, with
respect to each Party, all Know-How or other information, including
proprietary information and materials (whether or not patentable)
regarding or embodying such Party’s technology, products,
business information or objectives, that is communicated by or on
behalf of the Disclosing Party to the Receiving Party or its
permitted recipients, on or after the Effective Date, but only to
the extent that such Know-How or other information in written form
is marked or otherwise designated in writing as
“confidential” at the time of disclosure or within
[...***...] thereafter, and such Know-How or other
information disclosed orally or in non-tangible form is (a)
identified by the Disclosing Party as “confidential” at
the time of disclosure and (b) within [...***...]
thereafter, the Disclosing Party provides a written summary of such
Know-How or other information marked or otherwise designated in
writing as “confidential.” Confidential Information
does not include any Know-How or other information that (a) was
already known by the Receiving Party (other than under an
obligation of confidentiality to the Disclosing Party) at the time
of disclosure by or on behalf of the Disclosing Party, as evidenced
by written records in the possession of the Receiving Party, (b)
was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the Receiving Party,
(c) became generally available to the public or otherwise part of
the public domain after its disclosure to the Receiving Party,
other than through any act or omission of the Receiving Party in
breach of its obligations under this Agreement, (d) was disclosed
to the Receiving Party, other than under an obligation of
confidentiality, by a Third Party who had no obligation to the
Disclosing Party not to disclose such information to the Receiving
Party, as evidenced by written records in the possession of the
Receiving Party, or (e) was independently discovered or developed
by or on behalf of the Receiving Party without the use of any
Confidential Information belonging to the Disclosing Party, as
evidenced by written records in the possession of the Receiving
Party. The terms and conditions of this Agreement shall be
considered Confidential Information of both Parties.

 

“Control”
or “Controlled” means with respect to any intellectual
property right or material (including any Patent Right, Know-How or
other data, information or material), the ability (whether by sole,
joint or other ownership interest, license or otherwise, other than
pursuant to this Agreement) to, without violating the terms of any
agreement with a Third Party, grant a license or sublicense or
provide or provide access or other right in, to or under such
intellectual property right or material.

 

“Cover,”
“Covering” or “Covers” means, as to a
Product and Patent Rights, that, in the absence of a license
granted under, or ownership of, such Patent Rights, the
manufacture, use, offer for sale, sale or importation of such
Product would infringe such Patent Rights assuming the validity and
enforceability thereof.

 

“Data”
means any and all scientific, technical, test, marketing or sales
data pertaining to a Compound, Product, Pharmaceutical Product or
Product Delivery Device that is generated by or on behalf of Fosun
or its Affiliates or Sublicensees or by or on behalf of Palatin or
its Affiliates or sublicensees, including research data, clinical
pharmacology data, CMC data (including analytical and quality
control data and stability data), pre-clinical data, clinical data
or submissions made in association with any regulatory filings
(including any IND or NDA) with respect to any Compound, Product,
Pharmaceutical Product or Product Delivery Device.

 

“Derivatives”
means [...***...].

 

“Develop”
or “Developing” means to discover, research or
otherwise develop a process, compound or product, including
conducting non-clinical and clinical research and development
activities. When used as a noun, “Development” means
any and all activities involved in Developing.

 

“Development
Event” means each Development event listed in the table that
appears in Section 3.2.

 

“FD&C
Act” means the United States Federal Food, Drug, and Cosmetic
Act, as amended, and the rules and regulations promulgated
thereunder.

 

Exhibits-3

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“FDA”
means the United States Food and Drug Administration or any
successor agency thereto.

 

“Field”
means the treatment or prevention of human diseases. For clarity,
and without limiting the foregoing, Field includes female sexual
dysfunction and hypoactive sexual desire disorder in humans, and
any indication or use as monotherapy or in combination with other
marketed or to be marketed product.

 

“First
Commercial Sale” means, with respect to any Product and with
respect to any Jurisdiction of the Territory, the first sale of
such Product by Fosun or an Affiliate or Sublicensee of Fosun to a
Third Party in such Jurisdiction after such Product has been
granted Regulatory Approval by the appropriate Regulatory
Authority(ies) for such Jurisdiction.

 

“Fosun
Diligence Obligations” means Fosun’s Regulatory
Approval diligence obligations under Section 4.2.1 and
Fosun’s Commercialization diligence obligations under Section
4.2.2.

 

“Fosun
Know-How” means any Know-How that (a) is Controlled by Fosun
on the Effective Date or that comes into the Control of Fosun
during the Term (other than through the grant of a license by
Palatin) and (b) relates to the Development, Manufacture,
Commercialization or use of one or more Compounds or
Products.

 

“Fosun Patent
Right” means any Patent Right that (a) is Controlled by Fosun
on the Effective Date or that comes into the Control of Fosun
during the Term (other than through the grant of a license by
Palatin) and (b) claims any (a) Compound or Product (including the
composition of matter thereof), (b) method of making any Compound
or Product or (c) method of using any Compound or
Product.

 

“Fosun
Technology” means any and all Fosun Patent Rights and Fosun
Know-How.

 

“GAAP”
means United States generally accepted accounting principles,
consistently applied.

 

“Generic
Product” means any pharmaceutical product that (a) is sold by
a Third Party that is not an Affiliate or Sublicensee of Fosun
under a marketing authorization granted by a Regulatory Authority
to a Third Party, (b) contains the same Compound as a Product and
(c) for purposes of the United States, is approved in reliance on a
prior Regulatory Approval of a Product granted to Fosun or an Fosun
Affiliate or Sublicensee by the FDA or, for purposes of a country
or regulatory jurisdiction outside the United States, is approved
in reliance on a prior Regulatory Approval of a Product granted to
Fosun or an Fosun Affiliate or Sublicensee by the applicable
Regulatory Authority.

 

“Governmental
Authority” means any court, agency, legislative body,
department, authority or other instrumentality of any national,
multinational, supranational, federal, state, provincial, county,
city or other political subdivision.

 

Exhibits-4

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“ICH”
means the International Conference on Harmonization (of Technical
Requirements for Registration of Pharmaceuticals for Human
Use).

 

“IND”
means an Investigational New Drug Application submitted under the
FD&C Act, or an analogous application or submission with any
analogous agency or Regulatory Authority outside of the United
States for the purposes of obtaining permission to conduct Clinical
Trials.

 

“Initial
Indication” shall mean the treatment of hypoactive sexual
desire disorder in premenopausal women.

 

“Jurisdictions”
means China, Taiwan, Hong Kong or Macau, and
“Jurisdiction” means any of the foregoing.

 

 “Know-How”
means any invention, discovery, development, Data, information,
process, method, technique, material (including any chemical or
biological material), technology, result, cell line, compounds,
probe, sequence, regulatory correspondence or other know-how,
whether or not patentable, and any physical embodiments of any of
the foregoing.

 

“Law”
means any law, statute, rule, regulation, pronouncement having the
effect of law, order, judgment or ordinance of any Governmental
Authority.

 

“Manufacture”
or “Manufacturing” means to make, produce, manufacture,
process, fill, finish, package, label, perform quality assurance
testing, release, ship or store a compound or product or any
component thereof. When used as a noun, “Manufacture”
or “Manufacturing” means any and all activities
involved in Manufacturing a compound or product or any component
thereof.

 

“NDA”
means a new drug application or marketing authorization application
filed with the applicable Regulatory Authority in a Jurisdiction,
including without limitation an imported drug license application,
which application is required for marketing approval for a
pharmaceutical product.

 

 “Net
Sales” means: (a) with respect to a Product, the gross
amounts invoiced or otherwise billed by Fosun and its Affiliates
and Sublicensees with respect to sales of such Product to Third
Parties in the Territory, less in each (i) case sales returns and
allowances actually paid or granted in the ordinary course of
business, including trade, quantity and cash discounts, adjustments
granted on account of rejected goods, damaged or defective goods,
recalls, returns, rebates, chargeback rebates, (ii) customs or
excise duties, sales tax, consumption tax, value added tax, and
other taxes (except income taxes) or duties relating to sales, to
the extent paid or allowed by the selling party, (iii) any payment
in respect of sales to the United States government, any state
government or any foreign government, or to any other Governmental
Authority, or with respect to any government-subsidized program or
managed care organization, and (iv) freight and insurance (to the
extent that Fosun, its Affiliates or its Sublicensees bear the cost
of freight and insurance for the Product). Net Sales shall be
determined from books and records maintained in accordance with
GAAP, as consistently applied by Fosun with respect to sales of the
Product.

 

 

Exhibits-5

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“Palatin
Know-How” means any and all Know-How that (a) is Controlled
by Palatin or any of its Affiliates as of the Effective Date or
that comes into the Control of Palatin or any of its Affiliates
during the Term (other than through the grant of a license by
Fosun), (b) relates to any Compound, Product, Pharmaceutical
Product or Product Delivery Device or to the Development,
Manufacture, Commercialization or use of any of the foregoing and
(c) is necessary or useful in connection with the Development,
Manufacture, use or Commercialization of any Compound, Product,
Pharmaceutical Product or Product Delivery Device.

 

“Palatin
Patent Right” means any Patent Right that (a) is Controlled
by Palatin or any of its Affiliates as of the Effective Date or
comes into the Control of Palatin or any of its Affiliates during
the Term (other than through the grant of a license by Fosun) and
(b) claims any (i) Compound,
Product, Pharmaceutical Product or Product Delivery Device
(including the composition of matter thereof), (ii) method of
making any Compound, Product, Pharmaceutical Product or Product
Delivery Device, (iii) methods of using any Compound, Product,
Pharmaceutical Product or Product Delivery Device, or (iv) Palatin
Know-How. For the avoidance of doubt, and without limiting the
foregoing, Palatin Patent Rights include the Patent Rights listed
in Exhibit B.

 

“Palatin
Technology” means any and all Palatin Patent Rights and
Palatin Know-How.

 

“Patent
Rights” means any and all (a) issued patents,
(b) pending patent applications, including all provisional
applications, substitutions, continuations, continuations-in-part,
divisions and renewals, and all patents granted thereon, (c)
patents-of-addition, reissues, reexaminations and extensions or
restorations by existing or future extension or restoration
mechanisms, including patent term adjustments, patent term
extensions, supplementary protection certificates or the equivalent
thereof, (d) inventor’s certificates, (e) other forms of
government-issued rights substantially similar to any of the
foregoing, including utility model patents in the Territory, and
(f) United States and foreign counterparts of any of the
foregoing.

 

“Person”
means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust,
incorporated association, joint venture or similar entity or
organization, including a government or political subdivision or
department or agency of a government.

 

“Pharmaceutical
Product” means any pharmaceutical product containing one or
more Compounds, whether as sole active ingredients or in
combination with other active ingredients.

 

“Pivotal
Study” means a Clinical Trial designed to confirm the
preliminary evidence that an investigational product is safe and
effective for use in the intended indication and recipient
population and intended to support Regulatory Approval by a
Regulatory Authority.

 

Exhibits-6

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“Price
Approval” means, in any country or regulatory jurisdiction
where a Governmental Authority authorizes reimbursement for, or
approves or determines pricing for, pharmaceutical products,
receipt (or, if required to make such authorization, approval or
determination effective, publication) of such reimbursement
authorization or pricing approval or determination (as the case may
be).

 

“Product”
means any combination of (a) any Pharmaceutical Product and (b) any
Product Delivery Device.

 

“Product
Delivery Device” means any device for delivery or
administration of a Pharmaceutical Product.

 

“Regulatory
Approval” means all technical, medical and scientific
licenses, registrations, authorizations and approvals (including
approvals of NDAs, supplements and amendments, pre- and post-
approvals, Price Approvals, and labeling approvals) of any
Regulatory Authority, necessary for the use, Development,
Manufacture, and Commercialization of a pharmaceutical product in a
regulatory jurisdiction. For the sake of clarity, Regulatory
Approval shall not be achieved for a Product in a Jurisdiction
until all applicable Price Approvals have also been obtained by
Fosun or its designee for such Product in such
Jurisdiction.

 

“Regulatory
Authority” means, with respect to a Jurisdiction in the
Territory, any national (e.g., the FDA), supra-national, regional,
state or local regulatory agency, department, bureau, commission,
council or other Governmental Authority involved in the granting of
a Regulatory Approval or, to the extent required in such
Jurisdiction, Price Approval, for pharmaceutical products in such
Jurisdiction, including, without limitation, the CDE and the
CFDA.

 

“Regulatory
Exclusivity Period” means with respect to any particular
Product in any particular Jurisdiction in the Territory, the period
of time during which the data and information submitted by Fosun or
any of its Affiliates or Sublicensees to the relevant Regulatory
Authority in such Jurisdiction for purposes of obtaining Regulatory
Approval may not be disclosed, referenced or relied upon in any way
by such Regulatory Authority (including by relying upon the
Regulatory Authority’s previous findings regarding the safety
or effectiveness of the Product) to support the Regulatory Approval
or Commercialization of any product by a Third Party in such
Jurisdiction.

 

Exhibits-7

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“Relevant
Factors” means all relevant factors that may affect the
Development, Regulatory Approval or Commercialization of a
Compound, Product, Pharmaceutical Product or Product Delivery
Device, including (as applicable): actual and potential issues of
safety, efficacy or stability; product profile (including product
modality, category and mechanism of action); stage of development
or life cycle status; actual and projected Development, Regulatory
Approval, Manufacturing, and Commercialization costs; any issues
regarding the ability to Manufacture or have Manufactured any
Compound, Product, Pharmaceutical Product or Product Delivery
Device; the likelihood of obtaining Regulatory Approvals (including
satisfactory Price Approvals); the timing of such approvals; the
current guidance and requirements for Regulatory Approval for the
Product and similar products and the current and projected
regulatory status; labeling or anticipated labeling; the
then-current competitive environment and the likely competitive
environment at the time of projected entry into the market; past
performance of the Product or similar products; present and future
market potential; existing or projected pricing, sales,
reimbursement and profitability; pricing or reimbursement changes
in relevant countries; proprietary position, strength and duration
of patent protection and anticipated exclusivity; and other
relevant scientific, technical, operational and commercial
factors.

 

“Representatives”
means (a) with respect to Fosun, Fosun, its Affiliates, its
Sublicensees and each of their respective officers, directors,
employees, consultants, contractors and agents and (b) with respect
to Palatin, Palatin, its Affiliates and each of their respective
officers, directors, employees, consultants, contractors and
agents.

 

“Royalty
Term” means, with respect to any particular Product in any
particular Jurisdiction in the Territory, the period commencing
with the First Commercial Sale of such Product in such Jurisdiction
and continuing until the latest of (a) expiration or termination of
all regulatory approvals for the Product in any Jurisdiction,
including any renewal thereof, (b) the earliest date on which there
are no Valid Claims of Palatin Patent Rights Covering such Product
in such Jurisdiction, (c) the last day of the Regulatory
Exclusivity Period for such Product in such Jurisdiction and (d)
the tenth (10th) anniversary of the
First Commercial Sale of the Product in such Jurisdiction. For the
avoidance of doubt, the Royalty Term for a given Product in a given
Jurisdiction in the Territory (i) will not begin until the First
Commercial Sale of such Product in such Jurisdiction and (ii) if
not previously expired, will expire immediately upon expiration or
termination of this Agreement.

 

“Safety
Data” means Data related solely to any adverse drug
experiences and serious adverse drug experience as such information
is reportable to Regulatory Authorities in or outside the
Territory. Safety Data also includes “adverse events”,
“adverse drug reactions” and “unexpected adverse
drug reactions” as defined in the ICH Harmonised Tripartite
Guideline for Clinical Safety Data Management: Definitions and
Standards for Expedited Reporting.

 

 “Sublicensee”
means any Person to whom Fosun grants or has granted, directly or
indirectly, a sublicense of rights licensed by Palatin to Fosun
under this Agreement.

 

“Territory”
means, collectively, the Jurisdictions.

 

“Third
Party” means any Person other than Fosun, Palatin or their
respective Affiliates.

 

“Trademark”
means any trademark, trade name, service mark, service name, brand,
domain name, trade dress, logo, slogan or other indicia of origin
or ownership, including the goodwill and activities associated with
each of the foregoing.

 

Exhibits-8

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

“Valid
Claim” means, with respect to a particular Jurisdiction, a
claim of an issued and unexpired Palatin Patent Right that (a) has
not been held permanently revoked, unenforceable or invalid by a
decision of a court or other Governmental Authority of competent
jurisdiction, which decision is unappealed or unappealable within
the time allowed for appeal and (b) has not been cancelled,
withdrawn, abandoned, disclaimed or admitted to be invalid or
unenforceable through reissue, disclaimer or
otherwise.

 

The
following terms are defined in the section of this Agreement listed
opposite each term:

 

	

Defined Term

	

Section in Agreement

	

Additional
Third Party License

	

3.4.3(a)

	

Agreement

	

Preamble

	

cGMP

	

4.6.2

	

Continuation
Product

	

8.5.1(a)(v)(A)

	

Development
Milestone Payment

	

3.2

	

Diligence
Issue

	

4.2.4

	

Disclosing
Party

	

6.1

	

Effective
Date

	

Preamble

	

Fosun

	

Preamble

	

Fosun
Indemnified Party

	

9.3

	

Gross
Sales

	

3.4.3(c)

	

Indemnified
Party

	

9.4.1

	

Indemnifying
Party

	

9.4.1

	

Infringement
Claim

	

5.2.6

	

Initial
Payment Date

	

3.1

	

Liability

	

9.2

	

Licensed
Activities

	

5.2.5(a)

	

Litigation
Conditions

	

9.4.2

	

Manufacturing
Know-How

	

4.6.2

	

Marginal
Royalty Rate

	

3.4.1

	

Notice
of Dispute

	

10.9.1

	

Party
or Parties

	

Preamble

	

Palatin

	

Preamble

	

Palatin
Indemnified Party

	

9.2

	

Per
Product Annual Net Sales

	

3.4.1

	

Product
Brands

	

4.5.2

	

Receiving
Party

	

6.1

	

[...***...]

	

[...***...]

	

Sales
Milestone Payment

	

3.3

	

SEC

	

6.3

	

Term

	

8.2

	

Third
Party Claim

	

9.4.1

	

Total
Annual Net Sales

	

3.3

	

U.S.
CPP Holder

	

4.1

	
 

	
 

 

Exhibits-9

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

Exhibit B

Palatin Patent Rights Existing as of the Effective
Date

 

 

[...***...]

 

 

 

 

 

Exhibits-10

CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED
WITH “[...***...]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION
REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED
UNDER THE SECURITIES ACT OF 1934, AS AMENDED.

 

 

Exhibit C

Compounds Existing as of the Effective Date

 

 

[...***...]

Exhibit D

Section 7.3.5. Representation

 

 

 

As
disclosed in Palatin’s quarterly report on Form 10-Q for the
quarter ended March 31, 2008, as filed on May 13, 2008, on January
21, 2008, Palatin entered into a settlement agreement and release
with Competitive Technologies, Inc. (“CTI”), resolving
all outstanding disputes between Palatin and CTI. The arbitration
proceeding and the Connecticut Superior Court proceeding were
dismissed with prejudice. The existing license agreement between
CTI and Palatin was terminated. CTI retains all rights to a peptide
called variously MT-II or PT-14, which peptide was developed at the
University of Arizona, and Palatin expressly relinquished all
claims to any contractual or intellectual property rights to that
peptide or any patents licensed under the terminated license
agreement. Palatin retained all rights to bremelanotide, and CTI
expressly relinquished all claims to any contractual or
intellectual property rights to bremelanotide, including any claim
that making, using or selling bremelanotide infringes any patents
licensed under the terminated license agreement. The settlement
agreement and release also includes mutual covenants not to sue and
releases of all claims by either party against the other based on,
arising out of or in any way involving the subject matter of the
license agreement, the arbitration or the Connecticut Superior
Court proceeding.

 

 

 

 

 

 

 

Exhibits-11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]